,index,para,label,cls,document,predictions
256,256,"Example 1 The preparation of 2-fluoro-5- (pyridin-2-ethynyl) -N- (4-fluorophenyl) benzamide (ZD001)
",0.0,53986,EP3284738A1,2
257,257,"1.1 Synthesis of 2-fluoro-5-iodo-benzoyl chloride
",2.0,54036,EP3284738A1,1
1055,1055,"Phenyl 1-thio-β-D-galactopyranoside, 14
",2.0,36721,EP3305797A1,0
1073,1073," Preparation of 3,4-O-isopropylidene acetals.
",0.0,38365,EP3305797A1,2
1074,1074,"Phenil 3,4-O-isopropylidene-1-thio-β-D-galactopyranoside, 16.
",2.0,38427,EP3305797A1,1
1094,1094,1.4.,2.0,40776,EP3305797A1,0
1095,1095," Selective protection of the primary hydroxyl.
",1.0,40823,EP3305797A1,0
1096,1096,"Phenyl 3,4-O-isopropylidene-6-O-tert-butyldiphenylsilyl-1-thio-β-D-galactopyranoside, 18
",1.0,40912,EP3305797A1,2
1108,1108,1.5.,0.0,42160,EP3305797A1,2
1109,1109," Reaction of the hydroxyl in position 2 with p-fluorobenzyl derivatives.
",0.0,42233,EP3305797A1,1
1110,1110,"Phenyl 2-O-(p-fluorobenzyl)-3,4-O-isopropylidene-6-O-tert-butyldiphenylsilyl-1-thio-β-D-galactopyranoside, 19
",2.0,42343,EP3305797A1,1
1120,1120,"Phenyl 2-O-(p-fluorobenzyl)-3,4-O-isopropylidene-1-thio-α-L-arabinopyranoside, 20.
",2.0,44024,EP3305797A1,1
1130,1130,"2-O-(p-fluorobenzyl)-3,4-O-isopropylidene-6-O-tert-butyldiphenylsilyl-α,β-D-galactopyranose, 21
",2.0,45121,EP3305797A1,1
1144,1144,2.2.,0.0,47842,EP3305797A1,2
1145,1145," Formation of trichloroacetimidate.
",0.0,47878,EP3305797A1,1
1146,1146,"2-O-(p-fluorobenzyl)-3,4-O-isopropylidene-6-O-tert-butyldiphenylsilyl-α,β-D-galactopyranoside-trichloroacetimidate, 23
",2.0,47997,EP3305797A1,1
1153,1153,"2-O-(p-fluorobenzyl)-3,4-O-isopropylidene-α,β-L-arabinopyranoside-trichloroacetimidate, 24.
",2.0,48831,EP3305797A1,1
1164,1164,"α: anomer of (R)-{1-[3,5-bis-(trifluoromethyl)phenyl]ethyl} 2-O-p-fluorobenzyl-3,4-O-isopropylidene-6-O-tert-butyldiphenylsilyl-α-D-galactopyranoside, 25
",0.0,50246,EP3305797A1,2
1178,1178,"(R)-{1-3,5-bis-(trifluoromethyl)phenyl]ethyl} 2-O-p-fluorobenzyl-3,4-O-isopropylidene-β-L-arabinopyranoside, 8.
",0.0,52935,EP3305797A1,1
1188,1188,EXAMPLE 3.,2.0,54452,EP3305797A1,0
1189,1189," Selective deprotection of position 6.
",1.0,54491,EP3305797A1,0
1190,1190,"General procedure
",1.0,54509,EP3305797A1,2
1212,1212,EXAMPLE 4.,2.0,57152,EP3305797A1,0
1213,1213," Deprotection of positions 3 and 4.
",1.0,57188,EP3305797A1,0
1214,1214,"General procedure
",1.0,57206,EP3305797A1,2
1218,1218,"Galactose derivatives 4 and 3:
",0.0,57524,EP3305797A1,2
1219,1219,"Alpha anomer: (R)-{1-[3,4-bis-(trifluoromethyl)phenyl]ethyl} 2-O-p-fluorobenzyl-α-D-galactopyranose, 4
",2.0,57627,EP3305797A1,1
1234,1234,"Arabinose derivatives 6 and 5:
",0.0,59570,EP3305797A1,2
1235,1235,"(R)-{1-[3,4-bis-(trifluoromethyl)phenyl]ethyl} 2-O-p-fluorobenzyl-β-L-arabinopyranoside, 6.
",2.0,59662,EP3305797A1,1
1952,1952,"Reference Example 12: N6-(1,3-dimethyl-1H-pyrazol-4-yl)-3-[7-fluoro-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl]-1-(propan-2-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine
",2.0,121892,EP3312182A1,0
1953,1953,"A similar procedure to Reference Example 9 was carried out by using the compound prepared in Reference Example 11 instead of 1-(tert-butyldimethylsilyl)-1H-indol-5-ylboronic acid to give the title compound having the following physical properties.TLC: Rf 0.51 (ethyl acetate, NH silica);1H-NMR (CDCl3): δ1.54-1.64, 1.72-1.83, 2.06-2.23, 2.26, 2.55-2.70, 3.73-3.83, 3.88, 4.03-4.12, 4.98-5.16, 5.92-5.98, 6.34, 7.16-7.23, 7.31-7.36, 7.88, 8.25-8.26.
",1.0,122341,EP3312182A1,0
1954,1954,"Example 2: N6-(1,3-dimethyl-1H-pyrazol-4-yl)-3-(7-fluoro-1H-indazol-4-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine
",2.0,122468,EP3312182A1,0
1955,1955,"<img> id-imgb0038.tif </img>
",1.0,122497,EP3312182A1,0
1956,1956,"To a solution of the compound (61 mg) prepared in Reference Example 12 in dichloromethane (1 mL), trifluoroacetic acid (0.9 mL) was added at room temperature, and the mixture was stirred for 3 hours.",1.0,122696,EP3312182A1,0
1957,1957," To the reaction solution, a saturated sodium bicarbonate aqueous solution was added, and the solution was extracted with ethyl acetate.",1.0,122832,EP3312182A1,0
1958,1958," The obtained organic layer was washed with a saturated saline solution, and thereafter, was dried over anhydrous sodium sulfate, and was concentrated under a reduced pressure.",1.0,123008,EP3312182A1,0
1959,1959," The residue was purified by silica gel column chromatography to give the compound of the present invention (34 mg) having the following physical properties.TLC: Rf 0.27 (ethyl acetate, NH silica);1H-NMR (CDCl3): δ1.60-1.66, 2.27, 3.88, 5.00-5.09, 5.12-5.22, 6.39, 7.17-7.25, 7.34-7.40, 7.90, 8.33-8.36.
",1.0,123312,EP3312182A1,0
1960,1960,"Example 3: 3-(2,3-Dihydro-1-benzofuran-5-yl)-N6-(1,3-dimethyl-1H-pyrazol-4-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine
",2.0,123444,EP3312182A1,0
1961,1961,"<img> id-imgb0039.tif </img>
",1.0,123473,EP3312182A1,0
1962,1962,"A similar procedure to Reference Example 9 was carried out by using 2,3-dihydrobenzofuran-5-boronic acid instead of 1-(tert-butyldimethylsilyl)-1H-indol-5-ylboronic acid to give the compound of the present invention having the following physical properties.1H-NMR (DMSO-d6): δ1.41-1.46, 2.12, 3.24-3.30, 3.73, 4.57-4.62, 4.84-4.92, 6.10-6.40, 6.87-6.90, 7.32-7.36, 7.48, 7.93, 8.15.Purity (LC-MS/ELSD): 99.3% (Retention time: 0.77 minutes);MASS (ESI, Pos.",1.0,123928,EP3312182A1,0
1964,1964,"Reference Example 13: N6-[2-fluoro-4-(methylsulfonyl)phenyl]-3-iodo-1-(propan-2-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine
",2.0,124071,EP3312182A1,0
1965,1965,"A similar procedure to Reference Example 1 → Reference Example 8 was carried out by using 2-fluoro-4-(methylsulfonyl)aniline instead of 1,3-dimethylpyrazol-4-amine hydrochloride to give the title compound having the following physical properties.TLC: Rf 0.34 (hexane : ethyl acetate = 1 : 1);1H-NMR (CDCl3): δ1.54-1.62, 3.05, 4.89-5.03, 5.58-5.82, 7.37-7.43, 7.63-7.69, 7.75-7.79, 8.89-8.97.
",1.0,124463,EP3312182A1,0
1968,1968,"Example 4-1: 3-(7-Chloro-1H-indazol-4-yl)-N6-[2-fluoro-4-(methylsulfonyl)phenyl]-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine
",2.0,124993,EP3312182A1,0
1969,1969,"<img> id-imgb0040.tif </img>
",1.0,125022,EP3312182A1,0
1971,1971,"Example 4-2: N6-[2-fluoro-4-(methylsulfonyl)phenyl]-3-(1H-indazol-4-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine
",2.0,125313,EP3312182A1,0
1972,1972,"<img> id-imgb0041.tif </img>
",1.0,125342,EP3312182A1,0
1974,1974,"Example 4-3: 3-(7-Fluoro-1H-indazol-4-yl)-N6-[2-fluoro-4-(methylsulfonyl)phenyl]-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine
",2.0,125639,EP3312182A1,0
1975,1975,"<img> id-imgb0042.tif </img>
",1.0,125668,EP3312182A1,0
1977,1977,"Example 4-4: 4-(4-Amino-6-{[2-fluoro-4-(methylsulfonyl)phenyl]amino}-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indazole-7-carbonitrile
",2.0,126002,EP3312182A1,0
1978,1978,"<img> id-imgb0043.tif </img>
",1.0,126031,EP3312182A1,0
1983,1983,"Example 5-1: 3-(7-Fluoro-1H-indazol-4-yl)-1-isopropyl-N6-{3-methyl-1-[(methylsulfonyl)methyl]-1H-pyrazol-4-yl}-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine
",2.0,126874,EP3312182A1,0
1984,1984,"<img> id-imgb0044.tif </img>
",1.0,126903,EP3312182A1,0
1986,1986,"Example 5-2: 3-(7-Fluoro-1H-indazol-4-yl)-1-isopropyl-N6-[2-methoxy-4-(methylsulfonyl)phenyl]-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine
",2.0,127168,EP3312182A1,0
1987,1987,"<img> id-imgb0045.tif </img>
",1.0,127197,EP3312182A1,0
1989,1989,"Example 5-3: N6-[4-(cyclopropylsulfonyl)-2-fluorophenyl]-3-(1H-indazol-4-yl)-1-isopropyl-1 H-pyrazolo [3,4-d]pyrimidine-4,6-diamine
",2.0,127485,EP3312182A1,0
1992,1992,"Example 5-4: N6-(3-chloro-1-methyl-1H-pyrazol-4-yl)-3-(7-fluoro-1H-indazol-4-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine
",2.0,127844,EP3312182A1,0
1994,1994,"Example 5-5:1-(4-{[4-Amino-3-(7-fluoro-1H-indazol-4-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl]amino} -3 -fluorophenyl)ethanone di(trifluoroacetate)
",2.0,128151,EP3312182A1,0
2000,2000,"Example 6-1: 3-(1H-indol-5-yl)-1-isopropyl-N6-(3-methyl-1H-pyrazol-4-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine
",2.0,129011,EP3312182A1,0
2001,2001,"<img> id-imgb0046.tif </img>
",1.0,129040,EP3312182A1,0
2003,2003,"Example 6-2: N6-[1-(difluoromethyl)-3-methyl-1H-pyrazol-4-yl]-3-(1H-indol-5-yl)-1-isopropyl-1 H-pyrazolo [3,4-d]pyrimidine-4,6-diamine
",2.0,129339,EP3312182A1,0
2004,2004,"<img> id-imgb0047.tif </img>
",1.0,129368,EP3312182A1,0
2006,2006,"Example 6-3: N6-(1,3-dimethyl-1H-pyrazol-5-yl)-3-(1H-indol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine
",2.0,129650,EP3312182A1,0
2008,2008,"Example 6-4: 3-(1H-indol-5-yl)-1-isopropyl-N6-(5-pyrimidinyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine trifluoroacetate
",2.0,129933,EP3312182A1,0
2011,2011,"Example 6-5: 3-(1H-indol-5-yl)-1-isopropyl-N6-(6-methoxy-3-pyridinyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine trifluoroacetate
",2.0,130151,EP3312182A1,0
2014,2014,"Example 6-6: 5-{[4-Amino-3-(1H-indol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl]amino}-N,N-dimethyl-2-pyrimidinecarboxamide trifluoroacetate
",2.0,130390,EP3312182A1,0
2017,2017,"Example 6-7: N6-{4-[2-(dimethylamino)ethoxy]-2-fluorophenyl}-3-(1H-indol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine di(trifluoroacetate)
",2.0,130633,EP3312182A1,0
2020,2020,"Example 6-8: N6-[2-fluoro-4-(4-morpholinylmethyl)phenyl]-3-(1H-indol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine di(trifluoroacetate)
",2.0,130872,EP3312182A1,0
2023,2023,"Example 6-9: 5-{[4-Amino-3-(1H-indol-5-yl)-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl]amino}-1-indanone trifluoroacetate
",2.0,131085,EP3312182A1,0
2026,2026,"Example 7: 3-(6-Amino-5-methoxy-3-pyridinyl)-N6-[2-fluoro-4-(methylsulfonyl)phenyl]-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine
",2.0,131311,EP3312182A1,0
2027,2027,"<img> id-imgb0048.tif </img>
",1.0,131340,EP3312182A1,0
2028,2028,"A similar procedure to Reference Example 9 was carried out by using the compound prepared in Reference Example 13 instead of the compound prepared in Reference Example 8 and using 6-amino-5-methoxypyridine-3-boronic acid pinacol ester instead of 1-(tert-butyldimethylsilyl)-1H-indol-5-ylboronic acid to give the compound of the present invention having the following physical properties.TLC: Rf 0.25 (hexane : ethyl acetate =1:2);1H-NMR (CDCl3): δ1.59-1.64, 3.06, 3.94, 4.86-4.94, 4.97-5.11, 5.36-5.42, 7.23-7.26, 7.39-7.43, 7.62-7.69, 7.72-7.80, 7.95-7.97, 8.98-9.05.
",1.0,131909,EP3312182A1,0
2029,2029,"Example 8: 3-(1-Benzofuran-5-yl)-N6-(1,3-dimethyl-1H-pyrazol-4-yl)-1-(2,2,2-trifluoroethyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine di(trifluoroacetate)
",2.0,132063,EP3312182A1,0
2030,2030,"<img> id-imgb0049.tif </img>
",1.0,132092,EP3312182A1,0
2031,2031,"A similar procedure to Reference Example 4 → Reference Example 5 → Reference Example 6 → Reference Example 7 → Reference Example 8 → Reference Example 9 was carried out by using 2,2,2-trifluoroethanol instead of isopropanol and using benzofuran-5-boronic acid instead of 1-(tert-butyldimethylsilyl)-1H-indol-5-ylboronic acid to give the compound of the present invention having the following physical properties.",1.0,132504,EP3312182A1,2
2034,2034,"Example 9: N6-(1,3-dimethyl-1H-pyrazol-4-yl)-3-(7-fluoro-1H-indazol-4-yl)-1-(3-oxetanyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine
",2.0,132961,EP3312182A1,0
2035,2035,"<img> id-imgb0050.tif </img>
",1.0,132990,EP3312182A1,0
2036,2036,"A similar procedure to Reference Example 4 → Reference Example 5 → Reference Example 6 → Reference Example 7 → Reference Example 8 → Reference Example 9 → Example 2 was carried out by using oxetan-3-ol instead of isopropanol and using the boronic acid prepared in Reference Example 11 instead of 1-(tertbutyldimethylsilyl)-1H-indol-5-ylboronic acid to give the compound of the present invention having the following physical properties.1H-NMR (DMSO-d6): δ2.13, 3.76, 4.98-5.02, 5.12-5.16, 5.89-5.96, 6.30-6.80, 7.30-7.37, 8.03, 8.29-8.31, 8.45, 13.85.Purity (LC-MS/ELSD): 99.0% (Retention time: 0.61 minutes);MASS (ESI, Pos.",1.0,133614,EP3312182A1,2
2038,2038,"Example 10: 1-Cyclobutyl-N6-(1,3-dimethyl-1H-pyrazol-4-yl)-3-(1H-indol-6-yl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine trifluoroacetate
",2.0,133766,EP3312182A1,0
2039,2039,"<img> id-imgb0051.tif </img>
",1.0,133795,EP3312182A1,0
2040,2040,A similar procedure to Reference Example 4 → Reference Example 5 → Reference Example 6 → Reference Example 7 → Reference Example 8 → Reference Example 9 → Example 1 was carried out by using cyclobutanol instead of isopropanol and using 1-(tert-butyldimethylsilyl)-1H-indol-6-ylboronic acid instead of 1-(tert-butyldimethylsilyl)-1H-indol-5-ylboronic acid to give the compound of the present invention having the following physical properties.,1.0,134237,EP3312182A1,2
2052,2052,"Example 11: 3-(7-Fluoro-1H-indazol-4-yl)-N6-[2-fluoro-4-(methylsulfonyl)phenyl]-1-(2-methyl-2-propanyl)-1H-pyrazolo[3,4-d]pyrimidine-4,6-diamine
",2.0,136062,EP3312182A1,0
2053,2053,"<img> id-imgb0052.tif </img>
",1.0,136091,EP3312182A1,0
2054,2054,"A similar procedure to Reference Example 2 → Reference Example 5 → Reference Example 6 → Reference Example 7 → Reference Example 8 → Reference Example 9 → Example 2 was carried out by using the compound prepared in Reference Example 14 instead of 4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine and using the boronic acid prepared in Reference Example 11 instead of 1-(tert-butyldimethylsilyl)-1H-indol-5-ylboronic acid to give the compound of the present invention having the following physical properties.TLC: Rf 0.64 (hexane : ethyl acetate = 1 : 2);1H-NMR (CDCl3): δ1.89, 3.08, 5.23-5.31, 7.17-7.25, 7.34-7.40, 7.41-7.45, 7.65-7.71, 7.76, 7.82, 8.35-8.38, 8.97-9.03.
",1.0,136756,EP3312182A1,0
2055,2055,"Example 12: 4-{[4-Amino-1-cyclopentyl-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl]amino}-3-fluoro-N,N-dimethylbenzamide
",2.0,136885,EP3312182A1,0
2056,2056,"<img> id-imgb0053.tif </img>
",1.0,136914,EP3312182A1,0
2057,2057,"A similar procedure to Reference Example 1 → Reference Example 4 → Reference Example 5 → Reference Example 6 → Reference Example 7 → Reference Example 8 → Reference Example 9 was carried out by using 4-amino-3-fluoro-N,N-dimethylbenzamide instead of 1,3-dimethylpyrazol-4-amine hydrochloride, using cyclopentanol instead of isopropanol, and using 3-hydroxyphenylboronic acid instead of 1-(tert-butyldimethylsilyl)-1H-indol-5-ylboronic acid to give the compound of the present invention having the following physical properties.1H-NMR (DMSO-d6): δ1.65-1.68, 1.75-1.87, 2.02-2.12, 2.98, 5.00-5.11, 6.84-6.87, 7.04-7.06, 7.24-7.26, 7.29-7.35, 8.20-8.27, 8.72, 9.60-9.75.Purity (LC-MS/ELSD): 100% (Retention time: 0.89 minutes);MASS (ESI, Pos.",1.0,137653,EP3312182A1,0
2062,2062,"Example 13-1: 4-(4-Amino-2-{[2-fluoro-4-(methylsulfonyl)phenyl]amino}-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-1H-indazole-7-carbonitrile
",2.0,138645,EP3312182A1,0
2063,2063,"<img> id-imgb0054.tif </img>
",1.0,138674,EP3312182A1,0
2065,2065,"Example 13-2: 5-{[4-Amino-5-(1H-indazol-4-yl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-N,N-dimethyl-2-pyridinecarboxamide
",2.0,138975,EP3312182A1,0
2066,2066,"<img> id-imgb0055.tif </img>
",1.0,139004,EP3312182A1,0
2068,2068,"Example 13-3: 1-(4-{[4-Amino-5-(1H-indazol-4-yl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-3-methyl-1H-pyrazol-1-yl)-2-methyl-2-propanol
",2.0,139335,EP3312182A1,0
2070,2070,"Example 13-4: 2-(4-{[4-Amino-5-(1H-indazol-4-yl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-3-methyl-1H-pyrazol-1-yl)-N,N-dimethylacetamide
",2.0,139640,EP3312182A1,0
2072,2072,"Example 13-5: 2-(4-{[4-Amino-5-(1H-indazol-4-yl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-3-methyl-1H-pyrazol-1-yl)-1-(4-morpholinyl)ethanone
",2.0,139944,EP3312182A1,0
2074,2074,"Example 13-6: 2-(4-{[4-Amino-5-(1H-indazol-4-yl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-3-methyl-1 H-pyrazol-1-yl)-2-methyl-1,3-propanediol
",2.0,140258,EP3312182A1,0
2076,2076,"Example 13-7: 6-{[4-Amino-5-(1H-indazol-4-yl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-1-methyl-1,3-dihydro-2H-indol-2-one trifluoroacetate
",2.0,140563,EP3312182A1,0
2078,2078,"Example 13-8: [4-({4-Amino-7-isopropyl-5-[4-(trifluoromethyl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-2-yl}amino)-3-fluorophenyl](1-piperazinyl)methanone
",2.0,140884,EP3312182A1,0
2080,2080,"Example 13-9: 4-(4-Amino-2-{[2-fluoro-4-(1-piperazinylcarbonyl)phenyl]amino}-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)benzonitrile
",2.0,141189,EP3312182A1,0
2082,2082,"Example 13-10: [4-({4-Amino-7-isopropyl-5-[4-(trifluoromethoxy)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-2-yl}amino)-3-fluorophenyl](1-piperazinyl)methanone
",2.0,141510,EP3312182A1,0
2084,2084,"Example 13-11: (4-{[4-Amino-7-isopropyl-5-(3-methoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino-3-fluorophenyl)(1-piperazinyl)methanone
",2.0,141808,EP3312182A1,0
2086,2086,"Example 13-12: N2-(1,3-dimethyl-1H-pyrazol-4-yl)-5-(6-fluoro-1H-indazol-4-yl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
",2.0,142131,EP3312182A1,0
2088,2088,"Example 13-13: N2-(1,3-dimethyl-1H-pyrazol-4-yl)-7-isopropyl-5-(6-methyl-1H-indazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
",2.0,142400,EP3312182A1,0
2090,2090,"Example 13-14: N2-(1,3-dimethyl-1H-pyrazol-4-yl)-7-isopropyl-5-(7-methyl-1H-indazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
",2.0,142695,EP3312182A1,0
2092,2092,"Example 13-15: N2-(1,3-dimethyl-1H-pyrazol-4-yl)-7-isopropyl-5-(5-methyl-1H-indazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
",2.0,142977,EP3312182A1,0
2096,2096,"Example 14-1: 5-(1-Benzofuran-3-yl)-N2-(1,3-dimethyl-1H-pyrazol-4-yl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
",2.0,143947,EP3312182A1,0
2097,2097,"<img> id-imgb0056.tif </img>
",1.0,143976,EP3312182A1,0
2099,2099,"Example 14-2: 5-(1,2-Benzothiazol-5-yl)-N2-(1,3-dimethyl-1H-pyrazol-4-yl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
",2.0,144259,EP3312182A1,0
2100,2100,"<img> id-imgb0057.tif </img>
",1.0,144288,EP3312182A1,0
2102,2102,"Example 14-3: 5-(2,1-Benzothiazol-5-yl)-N2-(1,3-dimethyl-1H-pyrazol-4-yl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
",2.0,144567,EP3312182A1,0
2104,2104,"Example 14-4: N2-(1,3-dimethyl-1H-pyrazol-4-yl)-7-isopropyl-5-(1H-pyrrolo[2,3-b]pyridin-3-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
",2.0,144826,EP3312182A1,0
2106,2106,"Example 14-5: 5-(4-Amino-2-{[2-fluoro-4-(methylsulfbnyl)phenyl]amino}-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-1(2H)-isoquinolinone
",2.0,145140,EP3312182A1,0
2108,2108,"Example 14-6: N2 -[2-fluoro-4-(methylsulfonyl)phenyl]-7-isopropyl-5-(5-quinolinyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
",2.0,145398,EP3312182A1,0
2110,2110,"Example 14-7: Methyl(4-{[4-amino-5-(1-benzofuran-5-yl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-3-methyl-1H-pyrazol-1-yl)acetate
",2.0,145715,EP3312182A1,0
2112,2112,"Example 14-8: 5-(1-Benzofuran-5-yl)-N2-(1,5-dimethyl-1H-pyrazol-4-yl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
",2.0,145979,EP3312182A1,0
2114,2114,"Example 14-9: 5-(1-Benzofuran-5-yl)-N2-[1-(difluoromethyl)-3-methyl-1H-pyrazol-4-yl]-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
",2.0,146258,EP3312182A1,0
2116,2116,"Example 14-10: 5-(1-Benzofuran-5-yl)-N2-(2,5-dimethyl-1,3-thiazol-4-yl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
",2.0,146529,EP3312182A1,0
2118,2118,"Example 14-11: 5-(1-Benzofuran-5-yl)-7-isopropyl-N2-(3-methoxy-1-methyl-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
",2.0,146810,EP3312182A1,0
2120,2120,"Example 14-12: 5-[4-(Difluoromethoxy)phenyl]-N2-[2-fluoro-4-(methylsulfonyl)phenyl]-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
",2.0,147098,EP3312182A1,0
2122,2122,"Example 14-13: 4-{[4-Amino-5-(4-chloro-3-methoxyphenyl)-7-isopropyl-7H-pyrrolo [2,3-d]pyrimidin-2-yl]amino}-3-fluoro-N-methylbenzamide
",2.0,147407,EP3312182A1,0
2124,2124,"Reference Example 15: Methyl 4-{[4-amino-5-(1-benzofuran-5-yl)-7-(propan-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-3-fluorobenzoate
",2.0,147716,EP3312182A1,0
2125,2125,"A similar procedure to Reference Example 1 → Reference Example 2 → Reference Example 3 → Reference Example 4 → Reference Example 5 → Reference Example 6 → Reference Example 7 → Reference Example 8 → Reference Example 9 was carried out by using methyl 4-amino-3-fluorobenzoate instead of 1,3-dimethylpyrazol-4-amine hydrochloride, using 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine instead of 4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine, and using benzofuran-5-boronic acid instead of 1-(tert-butyldimethylsilyl)-1H-indol-5-ylboronic acid to give the title compound having the following physical properties.TLC: Rf 0.81 (hexane : ethyl acetate = 1 : 1);1H-NMR (CDCl3): δ1.55-1.62,3.90, 4.93-5.06, 6.81, 6.89, 7.22-7.28, 7.40-7.44, 7.56-7.61, 7.64-7.77, 7.84-7.91, 8.84-8.92.
",1.0,148484,EP3312182A1,0
2126,2126,"Example 15: 4-{[4-Amino-5-(1-benzofuran-5-yl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-3-fluorobenzoic acid
",2.0,148602,EP3312182A1,0
2127,2127,"<img> id-imgb0058.tif </img>
",1.0,148631,EP3312182A1,0
2128,2128,"To a solution of the compound (113 mg) prepared in Reference Example 15 in ethanol (5 mL), 2 N sodium hydroxide aqueous solution (1 mL) was added, and the mixture was stirred at 40°C for 3 hours.",1.0,148826,EP3312182A1,0
2129,2129," The reaction solution was neutralized with 2 N hydrochloric acid, and thereafter, was extracted with ethyl acetate.",1.0,148942,EP3312182A1,0
2130,2130," The obtained organic layer was dried over anhydrous sodium sulfate, and was concentrated under a reduced pressure.",1.0,149057,EP3312182A1,0
2131,2131," The residue was purified by silica gel column chromatography to give the compound of the present invention (65 mg) having the following physical properties.TLC: Rf 0.45 (hexane : ethyl acetate = 2 : 3);1H-NMR (DMSO-d6): δ1.43-1.49, 4.80-4.95, 6.00-6.30, 6.96-7.00, 7.26, 7.36-7.42, 7.60-7.76, 8.00-8.03, 8.25-8.43, 8.60-8.71.
",1.0,149384,EP3312182A1,0
2132,2132,"Example 16: [(4-{[4-Amino-5-(1-benzofuran-5-yl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-3-fluorophenyl)sulfonyl]acetic acid
",2.0,149519,EP3312182A1,0
2133,2133,"<img> id-imgb0059.tif </img>
",1.0,149548,EP3312182A1,0
2134,2134,"A similar procedure to Reference Example 1 → Reference Example 2 → Reference Example 3 → Reference Example 4 → Reference Example 5 → Reference Example 6 → Reference Example 7 → Reference Example 8 → Reference Example 9 → Example 15 was carried out by using ethyl[(4-amino-3-fluorophenyl)sulfonyl]acetate instead of 1,3-dimethylpyrazol-4-amine hydrochloride, using 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine instead of 4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine and using benzofuran-5-boronic acid instead of 1-(tert-butyldimethylsilyl)-1H-indol-5-ylboronic acid to give the compound of the present invention having the following physical properties.TLC: Rf 0.40 (ethyl acetate : methanol = 3 : 1);1H-NMR (DMSO-d6): δ1.40-1.50, 4.44, 4.87-4.98, 5.95-6.18, 6.98-7.01, 7.25, 7.37-7.42, 7.63-7.75, 8.00-8.02, 8.45-8.50, 8.81-8.90.
",1.0,150372,EP3312182A1,0
2135,2135,"Example 17: N2-(1,3-dimethyl-1H-pyrazol-4-yl)-5-(1H-indol-3-yl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine
",2.0,150488,EP3312182A1,0
2136,2136,"<img> id-imgb0060.tif </img>
",1.0,150517,EP3312182A1,0
2137,2137,"A similar procedure to Reference Example 1 → Reference Example 2 → Reference Example 3 → Reference Example 4 → Reference Example 5 → Reference Example 6 → Reference Example 7 → Reference Example 8 → Reference Example 9 → Example 1 was carried out by using 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine instead of 4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine, and using 1-(toluene-4-sulfonyl)-1H-indole-3-boronic acid N-tert-butyldimethylsilyl protected product instead of 1-(tert-butyldimethylsilyl)-1H-indol-5-ylboronic acid to give the compound of the present invention having the following physical properties.TLC: Rf 0.40 (ethyl acetate : methanol = 20 : 1);1H-NMR (CDCl3): δ1.50-1.57, 2.26, 3.86, 4.81-5.02, 6.22, 6.84, 7.13-7.21, 7.25-7.31, 7.41-7.45, 7.64-7.70, 7.93, 8.29.
",1.0,151290,EP3312182A1,0
2140,2140,"Example 18-1: (4-{[4-Amino-5-(1H-indazol-4-yl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-2,5-difluorophenyl)acetic acid
",2.0,152120,EP3312182A1,0
2141,2141,"<img> id-imgb0061.tif </img>
",1.0,152149,EP3312182A1,0
2143,2143,"Example 18-2: 2-(4-{[4-Amino-5-(1H-indazol-4-yl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]-2,3-difluorophenyl)-2-methylpropanoic acid
",2.0,152437,EP3312182A1,0
2144,2144,"<img> id-imgb0062.tif </img>
",1.0,152466,EP3312182A1,0
2146,2146,"Reference Example 16: Benzyl [4-({4-amino-7-(propan-2-yl)-5-[1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-2-yl}amino)-3-methyl-1H-pyrazol-1-yl]acetate
",2.0,152773,EP3312182A1,0
2147,2147,"A similar procedure to Reference Example 1 → Reference Example 2 → Reference Example 3 → Reference Example 4 → Reference Example 5 → Reference Example 6 → Reference Example 7 → Reference Example 8 → Reference Example 9 was carried out by using benzyl(4-amino-3-methyl-1H-pyrazol-1-yl)acetate instead of 1,3-dimethylpyrazol-4-amine hydrochloride, using 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine instead of 4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine, and using 1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl-4-boronic acid instead of 1-(tert-butyldimethylsilyl)-1H-indol-5-ylboronic acid to give the title compound having the following physical properties.TLC: Rf 0.62 (ethyl acetate);1H-NMR (CDCl3): δ1.42-1.58, 1.62-1.84, 2.04-2.23, 2.35, 2.54-2.67, 3.73-3.83, 4.03-4.11, 4.80-5.00, 5.22, 5.74-5.80, 6.22, 6.95, 7.19-7.38, 7.42-7.49, 7.52-7.57, 8.07.
",1.0,153620,EP3312182A1,0
2148,2148,"Reference Example 17: [4-({4-Amino-7-(propan-2-yl)-5-[1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-2-yl}amino)-3-methyl-1H-pyrazol-1-yl]acetic acid
",2.0,153796,EP3312182A1,0
2149,2149,"To a solution of the compound (20 mg) prepared in Reference Example 16 in ethanol (1 mL), 10% palladium on carbon (Pd/C) (4 mg) was added, and the mixture was stirred under a hydrogen gas atmosphere at room temperature for 3 hours.",1.0,154027,EP3312182A1,0
2150,2150," The reaction solution was filtered through Celite, and the filtrate was concentrated under a reduced pressure to give the compound of the present invention (15 mg) having the following physical properties.TLC: Rf 0.39 (ethyl acetate : methanol = 1 : 1);1H-NMR (CDCl3): δ1.42-1.58, 1.62-1.84, 2.00-2.65, 2.35, 3.68-3.83, 4.02-4.10, 4.78-4.95, 5.75-5.82, 6.98, 7.13-7.19, 7.42-7.48, 7.59-7.64, 7.71, 8.01.
",1.0,154432,EP3312182A1,0
2169,2169," A similar procedure to Example 2 was carried out by using the tetrahydropyran protected product (15 mg) to give the compound of the present invention having the following physical properties.TLC: Rf 0.29 (ethyl acetate);1H-NMR (CDCl3): δ1.56-1.61, 2.29, 4.88-5.04, 6.41, 7.02, 7.20-7.23, 7.43-7.48, 8.14, 8.22.
",2.0,157786,EP3312182A1,0
2170,2170,"Example 21: 4-{[4-Amino-5-(1-benzofuran-5-yl)-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-N-[2-(dimethylamino)ethyl]-3-fluorobenzamide
",2.0,157928,EP3312182A1,0
2171,2171,"<img> id-imgb0065.tif </img>
",1.0,157957,EP3312182A1,0
2172,2172,"To a solution of the compound (20 mg) prepared in Example 15 in N,N-dimethylformamide (4 mL), diisopropylethylamine (23 µL), N,N-dimethylethylenediamine (10 µL), and HATU (26 mg) were added at room temperature, and the mixture was stirred for 16 hours.",1.0,158209,EP3312182A1,2
2185,2185,"A similar procedure to Reference Example 2 → Reference Example 4 was carried out by using 2,4-dichloro-7H-pyrrolo[2,3-d]pyrimidine instead of 4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine, and using oxetan-3-ol instead of isopropanol to give the title compound having the following physical properties.TLC: Rf 0.51 (hexane : ethyl acetate = 2 : 1);1H-NMR (CDCl3): δ4.84-4.92, 5.15-5.23, 5.92-6.02, 7.89.
",1.0,160447,EP3312182A1,2
2191,2191,"Example 23: 1-(4-{[4-Amino-5-(1H-indazol-4-yl)-7-(3-oxetanyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-3-methyl-1H-pyrazol-1-yl)-2-methyl-2-propanol
",2.0,161320,EP3312182A1,0
2192,2192,"<img> id-imgb0067.tif </img>
",1.0,161349,EP3312182A1,0
2193,2193,"A similar procedure to Reference Example 1 → Reference Example 6 → Reference Example 7 → Reference Example 8 → Reference Example 9 → Example 2 was carried out by using the compound prepared in Reference Example 20 instead of the compound prepared in Reference Example 8, using 1-(4-amino-3-methyl-1H-pyrazol-1-yl)-2-methylpropan-2-ol instead of 1,3-dimethylpyrazol-4-amine hydrochloride, and using [1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-4-yl]boronic acid instead of the boronic acid prepared in Reference Example 11 to give the compound of the present invention having the following physical properties.TLC: Rf 0.51 (ethyl acetate : methanol = 9 : 1);1H-NMR (CDCl3): δ1.19, 2.29, 4.01, 4.84-4.96, 5.12-5.18, 5.34-5.40, 5.65-5.77, 6.33, 7.12, 7.20-7.23, 7.45-7.50, 8.12, 8.23.
",1.0,162127,EP3312182A1,2
2200,2200,"Example 24: 4-{[4-Amino-5-(1-benzofuran-5-yl)-7-(difluoromethyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino}-3-fluoro-N,N-dimethylbenzamide
",2.0,163180,EP3312182A1,0
2201,2201,"<img> id-imgb0068.tif </img>
",1.0,163209,EP3312182A1,0
2202,2202,"A similar procedure to Reference Example 1 → Reference Example 2 → Reference Example 3 → Reference Example 5 → Reference Example 6 → Reference Example 7 → Reference Example 8 → Reference Example 9 was carried out by using the compound prepared in Reference Example 21 instead of 4,6-dichloro-1H-pyrazolo[3,4-d]pyrimidine, using benzofuran-5-boronic acid instead of 1-(tert-butyldimethylsilyl)-1H-indol-5-ylboronic acid, and using 4-amino-3-fluoro-N,N-dimethylbenzamide instead of 2-fluoro-4-(methylsulfonyl)aniline to give the compound of the present invention having the following physical properties.TLC: Rf 0.37 (dichloromethane : methanol = 9 : 1);1H-NMR (CDCl3): δ3.00-3.18, 5.02-5.12, 6.82-6.84, 7.05, 7.16-7.19, 7.21-7.27, 7.40-7.45, 7.48-7.89, 8.58-8.64.
",1.0,163972,EP3312182A1,2
2238,2238,"Example 25: 4-{[4-Amino-5-(3-hydroxyphenyl)-7-isopropylpyrrolo[2,1-f][1,2,4]triazin-2-yl]amino}-3-fluoro-N,N-dimethylbenzamide
",2.0,169972,EP3312182A1,0
2239,2239,"<img> id-imgb0069.tif </img>
",1.0,170001,EP3312182A1,0
2247,2247,"Example 26-1: 4-{[4-Amino-5-(1H-indazol-4-yl)-7-isopropylpyrrolo[2,1-f][1,2,4]triazin-2-yl]amino}-3-fluoro-N,N-dimethylbenzamide trifluoroacetate
",2.0,171624,EP3312182A1,0
2248,2248,"<img> id-imgb0070.tif </img>
",1.0,171653,EP3312182A1,0
2252,2252,"Example 26-2: N2-[2-fluoro-4-(methylsulfonyl)phenyl]-5-(1H-indazol-4-yl)-7-isopropylpyrrolo[2,1-f][1,2,4]triazine-2,4-diamine trifluoroacetate
",2.0,171967,EP3312182A1,0
2253,2253,"<img> id-imgb0071.tif </img>
",1.0,171996,EP3312182A1,0
2256,2256,"Example 26-3: N2-(1,3-dimethyl-1H-pyrazol-4-yl)-5-(1H-indazol-4-yl)-7-isopropylpyrrolo[2,1-f][1,2,4]triazine-2,4-diamine trifluoroacetate
",2.0,172316,EP3312182A1,0
2533,2533,"Step 1: 1-(2-(4-fluoro-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl) - 1H-benzo[d]imidazol-2(3H)-one p-toluenesulfonate
",2.0,37150,EP3323817A1,0
2534,2534,"<img> id-imgb0029.tif </img>
",1.0,37179,EP3323817A1,0
2535,2535,"The title compound was prepared from 1-(2-chloropyrimidin-4-yl)-1H-benzo[d] imidazol-2(3H)-one and 4-fluoro-2-methoxy-5-nitroaniline by a method similar to that described in Step 4 of Example 1.1H NMR (DMSO-d6): δ 11.47 (1H, s), 9.12 (1H, s), 8.62 (1H, d, J = 8.4 Hz), 8.50 (1H, d, J = 5.6 Hz), 8.16-8.14 (1H, m), 7.82 (1H, d, J=5.6 Hz), 7.47-7.40 (3H, m), 7.15-7.09 (3H, m), 7.04 (1H, d, J= 7.6 Hz), 6.95-6.91 (1H, m), 3.96 (3H, s), 2.27 (3H, s).
",1.0,37627,EP3323817A1,0
2536,2536,"Step 2: 1-(2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
",2.0,37759,EP3323817A1,0
2537,2537,"<img> id-imgb0030.tif </img>
",1.0,37788,EP3323817A1,0
2538,2538,"The title compound was prepared from 1-(2-(4-fluoro-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one p-toluenesulfonate by a method similar to that described in Step 5 of Example 1.1H NMR (DMSO-d6): δ 11.39 (1H, s), 8.72 (1H, s), 8.42 (1H, d, J = 5.6 Hz), 8.12-8.03 (2H, m), 7.68 (1H, d, J= 5.6 Hz), 7.11-7.07 (1H, m), 7.02-7.00 (1H, m), 6.88-6.84 (1H, m), 6.81 (1H, s), 3.87 (3H, s), 3.28 (2H, t, J= 6.8 Hz), 2.85 (3H, s), 2.46 (2H, t, J= 6.8 Hz), 2.15 (6H, s).
",1.0,38278,EP3323817A1,0
2544,2544,"Step 1: N1-(2,5-dichloropyrimidin-4-yl)benzene-1,2-diamine
",2.0,39247,EP3323817A1,0
2545,2545,"<img> id-imgb0033.tif </img>
",1.0,39276,EP3323817A1,0
2546,2546,"The title compound was prepared from 2,4,5-trichloropyrimidine and o-phenylenediamine by a method similar to that described in Step 1 of Example 1.1H NMR (CDCl3): δ 8.18 (1H, s), 7.46 (1H, dd, J = 1.6 Hz, 7.2Hz), 7.15-7.11 (2H, m), 6.91-6.86 (2H, m), 3.67 (2H, br).
",1.0,39542,EP3323817A1,0
2547,2547,"Step 2: 1-(2,5-dichloropyrimidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
",2.0,39611,EP3323817A1,0
2548,2548,"<img> id-imgb0034.tif </img>
",1.0,39640,EP3323817A1,0
2549,2549,"N1-(2,5-dichloropyrimidin-4-yl)benzene-1,2-diamine (100 mg, 0.39 mmol) was dissolved in ethyl acetate (5 mL), and diisopropylethylamine (151 mg, 1.17 mmol) was added thereto and cooled in an ice-water bath.",1.0,39846,EP3323817A1,2
2555,2555,"<img> id-imgb0035.tif </img>
",1.0,40508,EP3323817A1,0
2556,2556,"The title compound was prepared from 1-(2,5-dichloropyrimidin-4-yl)-1H -benzo[d]imidazol-2(3H)-one by a method similar to that described in Step 3 of Example 1.1H NMR (CDCl3): δ 8.80 (1H, s), 7.27-7.23 (2H, m), 7.18-7.16 (1H, m), 7.06 (1H, d, J= 8.0Hz), 3.48 (3H, s ).
",1.0,40777,EP3323817A1,0
2557,2557,"Step 4: 1-(5-chloro-2-(4-fluoro-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl) -3-methyl-1H-benzo[d]imidazol-2(3H)-one
",2.0,40894,EP3323817A1,0
2558,2558,"<img> id-imgb0036.tif </img>
",1.0,40923,EP3323817A1,0
2559,2559,"1-(2,5-Dichloropyrimidin-4-yl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (50 mg, 0.17 mmol), 4-fluoro-2-methoxy-5-nitroaniline (63 mg, 0.34 mmol), BINAP (11 mg, 0.017 mmol) and cesium carbonate (110 mg, 0.34 mmol) were dispersed in anhydrous toluene (5 mL).",1.0,41177,EP3323817A1,0
2577,2577,"Step 1: 1-(5-chloro-2-(4-fluoro-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl) -1H-benzo[d]imidazol-2(3H)-one
",2.0,44324,EP3323817A1,0
2578,2578,"<img> id-imgb0041.tif </img>
",1.0,44353,EP3323817A1,0
2579,2579,"The title compound was prepared from 1-(2,5-dichloropyrimidin-4-yl)-1H-benzo [d]imidazol-2(3H)-one and 4-fluoro-2-methoxy-5-nitroaniline by a method similar to that described in Step 4 of Example 3.1H NMR (CDCl3): 9.24 (1H, d, J = 8.0 Hz), 8.68 (1H, s), 8.45 (1H, s), 7.83 (1H, s), 7.34 (1H, s), 7.22-7.10 (3H, m), 6.78 (1H, d, J = 12.0 Hz), 4.02 (3H, s).
",1.0,44709,EP3323817A1,0
2580,2580,"Step 2: 1-(5-chloro-2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
",2.0,44850,EP3323817A1,0
2581,2581,"<img> id-imgb0042.tif </img>1H NMR (CDCl3): δ 8.94 (1H, s), 8.66 (1H, s), 8.38 (1H, br), 7.84 (1H, s), 7.23-7.13 (4H, m), 4.05 (3H, s), 3.56 (2H, br), 3.08 (2H, br), 2.89 (3H, s) 2.69 (6H, s).
",1.0,45043,EP3323817A1,0
2588,2588,"Step 1: 2-chloro-N-(2-methoxyphenyl)pyrimidin-4-amine
",2.0,46203,EP3323817A1,0
2589,2589,"<img> id-imgb0045.tif </img>
",1.0,46232,EP3323817A1,0
2590,2590,"The title compound was prepared from o-methoxyaniline and 2,4-dichloropyrimidine by a method similar to that described in Step 1 of Example 1.1H NMR (CDCl3): δ 8.14 (1H, d, J= 5.6 Hz), 7.83 (1H, br), 7.27 (1H, m), 7.17-7.13 (1H, m), 7.04-6.99 (1H, m), 6.96-6.94(1H, m), 6.63-6.62 (1H, d, J= 6.0 Hz), 3.89 (3H, s).
",1.0,46546,EP3323817A1,0
2611,2611,"Step 1: 1-(2-(4-((2-hydroxyethyl)(methyl)amino)-2-methoxy-5-nitrophenylarmino) pyrimidin-4-yl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
",2.0,49942,EP3323817A1,0
2612,2612,"<img> id-imgb0052.tif </img>
",1.0,49971,EP3323817A1,0
2613,2613,"The title compound was prepared from 2-(methylamino)ethanol by a method similar to that described in Step 5 of Example 1.1H NMR (CDCl3): δ 8.97 (1H, s), 8.52 (1H, d, J = 6.0 Hz), 8.26 (1H, J = 7.2Hz), 7.83 (1H, d, J = 5.6 Hz), 7.56 (1H, s), 7.27-7.23 (1H, m), 7.18-7.16 (1H, m), 7.04 (1H, J = 7.2Hz), 6.70 (1H, s), 4.00 (3H, s), 3.79-3.76 (2H, m), 3.48 (3H, s), 3.40 (2H, t, J= 7.2 Hz ), 2.84 (3H, s ).
",1.0,50374,EP3323817A1,0
2617,2617,"Example 7: (E)-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4 -(3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)pyrimidin-2-ylamino)phenyl)-4 -methoxybut-2-enamide
",2.0,51298,EP3323817A1,0
2618,2618,"<img> id-imgb0054.tif </img>
",1.0,51327,EP3323817A1,0
2619,2619,"The title compound was prepared from 1-(2-(5-amino-4-((2-(dimethylamino)ethyl) (methyl)amino)-2-methoxyphenylamino)pyrimidin-4-yl)-3-methyl-1H-benzo[d]imidazol -2(3H)-one and (E)-4-methoxybut-2-enoyl chloride by a method similar to that described in Step 7 of Example 1.1H NMR (CDCl3): δ 12.32 (1H, br), 9.24 (1H, br), 9.17 (1H, br), 8.52 (1H, d, J= 5.6 Hz), 8.31 (1H, d, J = 8.0 Hz), 7.80 (1H, d, J = 5.6 Hz), 7.49 (1H, br), 7.19-7.10 (2H, m), 6.99-6.96 (2H, m), 6.90-6.84 (1H, m), 6.72 (1H, s), 4.14 (2H, d, J = 3.2 Hz), 3.90 (3H, s), 3.45 (3H, s), 3.40 (3H, s), 3.38-3.35 (2H, m), 3.12-3.08 (2H, m), 2.80 (6H, s), 2.74 (3H, s).
",1.0,51958,EP3323817A1,0
2622,2622,"Step 1: 1-(2-(2-methoxy-4-morpholino-5-nitrophenylamino)pyrimidin-4-yl)-3 -methyl-1H-benzo[d]imidazol-2(3H)-one
",2.0,52228,EP3323817A1,0
2623,2623,"<img> id-imgb0056.tif </img>
",1.0,52257,EP3323817A1,0
2624,2624,"The title compound was prepared from 1-(2-(4-fluoro-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one p-toluenesulfonate and morpholine by a method similar to that described in Step 5 of Example 1.1H NMR (CDCl3): δ 9.10 (1H, s), 8.54 (1H, d, J = 5.6 Hz), 8.27 (1H, d, J= 8.0 Hz), 7.85 (1H, d, J= 5.6 Hz), 7.59 (1H, s), 7.27-7.24 (1H, m), 7.19-7.17 (1H, m), 7.05 (1H, d, J = 8.0 Hz), 6.65 (1H, s), 4.04 (3H, s), 3.91-3.89 (4H, m), 3.49 (3H, s), 3.10-3.08 (4H, m).
",1.0,52755,EP3323817A1,0
2625,2625,"Step 2: N-(4-methoxy-5-(4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl) pyrimidin-2-ylamino)-2-morpholinophenyl)acrylamide
",2.0,52882,EP3323817A1,0
2626,2626,"<img> id-imgb0057.tif </img>
",1.0,52911,EP3323817A1,0
2627,2627,"The title compound was prepared from 1-(2-(2-methoxy-4-morpholino-5 -nitrophenylamino)pyrimidin-4-yl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one by a method similar to those described in Steps 6 and 7 of Example 1.1H NMR (CDCl3): δ 9.37 (1H, s), 8.55 (1H, d, J = 5.6 Hz), 8.48 (1H, s), 8.34 (1H, d, J = 8.0 Hz), 7.81 (1H, d, J = 5.6 Hz), 7.46 (1H, s), 7.20-7.16 (1H, m), 7.10-7.06 (1H, m), 7.01-6.99 (1H, m), 6.79 (1H, s), 6.36-6.22 (2H, m), 5.75-5.72 (1H, m), 3.91-3.88 (7H, m), 3.46 (3H, s), 2.90 (4H, t, J= 4.8 Hz).
",1.0,53426,EP3323817A1,0
2630,2630,"Step 1: N1-(2-chloropyrimidin-4-yl)-4-methylbenzene-1,2-diamine
",2.0,53692,EP3323817A1,0
2631,2631,"<img> id-imgb0059.tif </img>
",1.0,53721,EP3323817A1,0
2632,2632,"The title compound was prepared from 4-methylbenzene-1,2-diamine and 2,4-dichloropyrimidine by a method similar to that described in Step 1 of Example 1.1H NMR (CDCl3): δ 8.06 (1H, d, J= 6.0 Hz), 7.00 (1H, d, J = 8.0 Hz), 6.77 (1H, s), 6.66 (1H, s), 6.62 (1H, d, J= 8.0 Hz), 6.21 (1H, d, J= 6.0 Hz), 3.79 (2H, br), 2.31 (3H, s).
",1.0,54050,EP3323817A1,0
2633,2633,"Step 2: 1-(2-chloropyrimidin-4-yl)-5-methyl-1H-benzo[d]imidazol-2(3H)-one
",2.0,54124,EP3323817A1,0
2634,2634,"<img> id-imgb0060.tif </img>
",1.0,54153,EP3323817A1,0
2635,2635,"The title compound was prepared from N1-(2-chloropyrimidin-4-yl)-4 -methylbenzene-1,2-diamine and carbonyldiimidazole by a method similar to that described in Step 2 of Example 1.1H NMR (CDCl3): δ 8.62 (1H, d, J= 5.6 Hz), 8.47 (1H, d, J = 5.6 Hz), 8.34 (1H, d, J = 8.4 Hz), 7.97 (1H, s), 7.03 (1H, d, J= 8.4 Hz), 6.91 (1H, s), 2.42 (3H, s).
",1.0,54494,EP3323817A1,0
2636,2636,"Step 3: 1-(2-(4-fluoro-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-5-methyl-1H -benzo[d]imidazol-2(3H)-one p-toluenesulfonate
",2.0,54621,EP3323817A1,0
2637,2637,"<img> id-imgb0061.tif </img>
",1.0,54650,EP3323817A1,0
2638,2638,"The title compound was prepared from 1-(2-chloropyrimidin-4-yl)-5-methyl-1H -benzo[d]imidazol-2(3H)-one and 4-fluoro-2-methoxy-5-nitroaniline by a method similar to that described in Step 4 of Example 1.1H NMR (DMSO-d6): δ 11.39 (1H, s), 9.04 (1H, s), 8.61 (1H, d, J= 8.4 Hz), 8.49 (1H, d, J = 5.6 Hz), 8.04-8.02 (1H, m), 7.82 (1H, d, J= 5.6 Hz), 7.49-7.41 (3H, m), 7.11 (2H, d, J= 8.0 Hz), 6.93 (1H, s), 6.87 (1H, s), 6.76-6.74 (1H, m), 3.97 (3H, s), 2.33 (3H, s), 2.29 (3H, s).
",1.0,55130,EP3323817A1,0
2639,2639,"Step 4: 1-(2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-5-methyl-1H-benzo[d]imidazol-2(3H)-one
",2.0,55271,EP3323817A1,0
2640,2640,"<img> id-imgb0062.tif </img>
",1.0,55300,EP3323817A1,0
2641,2641,"The title compound was prepared from 1-(2-(4-fluoro-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-5-methyl-1H-benzo[d]imidazol-2(3H)-one p-toluenesulfonate and diisopropylethylamine by a method similar to that described in Step 5 of Example 1.1H NMR (CDCl3): δ 8.92 (1H, s), 8.50 (1H, d, J= 5.6 Hz), 8.30 (1H, br), 8.11 (1H, d, J= 8.0 Hz), 7.78 (1H, d, J= 5.6 Hz), 7.45 (1H, s), 6.94 (1H, d, J= 8.0 Hz), 6.89 (1H, s), 6.70 (1H, s), 3.98 (3H, s), 3.31 (2H, t, J= 6.8 Hz), 2.88 (3H, s), 2.61 (2H, t, J= 6.8 Hz), 2.40 (3H, s), 2.31 (6H, s).
",1.0,55838,EP3323817A1,0
2642,2642,"Step 5: N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-(4-(5-methyl-2-oxo-2,3-dihydrobenzo[d]imidazol-1-yl)pyrimidin-2-ylamino)phenyl)acrylamide hydrochloride
",2.0,56007,EP3323817A1,0
2643,2643,"<img> id-imgb0063.tif </img>
",1.0,56036,EP3323817A1,0
2644,2644,"The title compound was prepared from 1-(2-(4-((2-(dimethylamino)ethyl)(methyl) amino)-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-5-methyl-1H-benzo[d]imidazol-2(3H) -one by a method similar to those described in Steps 6 and 7 of Example 1.1H NMR (MeOD): δ 8.32 (1H, d, J = 6.0 Hz), 7.91 (1H, d, J= 8.0 Hz), 7.61 (1H, d, J = 5.6 Hz), 6.87-6.84 (2H, m), 6.78 (1H, s), 6.70 (1H, d, J =8.0 Hz), 6.40-6.26 (2H, m), 5.73-5.70 (1H, m), 3.86 (3H, s), 3.26 (2H, br), 2.93 (2H, br), 2.61 (3H, s), 2.59 (6H, s), 2.22 (3H, s).
",1.0,56552,EP3323817A1,0
2647,2647,"Step 1: N1-(2-dichloropyrimidin-4-yl)-4-fluorobenzene-1,2-diamine
",2.0,56831,EP3323817A1,0
2648,2648,"<img> id-imgb0065.tif </img>
",1.0,56860,EP3323817A1,0
2649,2649,"The title compound was prepared from 2,4-dichloropyrimidine and 4-fluorobenzene-1,2-diamine by a method similar to that described in Step 1 of Example 1.1H NMR (CDCl3): δ 8.06 (1H, d, J = 6.0 Hz), 7.06-7.03 (1H, m), 6.71 (1H, s), 6.52-6.44 (2H, m), 6.14 (1H, d, J= 6.0 Hz), 3.94 (2H, br).
",1.0,57149,EP3323817A1,0
2650,2650,"Step 2: 1-(2-chloropyrimidin-4-yl)-5-fluoro-1H-benzo[d]imidazol-2(3H)-one
",2.0,57223,EP3323817A1,0
2651,2651,"<img> id-imgb0066.tif </img>
",1.0,57252,EP3323817A1,0
2652,2652,"The title compound was prepared from N1-(2-dichloropyrimidin-4-yl) -4-fluorobenzene-1,2-diamine and carbonyldiimidazole by a method similar to that described in Step 2 of Example 1.1H NMR (DMSO-d6): δ 11.81 (1H, s), 8.77 (1H, d, J = 6.0 Hz), 8.40 (1H, d, J = 6.0 Hz), 8.24-8.21 (1H, m), 7.03-6.96 (2H, m).
",1.0,57558,EP3323817A1,0
2653,2653,"Step 3: 1-(2-chloropyrimidin-4-yl)-5-fluoro-3-methyl-1H-benzo[d]imidazol-2(3H)-one
",2.0,57641,EP3323817A1,0
2654,2654,"<img> id-imgb0067.tif </img>
",1.0,57670,EP3323817A1,0
2655,2655,"The title compound was prepared from 1-(2-chloropyrimidin-4-yl)-5-fluoro-1H -benzol[d]imidazol-2(3H)-one by a method similar to that described in Step 3 of Example 1.1H NMR (DMSO-d6): δ 8.77 (1H, d, J= 5.6 Hz), 8.38 (1H, d, J = 5.6 Hz), 8.23-8.19 (1H, m), 7.29 (1H, d, J= 8.8 Hz), 7.04-7.00 (1H, m), 3.36 (3H, s).
",1.0,57984,EP3323817A1,0
2656,2656,"Step 4: 5-fluoro-1-(2-(4-fluoro-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-3 -methyl-1H-benzo[d]imidazol-2(3H)-one p-toluenesulfonate
",2.0,58120,EP3323817A1,0
2657,2657,"<img> id-imgb0068.tif </img>
",1.0,58149,EP3323817A1,0
2658,2658,"The title compound was prepared from 1-(2-chloropyrimidin-4-yl)-5-fluoro-3-methyl -1H-benzo[d]imidazol-2(3H)-one and 4-fluoro-2-methoxy-5-nitroaniline by a method similar to that described in Step 4 of Example 1, and was directly used in the next reaction step.
",1.0,58411,EP3323817A1,0
2659,2659,"Step 5: 1-(2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-5-fluoro-3-methyl-1H-benzo[d]imidazol-2(3H)-one
",2.0,58561,EP3323817A1,0
2660,2660,"<img> id-imgb0069.tif </img>
",1.0,58590,EP3323817A1,0
2661,2661,"The title compound was prepared from 5-fluoro-1-(2-(4-fluoro-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one p-toluenesulfonate by a method similar to that described in Step 5 of Example 1.1H NMR (CDCl3): δ 8.86 (1H, s), 8.50 (1H, d, J= 5.6 Hz), 8.24-8.21 (1H, m), 7.81 (1H, d, J = 5.6 Hz), 7.42 (1H, s), 6.86-6.81 (1H, m), 6.76 (1H, dd, J = 2.8 Hz, 8.0 Hz), 6.69 (1H, s), 3.98 (3H, s), 3.44 (3 H, s), 3.29 (2H, t, J= 7.2 Hz), 2.89 (3H, s), 2.57 (2H, t, J= 7.2 Hz), 2.27 (6H, s).
",1.0,59107,EP3323817A1,0
2662,2662,"Step 6: N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-(4-(5-fluoro-3 -methyl-2-oxo-2,3 -dihydrobenzo [d]imidazol-1-yl)pyrimidin-2-ylamino)-4-methoxyphenyl) acrylamide hydrochloride
",2.0,59289,EP3323817A1,0
2663,2663,"<img> id-imgb0070.tif </img>
",1.0,59318,EP3323817A1,0
2664,2664,"The title compound was prepared from 1-(2-(4-((2-(dimethylamino)ethyl)(methyl) amino)-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-5-fluoro-3-methyl-1H-benzo[d] imidazol-2(3H)-one by a method similar to those described in Steps 6 and 7 of Example 1.1H NMR (DMSO-d6): δ 10.26 (1H, s), 9.78 (1H, s), 8.74 (1H, s), 8.43 (1H, d, J = 6.0 Hz), 8.17 (2H, s), 7.70 (1H, d, J= 6.0 Hz), 7.22 (1H, dd, J= 2.4 Hz, 8.8 Hz), 7.06-6.99 (1H, m), 6.97 (1H, s), 6.79-6.75 (1H, m), 6.21 (1H, dd, J= 2.0 Hz, 16.8 Hz), 5.71-5.68 (1H, m), 3.80 (3H, s), 3.63-3.57 (2H, m), 3.34 (3H, s), 3.16-3.09 (2H, m), 2.75 (6H, s), 2.63 (3H, s).
",1.0,59929,EP3323817A1,0
2667,2667,"Step 1: 5-fluoro-1-(2-(4-fluoro-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-1H -benzo[d]imidazol-2(3H)-one p-toluenesulfonate
",2.0,60259,EP3323817A1,0
2668,2668,"<img> id-imgb0072.tif </img>
",1.0,60288,EP3323817A1,0
2669,2669,"The title compound was prepared from 1-(2-chloropyrimidin-4-yl)-5-fluoro-1H -benzo[d]imidazol-2(3H)-one and 4-fluoro-2-methoxy-5-nitroaniline by a method similar to that described in Step 4 of Example 1.1H NMR (DMSO-d6): δ 11.68 (1H, s), 9.24 (1H, s), 8.64 (1H, d, J = 8.0 Hz), 8.51 (1H, d, J= 6.0 Hz), 8.23 (1H, br), 7.83 (1H, d, J= 6.0 Hz), 7.48 (2H, d, J= 8.0 Hz), 7.43 (1H, d, J = 8.0 Hz), 7.12 (2H, d, J = 8.0 Hz), 6.94-6.91 (1H, m), 6.80-6.75 (1H, m), 3.98 (3H, s), 2.29 (3H, s).
",1.0,60774,EP3323817A1,0
2670,2670,"Step 2: 1-(2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-5-fluoro-1H-benzo[d]imidazol-2(3H)-one
",2.0,60915,EP3323817A1,0
2671,2671,"<img> id-imgb0073.tif </img>
",1.0,60944,EP3323817A1,0
2672,2672,"The title compound was prepared from 5-fluoro-1-(2-(4-fluoro-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one p-toluenesulfonate by a method similar to that described in Step 5 of Example 1.1H NMR (DMSO-d6): δ 8.83 (1H, s), 8.47 (1H, d, J= 5.6 Hz), 8.26 (1H, s), 8.23-8.17 (1H, m), 7.77-7.68 (2H, m), 6.99-6.94 (2H, m), 6.77-6.72 (1H, m), 3.99 (3H, s), 3.63 (2H, m), 3.19-3.15 (2H, m), 2.88 (3H, s), 2.66 (6H, s).
",1.0,61385,EP3323817A1,0
2673,2673,"Step 3: N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-5-(4-(5-fluoro-2-oxo -2,3-dihydrobenzo[d]imidazol-1-yl)pyrimidin-2-ylamino)-4-methoxyphenyl)acrylamide hydrochloride
",2.0,61555,EP3323817A1,0
2674,2674,"<img> id-imgb0074.tif </img>
",1.0,61584,EP3323817A1,0
2675,2675,"The title compound was prepared from 1-(2-(4-((2-(dimethylamino)ethyl)(methyl) amino)-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-5-fluoro-1H-benzo[d]imidazol-2(3H)-one by a method similar to those described in Steps 6 and 7 of Example 1.1H NMR (CD3OD): δ 8.45 (1H, dd, J= 2.4 Hz, 5.6 Hz), 8.17-8.12 (1H, m), 7.73-7.69 (2H, m), 7.22 (1H, d, J= 8.0 Hz), 6.95 (1H, d, J= 3.6 Hz), 6.88-6.83 (1H, m), 6.77-6.71 (1H, m), 6.44-6.42 (1H,m), 5.84-5.81 (1H, m), 3.97 (3H, s), 3.49-3.46 (2H, m), 3.23 (2H, m), 2.84 (6H, s), 2.71 (3H, s).
",1.0,62113,EP3323817A1,0
2678,2678,"Step 1: tert-butyl 2-((5-methoxy-4-(4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]imidazol -1-yl)pyrimidin-2-ylamino)-2-nitrophenyl)(methyl)amino)ethyl(methyl)carbamate
",2.0,62471,EP3323817A1,0
2679,2679,"<img> id-imgb0076.tif </img>
",1.0,62500,EP3323817A1,0
2680,2680,The title compound was prepared from 1-(2-(4-fluoro-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one p-toluenesulfonate and tert-butyl 2-(methylamino)ethylcarbamate by a method similar to that described in Step 5 of Example 1.,1.0,62762,EP3323817A1,0
2682,2682,"Step 2: tert-butyl 2-((2-acrylamido-5-methoxy-4-(4-(3-methyl-2-oxo-2,3-dihydrobenzo [d]imidazol-1-yl)pyrimidin-2-ylamino)phenyl)(methyl)amino)ethyl(methyl) carbamate
",2.0,63222,EP3323817A1,0
2683,2683,"<img> id-imgb0077.tif </img>
",1.0,63251,EP3323817A1,0
2684,2684,"The title compound was prepared from tert-butyl 2-((5-methoxy-4-(4-(3-methyl-2 -oxo-2,3-dihydrobenzo[d]imidazol-1-yl)pyrimidin-2-ylamino)-2-nitrophenyl)(methyl)amino) ethyl(methyl) carbamate by a method similar to those described in Steps 6 and 7 of Example 1.1H NMR (CDCl3): δ 9.37 (1H, br), 8.67 (1H, br), 8.54 (1H, d, J = 5.6 Hz), 8.34 (1H, d, J= 7.6 Hz), 7.79 (1H, d, J= 5.6 Hz), 7.43 (1H, s), 7.19-7.15 (1H, m), 7.08-7.04 (1H, m), 6.98 (1H, d, J= 7.6 Hz), 6.79 (1H, s), 6.35 (2H, d, J= 2.4 Hz), 5.69-5.72 (1H, m), 3.89 (3H, s), 3.45 (3H, s), 3.40-3.37 (2H, m), 3.00-2.85 (2H, m), 2.85 (3H, s), 2.70 (3H, s), 1.47 (9H, s).
",1.0,63878,EP3323817A1,0
2685,2685,"Step 3: N-(4-methoxy-2-(methyl(2-(methylamino)ethyl)amino)-5-(4-(3-methyl-2-oxo -2,3-dihydrobenzo[d]imidazol-1-yl)pyrimidin-2-ylamino)phenyl)acrylamide hydrochloride
",2.0,64044,EP3323817A1,0
2686,2686,"<img> id-imgb0078.tif </img>
",1.0,64073,EP3323817A1,0
2687,2687,"Acetyl chloride (0.3 mL, 1.7 mmol) was slowly added dropwise to anhydrous methanol (3 mL) cooled with an external ice-water bath and stirring was continued for 1 hour.",1.0,64240,EP3323817A1,0
2727,2727,"Step 1: 4-bromo-N1-(2-chloropyrimidin-4-yl)benzene-1,2-diamine
",2.0,71260,EP3323817A1,0
2728,2728,"<img> id-imgb0089.tif </img>
",1.0,71289,EP3323817A1,0
2729,2729,"The title compound was prepared from 2,4-dichloropyrimidine and 4-bromo-1,2-phenylenediamine by a method similar to that described in Step 1 of Example 1.1H NMR (DMSO-d6): δ 9.13 (1H, s), 8.05 (1H, d, J = 6.0 Hz), 7.01 (1H, d, J= 8.8 Hz), 6.94 (1H, d, J= 2.4 Hz), 6.69 (1H, dd, J= 2.0 Hz, 8.4 Hz), 6.38 (1H, s), 5.31 (2H, br s).
",1.0,71618,EP3323817A1,0
2730,2730,"Step 2: 5-bromo-1-(2-chloropyrimidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one
",2.0,71691,EP3323817A1,0
2731,2731,"<img> id-imgb0090.tif </img>
",1.0,71720,EP3323817A1,0
2732,2732,"The title compound was prepared from 4-bromo-N1-(2-chloropyrimidin-4-yl) benzene-1,2-diamine and N,N'-carbonyldiimidazole by a method similar to that described in Step 2 of Example 1.1H NMR (DMSO-d6): δ 11.81 (1H, br s), 8.79 (1H, d, J = 5.6 Hz), 8.40 (1H, d, J = 5.6 Hz), 8.17 (1H, d, J= 8.8 Hz), 7.37 (1H, dd, J= 2.0 Hz, 8.8 Hz), 7.26 (1H, d, J= 2.0 Hz).
",1.0,72077,EP3323817A1,0
2733,2733,"Step 3: 5-bromo-1-(2-chloropyrimidin-4-yl)-3-methyl-1H-benzo[d]imidazol -2(3H)-one
",2.0,72160,EP3323817A1,0
2734,2734,"<img> id-imgb0091.tif </img>
",1.0,72189,EP3323817A1,0
2735,2735,"The title compound was prepared from 5-bromo-1-(2-chloropyrimidin-4-yl)-1H -benzo[d]imidazol-2(3H)-one by a method similar to that described in Step 3 of Example 1.1H NMR (DMSO-d6): δ 8.81 (1H, d, J= 6.0 Hz), 8.42 (1H, d, J= 8.0 Hz), 8.19 (1H, d, J= 8.4 Hz), 7.60 (1H, d, J= 2.0 Hz), 7.41 (1H, dd, J= 2.0 Hz, 8.4 Hz), 3.40 (3H, s).
",1.0,72521,EP3323817A1,0
2736,2736,"Step 4: 5-bromo-1-(2-(4-fluoro-2-methoxy-5-nitrophenylamino)pyrimidin-4-yl)-3 -methyl-1H-benzo[d]imidazol-2(3H)-one
",2.0,72637,EP3323817A1,0
2737,2737,"<img> id-imgb0092.tif </img>
",1.0,72666,EP3323817A1,0
2738,2738,"The title compound was prepared from 5-bromo-1-(2-chloropyrimidin-4-yl)-3 -methyl-1H-benzo[d]imidazol-2(3H)-one and 4-fluoro-2-methoxy-5-nitroaniline by a method similar to that described in Step 4 of Example 1.1H NMR (DMSO-d6): 9.22 (1H, s), 8.61 (1H, d, J = 8.4 Hz), 8.54 (1H, d, J = 5.6 Hz), 8.17 (1H, d, J= 8.0 Hz), 7.82 (1H, d, J = 5.6 Hz), 7.53 (1H, d, J= 2.0 Hz), 7.43 (1H, d, J = 13.2 Hz), 7.44-7.41 (2H, m), 7.14 (1H, dd, J= 2.0 Hz, 13.2 Hz), 3.97 (3H, s), 3.37 (3H, s).
",1.0,73146,EP3323817A1,0
2739,2739,"Step 5: 5-bromo-1-(2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one
",2.0,73295,EP3323817A1,0
2740,2740,"<img> id-imgb0093.tif </img>
",1.0,73324,EP3323817A1,0
2741,2741,"The title compound was prepared from 5-bromo-1-(2-(4-fluoro-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one by a method similar to that described in Step 5 of Example 1.1H NMR (CDCl3): δ 8.85 (1H, s), 8.50 (1H, d, J = 5.6 Hz), 8.15 (1H, d, J= 8.4 Hz), 7.79 (1H, d, J= 6.0 Hz), 7.42 (1H, s), 7.24 (1H, dd, J= 2.0 Hz, 8.4 Hz), 7.15 (1H, d, J = 2.0 Hz), 6.69 (1H, s), 3.98 (3H, s), 3.44 (3H, s) 3.30 (2H, t, J= 6.8 Hz), 2.90 (3H, s), 2.58 (2H, t, J = 7.2 Hz), 2.28 (6H, s).
",1.0,73832,EP3323817A1,0
2742,2742,"Step 6: 1-(2-(5-amino-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)pyrimidin-4-yl)-5-bromo-3-methyl-1H-benzo[d]imidazol-2(3H)-one
",2.0,73980,EP3323817A1,0
2743,2743,"<img> id-imgb0094.tif </img>
",1.0,74009,EP3323817A1,0
2744,2744,"5-Bromo-1-(2-(4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxy-5 -nitrophenylamino)pyrimidin-4-yl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (1.00 g) and zinc powder (1.24 g, 18.97 mmol) were dispersed in a mixed solution of dichloromethane/methanol (15 mL/15 mL).",1.0,74273,EP3323817A1,0
2745,2745," 20 mL of saturated ammonium chloride solution was added dropwise at room temperature, and the resulting mixture was stirred for 10 minutes and then filtered.",1.0,74431,EP3323817A1,0
2746,2746, To the filtrate was added water (30 mL) and the resulting mixture was extracted with dichloromethane (30 mL*3).,1.0,74543,EP3323817A1,0
2747,2747," The resulting organic phase was washed with saturated brine and concentrated under vacuum to remove the solvent to give the title compound, which was directly used in the next reaction step.
",1.0,74735,EP3323817A1,0
2748,2748,"Step 7: N-(5-(4-(5-bromo-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazole -1-yl)pyrimidin-2-ylamino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl) acrylamide hydrochloride
",2.0,74919,EP3323817A1,0
2749,2749,"<img> id-imgb0095.tif </img>
",1.0,74948,EP3323817A1,0
2750,2750,"The title compound was prepared from 1-(2-(5-amino-4-((2-(dimethylamino)ethyl) (methyl)amino)-2-methoxyphenylamino)pyrimidin-4-yl)-5-bromo-3-methyl-1H-benzo[d] imidazol-2(3H)-one by a method similar to that described in Step 7 of Example 1.1H NMR (DMSO-d6): δ 10.23 (1H, br s), 9.82 (1H, br s), 8.75 (1H, s), 8.44 (1H, d, J = 5.2 Hz), 8.20 (1H, s), 8.05 (1H, s), 7.65 (1H, d, J = 5.2 Hz), 7.49 (1H, d, J = 2.0 Hz), 7.08 (1H, d, J = 8.4 Hz), 7.00-6.96 (2H, m), 6.21 (1H, dd, J = 2.0 Hz, 17.2 Hz), 5.71 (1H, dd, J = 1.6 Hz, 10.4 Hz), 3.80 (3H, s), 3.36 (3H, s), 3.29-3.24 (2H, m), 3.16 (3H, s), 2.76-3.68 (2H, m), 2.65 (6H, s).
",1.0,75574,EP3323817A1,0
3069,3069,"Example 2: 2,2-Difluoro-2-(4-(thiophen-3-yl)-3-(3-(3-trifluoromethyl)phenyl)ureido)phenyl)-N-(2,2,2-trifluoroethyl)acetamide
",2.0,67069,EP3330263A1,0
3070,3070,"<img> id-imgb0047.tif </img>
",1.0,67098,EP3330263A1,0
3071,3071,"2,2-Dichloro-2-(4-(thiophen-3-yl)-3-(3-(3-trifluoromethyl)phenyl)ureido)phenyl)-N-(2,2,2-trifluoroethyl)acetamide was prepared referring to the synthetic method in Example 1.",1.0,67272,EP3330263A1,0
3093,3093,"Example 8: 2,2-Difluoro-N-(2-hydroxy-2-methylpropyl)-2-(4-(thiophen-3-yl)-3-(3-(3-(trifluoromethyl) phenyl)ureido)phenyl)acetamide
",2.0,70302,EP3330263A1,0
3094,3094,"<img> id-imgb0053.tif </img>
",1.0,70331,EP3330263A1,0
3095,3095,2.2-Dichloro-N-(2-hydroxy-2-methylpropyl)-2-(4-(thiophen-3-yl)-3-(3-(3-(trifluoromethyl)phenyl)ureido) phenyl)acetamide was prepared referring to the synthetic method in Example 1.,1.0,70511,EP3330263A1,0
3097,3097,"Example 9: N-cyclopropyl-2,2-difluoro-2-(4-(thiophen-3-yl)-3-(3-(2-(trifluoromethyl)pyridine -4-yl)ureido)phenyl)acetamide
",2.0,70839,EP3330263A1,0
3098,3098,"<img> id-imgb0054.tif </img>
",1.0,70868,EP3330263A1,0
3099,3099,"N-cyclopropyl-2,2-dichloro-2-(4-(thiophen-3-yl)-3-(3-(2-(trifluoromethyl)pyridin-4-yl)ureido) phenyl)acetamide was prepared referring to the synthetic method in Example 1.",1.0,71039,EP3330263A1,0
3101,3101,"Example 10: N-cyclopropyl-2,2-difluoro-2-(3-(3-(4-fluoro-3-(trifluoromethyl)phenyl) ureido)-4-(thiophen-3-yl)phenyl)acetamide
",2.0,71371,EP3330263A1,0
3102,3102,"<img> id-imgb0055.tif </img>
",1.0,71400,EP3330263A1,0
3103,3103,"N-cyclopropyl-2,2-dichloro-2-(3-(3-(4-fluoro-3-(trifluoromethyl)phenyl)ureido)-4-(thiophen-3-yl) phenyl)acetamide was prepared referring to the synthetic method in Example 1.",1.0,71574,EP3330263A1,0
3105,3105,"Example 11: N-cyclopropyl-2,2-difluoro-2-(3-(3-(3-(trifluoromethyl)phenyl)ureido)-4-(6-(trifluoromethyl)pyridin-2-yl)phenyl)acetamide
",2.0,71922,EP3330263A1,0
3106,3106,"<img> id-imgb0056.tif </img>
",1.0,71951,EP3330263A1,0
3107,3107,"N-cyclopropyl-2,2-dichloro-2-(3-(3-(3-(trifluoromethyl)phenyl)ureido)-4-(6-(trifluoromethy 1) pyridin-2-yl)phenyl)acetamide was prepared referring to the synthetic method in Example 1.",1.0,72135,EP3330263A1,0
3109,3109,"Example 12: N-cyclopropyl-2,2-difluoro-2-(2-(3-(3-(trifluoromethyl)phenyl)ureido)-[1,1'-biphenyl]-4-yl)acetamide
",2.0,72569,EP3330263A1,0
3110,3110,"<img> id-imgb0057.tif </img>
",1.0,72598,EP3330263A1,0
3111,3111,"N-cyclopropyl-2,2-dichloro-2-(2-(3-(3-(trifluoromethyl)phenyl)ureido)-[1,1 '-biphenyl]-4-yl) acetamide was prepared referring to the synthetic method in Example 1.",1.0,72761,EP3330263A1,0
3113,3113,"Example 13: N-cyclopropyl-2-(4-(1,3-dimethyl-1H-pyrazol-5-yl)-3-(3-(3-(trifluoromethyl) phenyl)ureido)phenyl)-2,2-difluoroacetamide
",2.0,73072,EP3330263A1,0
3114,3114,"<img> id-imgb0058.tif </img>
",1.0,73101,EP3330263A1,0
3115,3115,"N-cyclopropyl-2-(4-(1,3-dimethyl-1H-pyrazol-5-yl)-3-(3-(3-(trifluoromethyl)phenyl)ureido) phenyl)-2,2-difluoroacetamide was prepared referring to the synthetic method in Example 1.",1.0,73281,EP3330263A1,0
3160,3160,"Example 17: N-cyclopropyl-1-(4-(thiophen-3-yl)-3-(3-(3-(trifluoromethyl)phenyl)ureido)phenyl) cyclopropanecarboxamide
",2.0,79326,EP3330263A1,0
3161,3161,"<img> id-imgb0063.tif </img>
",1.0,79355,EP3330263A1,0
3162,3162,N-cyclopropyl-1-(4-(thiophen-3-yl)-3-(3-(3-(trifluoromethyl)phenyl)ureido)phenyl) cyclopropanecarboxamide was prepared referring to the synthetic method in Example 14.,1.0,79522,EP3330263A1,0
3164,3164,"Example 18: N-cyclopropyl-2-methyl-(3-(3-(3-oxoisoindol-5-yl)ureido)-4-(thiophen-3-yl)phenyl) propanamide
",2.0,79935,EP3330263A1,0
3165,3165,"<img> id-imgb0064.tif </img>
",1.0,79964,EP3330263A1,0
3166,3166,N-cyclopropyl-2-methyl-(3-(3-(3-oxoisoindol-5-yl)ureido)-4-(thiophen-3-yl)phenyl)propanamide was prepared referring to the synthetic method in Example 14.,1.0,80118,EP3330263A1,0
3168,3168,"Example 19: N-cyclopropyl-1-(4-(thiophen-3-yl)-3-(3-(3-(trifluoromethyl)phenyl)ureido)phenyl) cyclobutanecarboxamide
",2.0,80533,EP3330263A1,0
3169,3169,"<img> id-imgb0065.tif </img>
",1.0,80562,EP3330263A1,0
3170,3170,N-cyclopropyl-1-(4-(thiophen-3-yl)-3-(3-(3-(trifluoromethyl)phenyl)ureido)phenyl) cyclobutanecarboxamide was prepared referring to the synthetic method in Example 14.,1.0,80728,EP3330263A1,0
3326,3326,"Example 28: N-(4-(thiophen-3-yl)-3-(3-(3-(trifluoromethyl)phenyl)ureido)benzyl) cyclopropanecarboxamide
",2.0,102578,EP3330263A1,0
3327,3327,"<img> id-imgb0078.tif </img>
",1.0,102607,EP3330263A1,0
3328,3328,N-(4-(thiophen-3-yl)-3-(3-(3-(trifluoromethyl)phenyl)ureido)benzyl)cyclopropanecarboxami de was prepared referring to the synthetic method in Example 27.,1.0,102760,EP3330263A1,0
3330,3330,"Example 29: N-(4-(thiophen-3-yl)-3-(3-(3-(trifluoromethyl)phenyl)ureido)benzyl) cyclopropylsulfonamide
",2.0,103188,EP3330263A1,0
3331,3331,"<img> id-imgb0079.tif </img>
",1.0,103217,EP3330263A1,0
3332,3332,N-(4-(thiophen-3-yl)-3-(3-(3-(trifluoromethyl)phenyl)ureido)benzyl)cyclopropylsulfonamid e was prepared referring to the synthetic method in Example 27.,1.0,103369,EP3330263A1,0
3549,3549,"1H NMR (400 MHz, CDCl3): a (ppm) = 9.66 (br s, 1H), 9.17 (br s, 1H), 9.00 (br s, 2H), 7.73-7.85 (m, 15H), 3.74-3.79 (m, 2H), 3.63-3.67 (m, 2H), 3.38 (br s, 2H), 2.96 (br s, 2H), 2.49 (br s, 1H), 2.28 (br s, 2H), 2.06 (br s, 2H).
",1.0,26977,EP3674305A1,0
3550,3550,"The above compound, cyanoacetic acid (21 mg, 0.25 mmol), oxyma (35 mg, 0.25 mmol), DIEA (0.15 mL, 0.83 mmol) and EDCI (47 mg, 0.25 mmol) were dissolved in 1 mL of DMF, and the solution was stirred at room temperature for 14 hours.",1.0,27207,EP3674305A1,2
3552,3552,"10-oxo-2,3,5,6-tetrahydro-1H,4H,10H-11-oxa-3a-azabenzo
",0.0,27858,EP3674305A1,2
3553,3553,"[de]anthracene-9-carbaldehyde (36 mg, 0.13 mmol), compound 3 (70 mg, 0.13 mmol) and piperidine (13 µL, 0.13 mmol) were dissolved in 1 mL of 2-propanol, and the solution was heated at 60°C for 1 hour, and then cooled to room temperature.",0.0,28094,EP3674305A1,1
3554,3554," The solvent was removed by distillation under reduced pressure, and the remaining mixture was purified by SiO2 column chromatography (MeOH/CH2Cl2 5/95) to obtain the compound (MitoFreSH-PPh3) as a red solid (36 mg, 36%).
",0.0,28316,EP3674305A1,1
3556,3556,1-2.,0.0,28630,EP3674305A1,2
3557,3557," Synthesis of MitoFreSH-Piperazine (Formula IV)
",0.0,28678,EP3674305A1,1
3558,3558,"<img> id-EP3674305A1_00026.PNG </img>
",0.0,28716,EP3674305A1,1
3559,3559,"Compound 4
",0.0,28727,EP3674305A1,2
3560,3560,"<img> id-EP3674305A1_00027.PNG </img>
",0.0,28765,EP3674305A1,1
3561,3561,"Tert-butyl piperazine-1-carboxylate (1.0 g, 5.3 mmol) and cyanoacetic acid (0.54 g, 1.2 eq.)",0.0,28857,EP3674305A1,1
3562,3562," were dissolved in 10 mL of DMF, and DIEA (3.28 mL, 3.5 eq.)",0.0,28917,EP3674305A1,1
3563,3563," and EDCI (1.56 g, 1.5 eq.)",0.0,28944,EP3674305A1,1
3564,3564, were added to the solution.,0.0,28972,EP3674305A1,1
3565,3565," After stirring at room temperature for 12 hours, the solvent was removed by distillation under reduced pressure.",0.0,29085,EP3674305A1,1
3566,3566," The remaining mixture was purified by SiO2 column chromatography to obtain compound 4 as a white solid (1.13 g, 84%).1H NMR (400 MHz, CDCl3): a (ppm) = 3.603.64 (m, 2H), 3.503.55 (m, 2H), 3.51 (s, 2H), 3.433.48 (m, 4H), 1.47 (s, 9H); HRMS (m/z): [M+H]+ 254.1496.
",0.0,29349,EP3674305A1,1
3567,3567,"Compound 5
",0.0,29360,EP3674305A1,2
3568,3568,"<img> id-EP3674305A1_00028.PNG </img>
",0.0,29398,EP3674305A1,1
3569,3569,"Compound 4 (0.30 g, 1.2 mmol) was dissolved in 5 mL of a 4 M solution of HCl/dioxane, and then stirred at room temperature for 1 hour.",0.0,29532,EP3674305A1,1
3570,3570," The solvent was removed by distillation under reduced pressure, and the remaining compound 5 was used in the next reaction without purification.1H NMR (400 MHz, DMSO-d6): a (ppm) = 9.54 (br s, 2H), 4.12 (s, 2H), 3.673.70 (m, 2H), 3.583.61 (m, 2H), 3.043.12 (m, 4H).
",0.0,29799,EP3674305A1,1
3571,3571,"Compound 6
",0.0,29810,EP3674305A1,2
3572,3572,"<img> id-EP3674305A1_00029.PNG </img>
",0.0,29848,EP3674305A1,1
3573,3573,"Compound 5 (0.15 mmol) and (4-bromobutyl)triphenylphosphonium bromide (0.15 g, 0.30 mmol) were dissolved in 1 mL of acetonitrile (CH3CN), and sodium hydrogen carbonate (NaHCO3, 64 mg, 0.7545 mmol) was added to the solution.",0.0,30071,EP3674305A1,1
3574,3574," After stirring at 50°C for 20 hours, the solvent was removed by distillation under reduced pressure.",0.0,30172,EP3674305A1,1
3575,3575," The remaining mixture was purified by SiO2 column chromatography (MeOH/CH2Cl2 15/85) to obtain compound 6 as a white solid (71 mg, 71%).1H NMR (400 MHz, CDCl3): a (ppm) = 7.69-7.88 (m, 15H), 3.78-3.86 (m, 2H), 3.71 (s, 2H), 3.51-3.53 (t, J = 4.7 Hz, 2H), 3.47-3.49 (t, J = 4.7 Hz, 2H), 2.54- 2.56 (t, J = 4.1 Hz, 2H), 2.46-2.49 (t, J = 6.5 Hz, 2H), 2.38-2.40 (t, J = 5.1 Hz, 2H), 1.85-1.91 (m, 2H), 1.66-1.74 (m, 2H).
",0.0,30591,EP3674305A1,1
3576,3576,"MitoFreSH-Piperazine (Formula IV)
",0.0,30625,EP3674305A1,2
3577,3577,"<img> id-EP3674305A1_00030.PNG </img>
",0.0,30663,EP3674305A1,1
3578,3578,"10-oxo-2,3,5,6-tetrahydro-1H,4H,10H-11-oxa-3a-azabenzo[de]anthracetie-9-carbaldehyde (35 mg, 0.13 mmol), compound 6 (64 mg, 0.12 mmol) and piperidine (12 µL, 0.12 mmol) were dissolved in 1 mL of 2-propanol, and the solution was stirred at 60°C for 1 hour, and then cooled to room temperature.",0.0,30955,EP3674305A1,1
3579,3579," The solvent was removed by distillation under reduced pressure, and the remaining mixture was purified by SiO2 column chromatography (MeOH/CH2Cl2 6/94) to obtain the compound MitoFreSH-Piperazine as a red solid (61 mg, 66%).1H NMR (400 MHz, CDCl3): a (ppm) = 8.61 (s, 1H), 7.69-7.91 (m, 15H), 7.45 (s, 1H), 7.00 (s, 1H), 6.86 (s, 1H), 3.56 (br s, 4H), 3.35-3.39 (q, J = 5.9 Hz, 4H), 2.84-2.88 (t, J = 6.5 Hz, 2H), 2.75-2.78 (t, J = 6.3 Hz, 2H), 2.41-2.49 (m, 4H), 1.84-2.04 (m, 12H).
",0.0,31440,EP3674305A1,1
3584,3584,"5-benzyl N-(tert-butoxycarbonyl)-L-glutamate (0.10 g, 0.29 mmol), 1-hydroxybenzotriazole (HOBt, 80 mg, 2.0 eq.)",0.0,31643,EP3674305A1,1
3585,3585," and DIEA (0.18 mL, 3.5 eq.)",0.0,31671,EP3674305A1,1
3586,3586," were dissolved in 1 mL of DMF, and EDCI (0.11 g, 2.0 eq.)",0.0,31729,EP3674305A1,1
3587,3587," and compound 1 (0.13 g, 1.2 eq.)",0.0,31762,EP3674305A1,1
3588,3588, were added to the solution.,0.0,31790,EP3674305A1,1
3589,3589," After stirring at room temperature for 16 hours, the solution was diluted with ethyl acetate (EtOAc), and then washed with a 0.5 M aqueous solution of citric acid, a saturated aqueous solution of sodium hydrogen carbonate (NaHCO3) and a saturated aqueous solution of sodium chloride (NaCl).",0.0,32081,EP3674305A1,1
3590,3590," The organic layer was separated, dried with sodium sulfate (Na2SO4), and then filtered, and the filtrate was distilled under reduced pressure to remove the solvent.",0.0,32246,EP3674305A1,1
3591,3591," The remaining mixture was purified by SiO2 column chromatography to obtain compound 4 as a white solid (0.16 g, 76%).",0.0,32364,EP3674305A1,1
3593,3593,"Compound 8
",0.0,32914,EP3674305A1,2
3594,3594,"Compound 7 (1.2 g, 1.7 mmol) was dissolved in 5 mL of methanol (CH3OH) and 5 mL of distilled water, and 10% Pd-C (0.12 g) was added to the solution, followed by stirring in a reactor under an atmosphere of H2 gas (1 atm) for 12 hours.",0.0,33148,EP3674305A1,1
3595,3595," The solution was filtered through celite, and the filtrate was distilled under reduced pressure to remove the solvent.",0.0,33267,EP3674305A1,1
3596,3596," The remaining compound 8 (1.04 g, 99%) was used in the next reaction without purification.",0.0,33358,EP3674305A1,1
3598,3598,"Compound 9
",0.0,33581,EP3674305A1,2
3599,3599,"Compound 8 (0.15 g, 0.24 mmol), compound 5 (49 mg, 1.05 eq.)",0.0,33641,EP3674305A1,1
3600,3600," and DIEA (0.15 mL, 3.5 eq.)",0.0,33669,EP3674305A1,1
3601,3601," were dissolved in 2 mL of DMF, and HOBt (3 mg, 0.1 eq.)",0.0,33725,EP3674305A1,1
3602,3602," and EDCI (95 mg, 2.0 eq.)",0.0,33751,EP3674305A1,1
3603,3603, were added to the solution.,0.0,33779,EP3674305A1,1
3604,3604," After stirring at room temperature for 4 hours, the solvent was removed by distillation under reduced pressure, and the remaining mixture was purified by SiO2 column chromatography to obtain compound 9 as a yellow solid (0.14 g, 78%).",0.0,34014,EP3674305A1,1
3607,3607,"Compound 10
",0.0,34651,EP3674305A1,2
3608,3608,"Compound 9 (0.23 g, 0.31 mmol) was dissolved in 3 mL of a 4 M solution of HCl/dioxane, and then stirred at room temperature for 1 hour.",0.0,34786,EP3674305A1,1
3609,3609," The solvent was removed by distillation under reduced pressure, and the remaining compound 10 was used in the next reaction without purification.",0.0,34932,EP3674305A1,1
3611,3611,"Compound 11
",0.0,35170,EP3674305A1,2
3612,3612,"Compound 10 (0.10 g, 0.15 mmol) and 3-(chloromethyl)benzoyl chloride (25 µL, 1.05 eq.)",0.0,35256,EP3674305A1,1
3613,3613," were dissolved in 1 mL of CH2Cl2, and DIEA (58 µL, 2.0 eq.)",0.0,35316,EP3674305A1,1
3614,3614, was added to the solution.,0.0,35343,EP3674305A1,1
3615,3615," After stirring at room temperature for 1 hour, the solvent was removed by distillation under reduced pressure, and the remaining mixture was purified by SiO2 column chromatography to obtain compound 11 as a white solid (0.10 g, 85%).",0.0,35577,EP3674305A1,1
3617,3617,"MitoFreSH-Cl (Formula V)
",0.0,36356,EP3674305A1,2
3618,3618,"Compound 11 (0.12 g, 0.16 mmol) and 10-oxo-2,3,5,6-tetrahydro-1H,4H,10H-11-oxa-3a-azabenzo[de]-anthracene-9-carbaldehyde (46 mg, 1.1 eq.)",0.0,36493,EP3674305A1,1
3619,3619," were dissolved in 1 mL of DMF, and chlorotrimethylsilane (60 µL, 3.0 eq.)",0.0,36567,EP3674305A1,1
3620,3620," was added to the solution, followed by stirring at 130°C for 5 hours.",0.0,36637,EP3674305A1,1
3621,3621," After cooling to room temperature, the solvent was removed by distillation under reduced pressure, and the remaining mixture was purified by SiO2 column chromatography to obtain the compound MitoFreSH-Cl as a red solid (79 mg, 50%).",0.0,36870,EP3674305A1,1
3643,3643,"Compound 1, cyanoacetic acid (1.2 eq.",0.0,38601,EP3674305A1,2
3644,3644,"), 1-hydroxybenzotriazol (HOBt; 1.5 eq.",0.0,38640,EP3674305A1,1
3645,3645,"), N,N-diisopropylethylamine (DIEA; 2.0 eq.)",0.0,38684,EP3674305A1,1
3646,3646, and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDCI; 2.5 eq.),0.0,38751,EP3674305A1,1
3647,3647," were dissolved in N,N-dimethylformamide (DMF), and the solution was stirred at room temperature for 15 to 20 hours.",0.0,38867,EP3674305A1,1
3648,3648," The solvent was removed by distillation under reduced pressure, and the remaining mixture was diluted with ethyl acetate (EtOAc) and then washed with a saturated aqueous solution of sodium chloride (NaCl).",0.0,39073,EP3674305A1,1
3649,3649," The organic layer was separated, dried with sodium sulfate (Na2SO4), and then filtered, and the filtrate was distilled under reduced pressure to remove the solvent.",0.0,39238,EP3674305A1,1
3650,3650," The remaining mixture was purified by SiO2 column chromatography to obtain compound 2.
",0.0,39326,EP3674305A1,1
3654,3654,"Compound 3
",0.0,39903,EP3674305A1,2
3655,3655,"<img> id-EP3674305A1_00037.PNG </img>
",0.0,39941,EP3674305A1,1
3656,3656,"10-oxo-2,3,5,6-tetrahydro-1H,4H,10H-11-oxa-3a-azabenzo[de]anthracene-9-carbaldehyde, compound 2 (1.0 eq.)",0.0,40046,EP3674305A1,1
3657,3657, and piperidine (1.0 eq.),0.0,40071,EP3674305A1,1
3658,3658," were dissolved in 2-propanol, and the solution was heated at 60°C for 2 to 4 hours, and then cooled to room temperature.",0.0,40192,EP3674305A1,1
3659,3659," The solvent was removed by distillation under reduced pressure, and the remaining mixture was purified by SiO2 column chromatography to obtain compound 3.
",0.0,40348,EP3674305A1,1
3663,3663,"GogiFreSH
",0.0,41231,EP3674305A1,2
3664,3664,"<img> id-EP3674305A1_00038.PNG </img>
",0.0,41269,EP3674305A1,1
3665,3665,"Compound 3 was dissolved in a solution of trifluoroacetic acid (TFA)/dichloromethane (1/1), and then stirred at room temperature for 1 to 2 hours.",0.0,41415,EP3674305A1,1
3666,3666," The solvent was removed by distillation under reduced pressure, and the remaining compound, indomethacin (1.1 eq.",0.0,41529,EP3674305A1,1
3667,3667,"), HOBt (2.5 eq.",0.0,41545,EP3674305A1,1
3668,3668,"), DIEA (3.0 eq.)",0.0,41562,EP3674305A1,1
3669,3669, and EDCI (2.5 eq.),0.0,41581,EP3674305A1,1
3670,3670," were dissolved in DMF, and the solution was stirred at room temperature for 7 to 8 hours.",0.0,41671,EP3674305A1,1
3671,3671," The solvent was removed by distillation under reduced pressure, and the remaining mixture was diluted with EtOAc, and then washed with a saturated aqueous solution ofNaCl.",0.0,41843,EP3674305A1,1
3672,3672," The organic layer was separated, dried with Na2SO4, and then filtered, and the filtrate was distilled under reduced pressure to remove the solvent.",0.0,41991,EP3674305A1,1
3673,3673," The remaining mixture was purified by SiO2 column chromatography to obtain GolgiFreSH.
",0.0,42079,EP3674305A1,1
3838,3838,"Then, ethyl acetoacetate (Compound 4) in which the alpha position is substituted is synthesized by allowing Compound 3 to react with tributyltinhydride (n-Bu3SnH) in a toluene solvent.",0.0,22269,EP3708563A1,2
3839,3839," Then, an oxime (Compound 5) is synthesized by adding butyl nitrite (n-BuONO) to Compound 4 in the presence of an ethanolic ethoxide base.",0.0,22407,EP3708563A1,1
3895,3895," Then, 1.804 g of Compound 8 was synthesized by a condensation reaction of 1.618 g of Compound 7 with 987.6 mg of N-hydroxysuccinimide in 32 mL of a dioxane solvent (1,4-dioxane) using 1.472 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide for 21.5 hours.",1.0,33691,EP3708563A1,2
3897,3897," Thereafter, compounds were also synthesized in Examples 2 to 14 in the same manner as described above.
",1.0,34279,EP3708563A1,0
3898,3898,"Further, in the present Examples 1 to 28, a selenopsammaplin A monomer derivative as illustrated in FIG.",2.0,34383,EP3708563A1,0
3899,3899," 1B is prepared, and the compounds in Examples 1 to 28 are prepared according to the above-described Reaction Scheme 1 (FIG.",1.0,34507,EP3708563A1,0
3903,3903,"Nuclear magnetic resonance spectra (1H and 13C NMR) were recorded on a 800-MHz Bruker Avance III HD spectrometer with a 5-mm triple resonance inverse (TCI) CryoProbe spectrometer using DMSO-d6, CD3OD and CDCl3 solutions, and chemical transfer is described in units of parts per million (ppm).",0.0,35417,EP3708563A1,1
3936,3936,"According to the method of Reaction Scheme 1, SSM-8 was obtained using 3,5-difluorobenzaldehyde as a starting material.",1.0,38895,EP3708563A1,2
3939,3939," Preparation of (2E,2'E)-N,N'-(diselanediylbis(ethane-2,1-diyl))bis(3-(3,4-dichlorophenyl)-2-(hydroxyimino)propanamide) (SSM-9)
",1.0,39203,EP3708563A1,2
4293,4293,Melting points were determined with a Barnested electrothermal melting point apparatus and are uncorrected.,0.0,30408,US10654800B1,1
4294,4294," The chemicals, reagents and solvents were purchased from Aldrich chemical company and other international companies through Bayouni trading companies in Saudi Arabia.
",0.0,30576,US10654800B1,1
4296,4296,N.B.,0.0,30606,US10654800B1,2
4297,4297," All compounds were confirmed with LC/MS and showed excellent purities (over 95%) 1H NMR of GLP-1: DMSO-d6, δ 1.43 (brs, 2H, CH2), 1.46 (brs, 6H, 2CH2, 2 CH), 1.50-1.51 (brs, 4H, 2CH2), 2.13 (brs, 2H, CH2), 2.33 (br, 1H, NH—CH2), 3.24 (brs, 2H, CH2), 4.45 (brs, 1H, OH), 7.04-7.07 (t, 1H, Arom-H), 7.29-7.33 (t, 2H, Arom-H) 7.60-7.63 (d, 2H, Arom-H), 9.88 (brs, 1H, NH).
",0.0,30977,US10654800B1,1
4736,4736,"<img> id-US10815179B1_00018.PNG </img>
",1.0,13801,US10815179B1,0
5107,5107,"(Example 1) Production of the Compound Represented by Formula (I-1)
",0.0,78606,US20180002276A1,2
5108,5108,"<img> id-US20180002276A1-20180104-C00098.TIF </img><img> id-US20180002276A1-20180104-C00099.TIF </img>
",0.0,78709,US20180002276A1,1
5109,5109,"To a reaction container, 5.00 g of the compound represented by Formula (I-1-1), 10.00 g of potassium carbonate, 6.10 g of the compound represented by Formula (I-1-2), and 100 mL of dimethylformamide were added.",2.0,78919,US20180002276A1,1
5113,5113," Hereby, 3.21 g of the compound represented by Formula (I-1-3) was prepared.
",1.0,79196,US20180002276A1,2
5114,5114,"To a reaction container, 3.20 g of the compound represented by Formula (I-1-3), 6.10 g of the compound represented by Formula (I-1-4), 0.05 g of N,N-dimethylaminopyridine, and 30 mL of dichloromethane were added.",2.0,79408,US20180002276A1,1
5118,5118," Hereby, 7.98 g of the compound represented by Formula (I-1-5) was prepared.
",1.0,79735,US20180002276A1,2
5119,5119,"To a reaction container, 7.5 g of the compound represented by Formula (I-1-5), 1.45 g of the compound represented by Formula (I-1-6), 100 mL of tetrahydrofuran, and 100 mL of ethanol were added.",2.0,79929,US20180002276A1,1
5132,5132,"(Example 4) Production of the Compound Represented by Formula (I-93)
",0.0,80777,US20180002276A1,2
5133,5133,"<img> id-US20180002276A1-20180104-C00102.TIF </img>
",0.0,80829,US20180002276A1,1
5134,5134,"To a reaction container, 5.0 g of the compound represented by Formula (I-93-1), 3.2 g of magnesium chloride, 2.0 g of para-formaldehyde, 20 mL of triethylamine, and 80 mL of acetonitrile were added.",2.0,81027,US20180002276A1,1
5138,5138," Hereby, 5.3 g of the compound represented by Formula (I-93-2) was prepared.
",1.0,81439,US20180002276A1,2
5139,5139,"In a nitrogen atmosphere, 2.0 g of the compound represented by Formula (I-93-2), 3.4 g of the compound represented by Formula (I-93-3), 0.1 g of N,N-dimethylaminopyridine, and 30 mL of dichloromethane were added to a reaction container.",2.0,81675,US20180002276A1,1
5144,5144," Hereby, 4.2 g of the compound represented by Formula (I-93-4) was prepared.
",1.0,82180,US20180002276A1,2
5145,5145,"To a reaction container, 4.2 g of the compound represented by Formula (I-93-4), 1.9 g of the compound represented by Formula (I-93-5), 0.5 g of (±)-10-camphorsulfonic acid, 20 mL of tetrahydrofuran, and 20 mL of ethanol were added.",2.0,82411,US20180002276A1,1
5148,5148," Hereby, 4.2 g of the compound represented by Formula (I-93-6) was prepared.
",1.0,82797,US20180002276A1,2
5149,5149,"In a nitrogen atmosphere, 4.2 g of the compound represented by Formula (I-93-6), 0.9 g of diisopropylethylamine, and 40 mL of dichloromethane were added to a reaction container.",2.0,82974,US20180002276A1,1
5156,5156,"(Example 5) Production of the Compound Represented by Formula (I-105)
",0.0,83649,US20180002276A1,2
5157,5157,"<img> id-US20180002276A1-20180104-C00103.TIF </img><img> id-US20180002276A1-20180104-C00104.TIF </img><img> id-US20180002276A1-20180104-C00105.TIF </img><img> id-US20180002276A1-20180104-C00106.TIF </img>
",0.0,83854,US20180002276A1,1
5158,5158,"In a nitrogen atmosphere, 10.0 g of the compound represented by Formula (I-105-1), 6.0 g of triethylamine, and 40 mL of tetrahydrofuran were added to a reaction container.",2.0,84025,US20180002276A1,1
5168,5168," Hereby, 7.4 g of the compound represented by Formula (I-105-2) was prepared.
",1.0,84924,US20180002276A1,2
5169,5169,"In a nitrogen atmosphere, 7.4 g of the compound represented by Formula (I-105-2), 4.1 g of pyridine, and 35 mL of dichloromethane were added to a reaction container.",2.0,85089,US20180002276A1,1
5174,5174," Hereby, 7.5 g of the compound represented by Formula (I-105-3) was prepared.
",1.0,85609,US20180002276A1,2
5175,5175,"In a nitrogen atmosphere, 25.0 g of the compound represented by Formula (I-105-4), 100 mL of acetic acid, and 100 mL of 48%-hydrobromic acid were added to a reaction container.",2.0,85785,US20180002276A1,1
5181,5181," Hereby, 12.0 g of the compound represented by Formula (I-105-5) was prepared.
",1.0,86298,US20180002276A1,2
5182,5182,"In a nitrogen atmosphere, 2.1 g of the compound represented by Formula (I-105-5), 7.5 g of the compound represented by Formula (I-105-3), 6.2 g of potassium carbonate, and 70 mL of N,N-dimethylformamide were added to a reaction container.",2.0,86536,US20180002276A1,1
5186,5186," Hereby, 4.8 g of the compound represented by Formula (I-105-6) was prepared.
",1.0,86937,US20180002276A1,2
5187,5187,"In a nitrogen atmosphere, 4.8 g of the compound represented by Formula (I-105-6), 20 mL of tetrahydrofuran, 20 mL of methanol, and 10 mL of a 25%-aqueous sodium hydroxide solution were added to a reaction container.",2.0,87152,US20180002276A1,1
5192,5192," Hereby, 4.0 g of the compound represented by Formula (I-105-7) was prepared.
",1.0,87697,US20180002276A1,2
5193,5193,"To a reaction container, 15.0 g of the compound represented by Formula (I-105-8), 17.7 g of the compound represented by Formula (I-105-9), 16.0 g of potassium carbonate, and 100 mL of N,N-dimethylformamide were added.",2.0,87914,US20180002276A1,1
5197,5197,"To a reaction container, 24.2 g of the compound represented by Formula (I-105-10), 60 mL of tetrahydrofuran, 60 mL of methanol, and 1 mL of concentrated hydrochloric acid were added.",2.0,88485,US20180002276A1,1
5203,5203,"In a nitrogen atmosphere, 3.8 g of the compound represented by Formula (I-105-11), 3.0 g of the compound represented by Formula (I-105-7), 0.9 g of N,N-dimethylaminopyridine, and 200 mL of dichloromethane were added to a reaction container.",2.0,89172,US20180002276A1,1
5209,5209,"In a nitrogen atmosphere, 7.5 g of the compound represented by Formula (I-105-13), 5.0 g of the compound represented by Formula (I-105-14), 6.3 g of potassium carbonate, and 50 mL of N,N-dimethylformamide were added to a reaction container.",2.0,90017,US20180002276A1,1
5213,5213,"To a reaction container, 1.5 g of the compound represented by Formula (I-105-16), 4.3 g of the compound represented by Formula (I-105-12), 0.6 g of (±)-10-camphorsulfonic acid, 20 mL of tetrahydrofuran, and 20 mL of ethanol were added.",2.0,90687,US20180002276A1,1
5218,5218,"(Example 6) Production of the Compound Represented by Formula (I-106)
",0.0,91430,US20180002276A1,2
5219,5219,"<img> id-US20180002276A1-20180104-C00107.TIF </img><img> id-US20180002276A1-20180104-C00108.TIF </img><img> id-US20180002276A1-20180104-C00109.TIF </img>
",0.0,91584,US20180002276A1,1
5220,5220,"In a nitrogen atmosphere, 20.0 g of the compound represented by Formula (I-106-1), 8.8 g of tert-butyl alcohol, 1.3 g of N,N-dimethylaminopyridine, and 100 mL of dichloromethane were added to a reaction container.",2.0,91797,US20180002276A1,1
5226,5226,"To a reaction container, 20.8 g of the compound represented by Formula (I-106-2), 200 mL of methanol, and 30 mL of a 25%-aqueous sodium hydroxide solution were added.",2.0,92452,US20180002276A1,1
5233,5233,"In a nitrogen atmosphere, 17.7 g of the compound represented by Formula (I-106-3) and 100 mL of tetrahydrofuran were added to a reaction container.",2.0,93175,US20180002276A1,1
5239,5239,"In a nitrogen atmosphere, 14.9 g of the compound represented by Formula (I-106-4), 7.2 g of pyridine, and 150 mL of dichloromethane were added to a reaction container.",2.0,93846,US20180002276A1,1
5245,5245,"In a nitrogen atmosphere, 25.0 g of the compound represented by Formula (I-106-6) and 200 mL of dichloromethane were added to a reaction container.",2.0,94506,US20180002276A1,1
5251,5251,"In a nitrogen atmosphere, 2.5 g of the compound represented by Formula (I-106-7), 10.6 g of the compound represented by Formula (I-106-5), 7.5 g of potassium carbonate, and 70 mL of N,N-dimethylformamide were added to a reaction container.",2.0,95224,US20180002276A1,1
5254,5254," Hereby, 7.7 g of the compound represented by Formula (I-106-8) was prepared.
",1.0,95627,US20180002276A1,2
5255,5255,"To a reaction container, 7.7 g of the compound represented by Formula (I-106-8), 150 mL of dichloromethane, and 100 mL of formic acid were added.",2.0,95772,US20180002276A1,1
5258,5258," Hereby, 5.5 g of the compound represented by Formula (I-106-9) was prepared.
",1.0,96011,US20180002276A1,2
5259,5259,"In a nitrogen atmosphere, 5.5 g of the compound represented by Formula (I-106-9), 6.9 g of the compound represented by Formula (I-106-10), 0.8 g of N,N-dimethylaminopyridine, and 200 mL of dichloromethane were added to a reaction container.",2.0,96251,US20180002276A1,1
5264,5264,"In a nitrogen atmosphere, 7.0 g of the compound represented by Formula (I-106-13), 70 mL of 1,2-dimethoxyethane, and 5.0 g of triethylamine were added to a reaction container.",2.0,97032,US20180002276A1,1
5268,5268," Hereby, 6.0 g of the compound represented by Formula (I-106-14) was prepared.
",1.0,97480,US20180002276A1,2
5269,5269,"To a reaction container, 1.1 g of the compound represented by Formula (I-106-14), 5.0 g of the compound represented by Formula (I-106-11), 0.6 g of (±)-10-camphorsulfonic acid, 20 mL of tetrahydrofuran, and 20 mL of ethanol were added.",2.0,97715,US20180002276A1,1
5271,5271," Hereby, 4.2 g of the compound represented by Formula (I-106-15) was prepared.
",1.0,98045,US20180002276A1,2
5272,5272,"In a nitrogen atmosphere, 4.2 g of the compound represented by Formula (I-106-15), 0.6 g of diisopropylethylamine, and 50 mL of dichloromethane were added to a reaction container.",2.0,98224,US20180002276A1,1
5279,5279,"(Example 7) Production of the Compound Represented by Formula (I-107)
",0.0,99293,US20180002276A1,2
5280,5280,"<img> id-US20180002276A1-20180104-C00110.TIF </img><img> id-US20180002276A1-20180104-C00111.TIF </img>
",0.0,99396,US20180002276A1,1
5281,5281,"In a nitrogen atmosphere, 10.0 g of the compound represented by Formula (I-107-1), 9.2 g of diisopropylethylamine, and 60 mL of dichloromethane were added to a reaction container.",2.0,99575,US20180002276A1,1
5285,5285," Hereby, 11.9 g of the compound represented by Formula (I-107-2) was prepared.
",1.0,100018,US20180002276A1,2
5286,5286,"In a nitrogen atmosphere, 8.8 g of the compound represented by Formula (I-107-2), 5.0 g of the compound represented by Formula (I-107-3), 6.3 g of potassium carbonate, and 60 mL of N,N-dimethylformamide were added to a reaction container.",2.0,100256,US20180002276A1,1
5289,5289," Hereby, 6.4 g of the compound represented by Formula (I-107-4) was prepared.
",1.0,100690,US20180002276A1,2
5290,5290,"To a reaction container, 1.5 g of the compound represented by Formula (I-107-5), 0.5 g of the compound represented by Formula (I-107-4), 0.6 g of (±)-10-camphorsulfonic acid, 20 mL of tetrahydrofuran, and 20 mL of ethanol were added.",2.0,100923,US20180002276A1,1
5296,5296,"(Example 8) Production of the Compound Represented by Formula (I-108)
",0.0,101835,US20180002276A1,2
5297,5297,"<img> id-US20180002276A1-20180104-C00112.TIF </img><img> id-US20180002276A1-20180104-C00113.TIF </img><img> id-US20180002276A1-20180104-C00114.TIF </img>
",0.0,101989,US20180002276A1,1
5298,5298,"To a reaction container, 15.0 g of the compound represented by Formula (I-108-1), 13.8 g of the compound represented by Formula (I-108-2), 37.7 g of cesium carbonate, and 100 mL of dimethyl sulfoxide were added.",2.0,102200,US20180002276A1,1
5302,5302,"To a reaction container, 18.9 g of the compound represented by Formula (I-108-3), 80 mL of tetrahydrofuran, 80 mL of methanol, and 1 mL of concentrated hydrochloric acid were added.",2.0,102768,US20180002276A1,1
5307,5307," Hereby, 11.0 g of the compound represented by Formula (I-108-4) was prepared.
",1.0,103168,US20180002276A1,2
5308,5308,"In a nitrogen atmosphere, 5.0 g of the compound represented by Formula (I-108-5), 5.3 g of the compound represented by Formula (I-108-4), 0.7 g of N,N-dimethylaminopyridine, and 200 mL of dichloromethane were added.",2.0,103383,US20180002276A1,1
5313,5313,"In a nitrogen atmosphere, 100 mL of hydrazine monohydrate and 100 mL of ethanol were added to a reaction container.",2.0,104095,US20180002276A1,1
5317,5317," Hereby, 8.6 g of the compound represented by Formula (I-108-8) was prepared.
",1.0,104549,US20180002276A1,2
5318,5318,"In a nitrogen atmosphere, 10.8 g of the compound represented by Formula (I-108-9), 100 mL of 1,2-dimethoxyethane, and 7.7 g of triethylamine were added to a reaction container.",2.0,104725,US20180002276A1,1
5323,5323,"To a reaction container, 1.4 g of the compound represented by Formula (I-108-10), 5.0 g of the compound represented by Formula (I-108-6), 0.6 g of (±)-10-camphorsulfonic acid, 20 mL of tetrahydrofuran, and 20 mL of ethanol were added.",2.0,105403,US20180002276A1,1
5325,5325," Hereby, 5.0 g of the compound represented by Formula (I-108-11) was prepared.
",1.0,105732,US20180002276A1,2
5326,5326,"In a nitrogen atmosphere, 5.0 g of the compound represented by Formula (I-108-11), 0.8 g of diisopropylethylamine, and 80 mL of dichloromethane were added to a reaction container.",2.0,105911,US20180002276A1,1
5332,5332,"(Example 9) Production of the Compound Represented by Formula (I-109)
",0.0,106522,US20180002276A1,2
5333,5333,"<img> id-US20180002276A1-20180104-C00115.TIF </img><img> id-US20180002276A1-20180104-C00116.TIF </img>
",0.0,106625,US20180002276A1,1
5334,5334,"To a reaction container equipped with a Dean and Stark device, 30.0 g of the compound represented by Formula (I-109-1), 19.0 g of acrylic acid, 2.1 g of p-toluenesulfonic acid monohydrate, 300 mL of cyclohexane, and 150 mL of diisopropyl ether were added.",2.0,106880,US20180002276A1,1
5338,5338," Hereby, 33.5 g of the compound represented by Formula (I-109-2) was prepared.
",1.0,107302,US20180002276A1,2
5339,5339,"To a reaction container, 10.0 g of the compound represented by Formula (I-109-2), 28.9 g of hydroquinone, 21.7 g of potassium carbonate, and 150 mL of acetone were added.",2.0,107472,US20180002276A1,1
5344,5344,"In a nitrogen atmosphere, 9.7 g of the compound represented by Formula (I-109-3), 7.9 g of the compound represented by Formula (I-109-4), 0.4 g of N,N-dimethylaminopyridine, and 100 mL of dichloromethane were added to a reaction container.",2.0,108127,US20180002276A1,1
5349,5349,"To a reaction container, 11.9 g of the compound represented by Formula (I-109-5) and 80 mL of dichloromethane were added.",2.0,108785,US20180002276A1,1
5355,5355,"In a nitrogen atmosphere, 9.1 g of the compound represented by Formula (I-109-6), 1.5 g of the compound represented by Formula (I-109-7), 0.1 g of N,N-dimethylaminopyridine, and 150 mL of dichloromethane were added to a reaction container.",2.0,109428,US20180002276A1,1
5359,5359," Hereby, 7.1 g of the compound represented by Formula (I-109-8) was prepared.
",1.0,110025,US20180002276A1,2
5360,5360,"To a reaction container, 10.0 g of the compound represented by Formula (I-109-9), 13.8 g of the compound represented by Formula (I-109-2), 12.5 g of potassium carbonate, and 100 mL of N,N-dimethylformamide were added.",2.0,110242,US20180002276A1,1
5363,5363," Hereby, 11.6 g of the compound represented by Formula (I-109-10) was prepared.
",1.0,110613,US20180002276A1,2
5364,5364,"To a reaction container, 2.0 g of the compound represented by Formula (I-109-10), 5.9 g of the compound represented by Formula (I-109-8), 0.7 g of (±)-10-camphorsulfonic acid, 24 mL of tetrahydrofuran, and 24 mL of ethanol were added.",2.0,110847,US20180002276A1,1
5630,5630,The synthesis can refer to Example 1.,1.0,48793,US20180008574A1,0
5660,5660,"Example 9: Synthesis of N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4-fluorobenzenesulfonamide
",2.0,52674,US20180008574A1,0
5661,5661,"<img> id-US20180008574A1-20180111-C00026.TIF </img>
",1.0,52726,US20180008574A1,0
5662,5662,The synthesis can refer to Example 1.,1.0,52763,US20180008574A1,0
5692,5692,"Example 17: Synthesis of 3-chloro-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-2-fluorobenzenesulfonamide
",2.0,56045,US20180008574A1,0
5693,5693,"<img> id-US20180008574A1-20180111-C00034.TIF </img>
",1.0,56097,US20180008574A1,0
5694,5694,The synthesis can refer to Example 1.,1.0,56134,US20180008574A1,0
5724,5724,"Example 25: Synthesis of Methyl 4-(N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)sulfamoyl)benzoate
",2.0,59637,US20180008574A1,0
5725,5725,"<img> id-US20180008574A1-20180111-C00042.TIF </img>
",1.0,59689,US20180008574A1,0
5726,5726,The synthesis can refer to Example 1.,1.0,59726,US20180008574A1,0
5740,5740,"Example 29: Synthesis of N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonamide
",2.0,61250,US20180008574A1,0
5741,5741,"<img> id-US20180008574A1-20180111-C00046.TIF </img>
",1.0,61302,US20180008574A1,0
5742,5742,The synthesis can refer to Example 1.,1.0,61339,US20180008574A1,0
5754,5754,The synthesis can refer to Example 1.,1.0,62705,US20180008574A1,0
5756,5756,"Example 33: Synthesis of N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-2,5-dimethoxybenzenesulfonamide
",2.0,63063,US20180008574A1,0
5757,5757,"<img> id-US20180008574A1-20180111-C00050.TIF </img>
",1.0,63115,US20180008574A1,0
5758,5758,The synthesis can refer to Example 1.,1.0,63152,US20180008574A1,0
5784,5784,"Example 40: Synthesis of N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-1-(4-(trifluoromethyl)phenyl)methanesulfonamide
",2.0,66223,US20180008574A1,0
5785,5785,"<img> id-US20180008574A1-20180111-C00057.TIF </img>
",1.0,66275,US20180008574A1,0
5786,5786,The synthesis can refer to Example 1.,1.0,66312,US20180008574A1,0
5788,5788,"Example 41: Synthesis of N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-1-(p-tolyl)methanesulfonamide
",2.0,66663,US20180008574A1,0
5789,5789,"<img> id-US20180008574A1-20180111-C00058.TIF </img>
",1.0,66715,US20180008574A1,0
5790,5790,The synthesis can refer to Example 1.,1.0,66752,US20180008574A1,0
5809,5809,"Example 46: Synthesis of N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-4-fluorobenzamide
",2.0,68930,US20180008574A1,0
5810,5810,"<img> id-US20180008574A1-20180111-C00063.TIF </img>
",1.0,68982,US20180008574A1,0
5811,5811,"6-amino-1-ethylbenzo[cd]indol-2(1H)-one can refer to Example 1.
",1.0,69046,US20180008574A1,2
5820,5820,"Example 47: Synthesis of 2-(4-chlorophenyl)-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)acetamide
",2.0,70140,US20180008574A1,0
5821,5821,"<img> id-US20180008574A1-20180111-C00064.TIF </img>
",1.0,70192,US20180008574A1,0
5822,5822,The synthesis can refer to Example 46.,1.0,70230,US20180008574A1,0
5826,5826,The synthesis can refer to Example 46.,1.0,70671,US20180008574A1,0
5828,5828,"Example 49: Synthesis of 2-(2,4-dichlorophenyl)-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)acetamide
",2.0,71014,US20180008574A1,0
5829,5829,"<img> id-US20180008574A1-20180111-C00066.TIF </img>
",1.0,71066,US20180008574A1,0
5830,5830,The synthesis can refer to Example 46.,1.0,71104,US20180008574A1,0
5842,5842,The synthesis can refer to Example 46.,1.0,72481,US20180008574A1,0
5846,5846,The synthesis can refer to Example 46.,1.0,72892,US20180008574A1,0
5848,5848,"Example 54: Synthesis of N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-2-(p-tolyl)acetamide
",2.0,73198,US20180008574A1,0
5849,5849,"<img> id-US20180008574A1-20180111-C00071.TIF </img>
",1.0,73250,US20180008574A1,0
5850,5850,The synthesis can refer to Example 46.,1.0,73288,US20180008574A1,0
5852,5852,"Example 55: Synthesis of (E)-N-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indol-6-yl)-3-(furan-2-yl)acrylamide
",2.0,73654,US20180008574A1,0
5853,5853,"<img> id-US20180008574A1-20180111-C00072.TIF </img>
",1.0,73706,US20180008574A1,0
5854,5854,The synthesis can refer to Example 46.,1.0,73744,US20180008574A1,0
5883,5883,"Example 61: Synthesis of 6-((4-chlorobenzyl)amino)-1-ethylbenzo[cd]indol-2(1H)-one
",2.0,77129,US20180008574A1,0
5884,5884,"<img> id-US20180008574A1-20180111-C00078.TIF </img>
",1.0,77181,US20180008574A1,0
5885,5885,The synthesis can refer to Example 56.,1.0,77219,US20180008574A1,0
5888,5888,"<img> id-US20180008574A1-20180111-C00079.TIF </img>
",1.0,77646,US20180008574A1,0
5889,5889,The synthesis can refer to Example 56.,1.0,77684,US20180008574A1,0
5914,5914,"Example 65: Synthesis of 1-ethyl-N-((3-isopropyl-4,5-dihydroisoxazol-5-yl)methyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide
",2.0,80655,US20180008574A1,0
5915,5915,"<img> id-US20180008574A1-20180111-C00083.TIF </img>
",1.0,80707,US20180008574A1,0
5916,5916,The synthesis can refer to Example 63.,1.0,80745,US20180008574A1,0
5919,5919,"Example 66: Synthesis of N-((3,5-dimethyl-4,5-dihydroisoxazol-5-yl)methyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide
",2.0,81157,US20180008574A1,0
5920,5920,"<img> id-US20180008574A1-20180111-C00084.TIF </img>
",1.0,81209,US20180008574A1,0
5921,5921,The synthesis can refer to Example 63.,1.0,81247,US20180008574A1,0
5980,5980,The synthesis can refer to Example 67.,1.0,88025,US20180008574A1,0
5984,5984,The synthesis can refer to Example 67.,1.0,88405,US20180008574A1,0
6012,6012,The synthesis can refer to Example 67.,1.0,91738,US20180008574A1,0
6016,6016,The synthesis can refer to Example 67.,1.0,92177,US20180008574A1,0
6044,6044,"Example 93: Synthesis of N-(2-(4-chlorophenoxy)ethyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide
",2.0,96051,US20180008574A1,0
6045,6045,"<img> id-US20180008574A1-20180111-C00111.TIF </img>
",1.0,96103,US20180008574A1,0
6046,6046,The synthesis can refer to Example 67.,1.0,96141,US20180008574A1,0
6076,6076,"Example 101: Synthesis of 1-ethyl-N-(3-(4-methylpiperazin-1-yl)propyl)-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide
",2.0,99842,US20180008574A1,0
6077,6077,"<img> id-US20180008574A1-20180111-C00119.TIF </img>
",1.0,99894,US20180008574A1,0
6078,6078,The synthesis can refer to Example 67.,1.0,99932,US20180008574A1,0
6108,6108,"Example 64: Synthesis of tert-butyl4-(2-(1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamido)ethyl)piperazine-1-carboxylate
",2.0,103778,US20180008574A1,0
6109,6109,"<img> id-US20180008574A1-20180111-C00127.TIF </img>
",1.0,103830,US20180008574A1,0
6110,6110,The synthesis can refer to Example 67.,1.0,103868,US20180008574A1,0
6136,6136,"Example 116: Synthesis of N-butyl-1-isobutyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide
",2.0,107126,US20180008574A1,0
6137,6137,"<img> id-US20180008574A1-20180111-C00134.TIF </img>
",1.0,107178,US20180008574A1,0
6138,6138,The synthesis can refer to Example 67.,1.0,107216,US20180008574A1,0
6140,6140,"Example 117: Synthesis of N-cyclohexyl-1-isobutyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide
",2.0,107656,US20180008574A1,0
6141,6141,"<img> id-US20180008574A1-20180111-C00135.TIF </img>
",1.0,107708,US20180008574A1,0
6142,6142,The synthesis can refer to Example 67.,1.0,107746,US20180008574A1,0
6155,6155,The synthesis can refer to Example 67.,1.0,109207,US20180008574A1,0
6157,6157,"Example 121: Synthesis of 1-ethyl-2-oxo-N-phenyl-1,2-dihydrobenzo[cd]indole-6-sulfonamide
",2.0,109530,US20180008574A1,0
6158,6158,"<img> id-US20180008574A1-20180111-C00139.TIF </img>
",1.0,109582,US20180008574A1,0
6159,6159,The synthesis can refer to Example 67.,1.0,109620,US20180008574A1,0
6161,6161,"Example 122: Synthesis of N-(2-chlorophenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide
",2.0,109974,US20180008574A1,0
6162,6162,"<img> id-US20180008574A1-20180111-C00140.TIF </img>
",1.0,110026,US20180008574A1,0
6163,6163,The synthesis can refer to Example 67.,1.0,110064,US20180008574A1,0
6165,6165,"Example 123: Synthesis of N-(3-chlorophenyl)-1-ethyl-2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide
",2.0,110455,US20180008574A1,0
6166,6166,"<img> id-US20180008574A1-20180111-C00141.TIF </img>
",1.0,110507,US20180008574A1,0
6167,6167,The synthesis can refer to Example 67.,1.0,110545,US20180008574A1,0
7417,7417,"Intermediate 1
",2.0,119511,US20180016269A1,0
7418,7418,"(Z)-2-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-N-methylethan-1-amine
",1.0,119578,US20180016269A1,2
7456,7456,"N1-(2-(4-((Z)-1,2-diphenylbut-1-en-1-yl)phenoxy)ethyl)-N8-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methyloctanediamide
",1.0,124585,US20180016269A1,2
7463,7463,Example 3.,2.0,126212,US20180016269A1,0
7464,7464," Synthesis of Exemplary Compounds
",1.0,126246,US20180016269A1,0
7465,7465,"General Procedure for Linker Coupling
",1.0,126284,US20180016269A1,2
7470,7470,"<img> id-US20180016269A1-20180118-C00142.TIF </img>
",2.0,126939,US20180016269A1,1
7471,7471,"4-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-4-oxobutanoic acid
",1.0,127085,US20180016269A1,2
7514,7514,"<img> id-US20180016269A1-20180118-C00151.TIF </img>
",2.0,132142,US20180016269A1,1
7515,7515,"N1-(2-(4-((Z)-1,2-Diphenylbut-1-en-1-yl)phenoxy)ethyl)-N4-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylsuccinamide
",1.0,132339,US20180016269A1,2
7520,7520,"N1-(2-(4-((Z)-1,2-Diphenylbut-1-en-1-yl)phenoxy)ethyl)-N5-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylglutaramide
",1.0,133245,US20180016269A1,2
7525,7525,"N1-(2-(4-((Z)-1,2-diphenylbut-1-en-1-yl)phenoxy)ethyl)-N6-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methyladipamide
",1.0,134259,US20180016269A1,2
7530,7530,"N1-(2-(4-((Z)-1,2-diphenylbut-1-en-1-yl)phenoxy)ethyl)-N7-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylheptanediamide
",1.0,135246,US20180016269A1,2
7535,7535,"N1-(2-(4-((Z)-1,2-Diphenylbut-1-en-1-yl)phenoxy)ethyl)-N8-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methyloctanediamide
",1.0,136227,US20180016269A1,2
7540,7540,"N1-(2-(4-((Z)-1,2-Diphenylbut-1-en-1-yl)phenoxy)ethyl)-N9-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylnonanediamide
",1.0,137281,US20180016269A1,2
7545,7545,"N1-(2-(4-((Z)-1,2-Diphenylbut-1-en-1-yl)phenoxy)ethyl)-N10-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methyldecanediamide
",1.0,138422,US20180016269A1,2
7549,7549,"<img> id-US20180016269A1-20180118-C00158.TIF </img>
",2.0,139252,US20180016269A1,0
7550,7550,"N1-(2-(4-((Z)-1,2-diphenylbut-1-en-1-yl)phenoxy)ethyl)-N11-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylundecanediamide
",1.0,139454,US20180016269A1,2
7580,7580,"N1-(2-(4-((Z)-1,2-Diphenylbut-1-en-1-yl)phenoxy)ethyl)-N16-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methyl-4,7,10,13-tetraoxahexadecanediamide
",1.0,145172,US20180016269A1,2
7584,7584,"<img> id-US20180016269A1-20180118-C00165.TIF </img>
",2.0,145987,US20180016269A1,0
7585,7585,"N1-(2-(4-((Z)-1,2-Diphenylbut-1-en-1-yl)phenoxy)ethyl)-N17-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-di methyl-1-oxobutan-2-yl)-N1-methyl-3,6,9,12,15-pentaoxaheptadecanediamide
",1.0,146214,US20180016269A1,2
7590,7590,"N1-(2-(4-((Z)-1,2-diphenylbut-1-en-1-yl)phenoxy)ethyl)-N19-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methyl-4,7,10,13,16-pentaoxanonadecanediamide
",1.0,147182,US20180016269A1,2
7595,7595,"N1-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N4-(2-(4-(1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenoxy)ethyl)-N4-methylsuccinamide
",1.0,148195,US20180016269A1,2
7600,7600,"N1-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N5-(2-(4-(1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenoxy)ethyl)-N5-methylglutaramide
",1.0,149167,US20180016269A1,2
7605,7605,"N1-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N6-(2-(4-(1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenoxy)ethyl)-N6-methyladipamide
",1.0,150152,US20180016269A1,2
7610,7610,"N1-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N7-(2-(4-(1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenoxy)ethyl)-N7-methylheptanediamide
",1.0,151136,US20180016269A1,2
7614,7614,"<img> id-US20180016269A1-20180118-C00171.TIF </img>
",2.0,151893,US20180016269A1,0
7615,7615,"N1-((S)-1-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N8-(2-(4-(1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenoxy)ethyl)-N8-methyloctanediamide
",1.0,152104,US20180016269A1,0
7620,7620,"N1-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-di methyl-1-oxobutan-2-yl)-N8-(2-(4-(1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenoxy)ethyl)octanediamide
",1.0,153175,US20180016269A1,2
7625,7625,"N1-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N9-(2-(4-(1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenoxy)ethyl)-N9-methylnonanediamide
",1.0,154127,US20180016269A1,2
7630,7630,"N1-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N10-(2-(4-(1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenoxy)ethyl)-N10-methyldecanediamide
",1.0,155146,US20180016269A1,2
7635,7635,"N1-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N11-(2-(4-(1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenoxy)ethyl)-N11-methylundecanediamide
",1.0,156191,US20180016269A1,2
7640,7640,"N1-((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N8-(2-(4-(1-(4-hydroxyphenyl)-2-phenylbut-1-en-1-yl)phenoxy)ethyl)octanediamide
",1.0,157227,US20180016269A1,2
7647,7647,"N1-(2-(4-((Z)-1,2-Diphenylbut-1-en-1-yl)phenoxy)ethyl)-N11-((S)-1-((2S,4R)-4-hydroxy-2-((4-(quinazolin-6-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)-N1-methylundecanediamide
",2.0,158374,US20180016269A1,0
8479,8479,"incubation of C4-benzyl SAHA analog ((S)-1f) with
",0.0,34236,US20180057448A1,2
8566,8566," The asymmetric syntheses of both enantiomers were carried out utilizing Evan's oxazolidinone chiral auxiliary (R)-8 (Scheme 2).48 To ultimately prepare (R)-1f, 4-pentenoyl chloride was reacted with chiral auxiliary (R)-8 using n-butyllithium, which yielded pentenoyl oxazolidinone intermediate (R)-9 (Scheme 2A).",0.0,41757,US20180057448A1,2
8567,8567, Enantioselective reaction of benzyl bromide with (R)-9 gave the diastereomeric intermediate (RS)-10.,0.0,41858,US20180057448A1,1
8568,8568," To ultimately prepare (S)-1f, a similar procedure was employed (Scheme 2B), but reacting 3-phenylpropanoyl chloride with chiral auxiliary (R)-8, followed by enantioselective reaction with allyl bromide to give diastereomeric intermediate (RR)-10.",0.0,42105,US20180057448A1,1
8569,8569," Both diastereomers were obtained with high diastereomeric ratios (dr), which were assessed by 1HNMR analysis (99:1 dr for (RS)-10, and 97:3 dr for (RR)-10).
",0.0,42263,US20180057448A1,1
8570,8570,"To remove the chiral auxiliary from (RS)-10 and (RR)-10, each diastereomer was reacted with lithium aluminum hydride, which produced alcohols (S)-11 and (R)-11 (Scheme 2).",0.0,42434,US20180057448A1,1
8571,8571," To assess the optical purity and enantiomeric excess (ee) of the alcohol intermediates (S)-11 and (R)-11, Mosher esters were synthesized by coupling each alcohol with (R)-(+)-α-Methoxy-α-trifluoromethylphenylacetic acid ((R)-MTPA) using EDCI and DMAP (Scheme S1).49 Analysis of the 1HNMR spectra showed that both Mosher esters were observed in high diastereomeric ratios (99:1 dr for (S)-11-(R)-MTPA, and 98:2 dr for (R)-11-(R)-MTPA), which implies that the alcohol intermediates (S)-11 and (R)-11 were obtained with high enantiomeric ratios (98% ee for (S)-11 and 96% ee (R)-11).
",0.0,43016,US20180057448A1,1
8572,8572,"<img> id-US20180057448A1-20180301-C00006.TIF </img>
",0.0,43068,US20180057448A1,1
8573,8573,"To synthesize enantiopure C4-benzyl SAHA analogs (R)-1f and (S)-1f, both alcohols (S)-11 and (R)-11 were then converted to methanesulfonate esters, followed by substitution with dimethyl malonate to give diesters (R)-13 and (S)-13, respectively (Schemes 3).",0.0,43325,US20180057448A1,1
8574,8574, Krapcho decarboxylation afforded methyl ester intermediates (S)-14 and (R)-14.,0.0,43404,US20180057448A1,1
8575,8575," Cross metathesis of the methyl esters with N-phenyl acrylamide 15 using Grubbs' second generation catalyst afforded ester amides (S)-16 and (R)-16.5 Finally, reduction followed by substitution with hydroxyl amine gave both enantiomers of C4-benzyl SAHA analog, (R)-1f and (S)-1f (Schemes 3).
",0.0,43697,US20180057448A1,2
8635,8635,II.A.,2.0,51651,US20180057448A1,0
8636,8636," Synthesis Procedures for 1a-1f
",1.0,51683,US20180057448A1,2
8640,8640," The spectral data for the synthesized compound was consistent with the reported data in literature.57
",1.0,52480,US20180057448A1,0
8695,8695,"The procedure was similar to 7b except the following: crude 6a from prior step, MeOH (20 mL) and Pd(OH)2 (413 mg of 20 wt.",0.0,59982,US20180057448A1,1
8696,8696," % Pd(OH)2 on carbon, 0.59 mmol).",0.0,60015,US20180057448A1,1
8697,8697, The reaction was stirred under hydrogen for 3.5 hours.,0.0,60070,US20180057448A1,1
8698,8698," The reaction was filtered through a celite plug, and the solvent was evaporated.",0.0,60151,US20180057448A1,1
8699,8699," The crude product was used in the following reaction
",0.0,60205,US20180057448A1,1
8700,8700,"The crude product 7a was dissolved in acetonitrile (10 mL), followed by addition of DIPEA (946 mg, 7.32 mmol) and TBTU (1.76 g, 5.49 mmol), and the reaction was left to stir for 20 minutes.",0.0,60394,US20180057448A1,1
8701,8701," Aniline (0.51 g, 5.49 mmol) was added, and the reaction was left to stir for 4.5 hours.",0.0,60482,US20180057448A1,1
8702,8702, The reaction was quenched with 10% aqueous HCl (20 mL).,0.0,60538,US20180057448A1,1
8703,8703, The aqueous layer was extracted with ethyl acetate (4×20 mL).,0.0,60600,US20180057448A1,1
8704,8704," The combined organic extracts were washed with a saturated NaHCO3 (10 mL) and then dried over anhydrous Na2SO4, filtered, and evaporated.",0.0,60738,US20180057448A1,1
8705,8705," The product was purified by silica flash chromatography (ethyl acetate:hexanes 1:4) to afford 8a (434 mg, 43% over four steps).",0.0,60866,US20180057448A1,1
8710,8710,"Synthesis of methyl 4-ethyl-8-oxo-8-(phenylamino)octanoate (8b)
",0.0,61479,US20180057448A1,2
8711,8711,"The procedure was similar to the last step of 8a except the following reagents were used: DIPEA (319 mg, 2.47 mmol), TBTU (594 mg, 1.85 mmol) and aniline (172 mg, 185 mmol).",0.0,61652,US20180057448A1,1
8712,8712, The extraction was done with dichloromethane (4×20 mL).,0.0,61708,US20180057448A1,1
8713,8713," The product was purified by silica gel flash chromatography (ethyl acetate:hexanes 1:4) to afford 8b (250 mg, 75%).",0.0,61824,US20180057448A1,1
8718,8718,"Synthesis of methyl 4-butyl-8-oxo-8-(phenylamino)octanoate (8c)
",0.0,62438,US20180057448A1,2
8719,8719,"The procedure was similar to that of 7b except the following reagents were used: 6c (1.2 g, 3.6 mmol) Pd(OH)2 (504 mg of 20 wt.",0.0,62565,US20180057448A1,1
8720,8720," % Pd(OH)2 on carbon, 0.72 mmol).",0.0,62598,US20180057448A1,1
8721,8721," The crude product was used in the following reaction.
",0.0,62653,US20180057448A1,1
8722,8722,"The procedure was similar to the last step of 8a except the following reagents were used: Crude 7c from prior reaction, DIPEA (464 mg, 3.59 mmol), TBTU (865 mg, 2.69 mmol) and aniline (250 mg, 2.69 mmol).",0.0,62857,US20180057448A1,1
8723,8723," The product was purified by silica gel flash chromatography (ethyl acetate:hexanes 1:6) to afford 8c (250 mg, 44% over two steps).",0.0,62988,US20180057448A1,1
8728,8728,"Synthesis of methyl 4-hexyl-8-oxo-8-(phenylamino)octanoate (8d)
",0.0,63625,US20180057448A1,2
8729,8729,"The procedure was similar to that of 6b except the following reagents were used: 4 (460 mg, 3.24 mmol) dry THF (20 mL), copper(I)bromide dimethyl sulfide (2 g, 9.73 mmol), n-hexyllithium (8.46 ml of a 2.3 M solution in hexanes, 1.792 g, 19.46 mmol), chlorotrimethylsilane (3.17 g, 29.19 mmol) and methyl pent-4-enoate 4 (461 mg, 3.24 mmol), NaH (259 mg of 60% NaH in mineral oil, 6.48 mmol), and benzyl diethyl phosphonoacetate 5b (1.85 g, 6.48 mmol).",0.0,64076,US20180057448A1,1
8730,8730, The reaction was heated to reflux for 4.5 hours.,0.0,64125,US20180057448A1,1
8731,8731, The product was purified by silica gel flash chromatography (ethyl acetate:hexanes 1:10).,0.0,64215,US20180057448A1,1
8732,8732," The purified product was used in the following reaction.
",0.0,64273,US20180057448A1,1
8733,8733,"The procedure was similar to that of 7b except the following reagents were used: 6d from prior reaction, Pd(OH)2 (228 mg of 20 wt.",0.0,64403,US20180057448A1,1
8734,8734," % Pd(OH)2 on carbon, 0.32 mmol).",0.0,64436,US20180057448A1,1
8735,8735," The crude product was used in the following reaction.
",0.0,64491,US20180057448A1,1
8736,8736,"The procedure was similar to that of 8a except the following: 7d from prior reaction, acetonitrile (15 mL), DIPEA (838 mg, 6.48 mmol), TBTU (1.56 g, 4.86 mmol) and aniline (452 mg, 4.86 mmol).",0.0,64683,US20180057448A1,1
8737,8737, The reaction was quenched with 10% aqueous HCl (10 mL).,0.0,64739,US20180057448A1,1
8738,8738," The product was purified by silica gel flash chromatography (ethyl acetate:hexanes 1:6) to afford 8d (214 mg, 19% over four steps).",0.0,64871,US20180057448A1,1
8743,8743,"Synthesis of methyl 8-oxo-4-phenyl-8-(phenylamino)octanoate (8e)
",0.0,65553,US20180057448A1,2
8744,8744,"8-Methoxy-8-oxo-5-phenyloctanoic acid 7e (0.763 g, 2.89 mmol) was dissolved in dichloromethane (25 mL), then aniline (0.32 mL, 3.47 mmol) was added, followed by 4-(dimethylamino)pyridine (0.424 g, 3.47 mmol).",0.0,65761,US20180057448A1,1
8745,8745," The mixture was stirred until 4-(dimethylamino)pyridine was completely dissolved, then dicyclohexyl carbodiimide (0.716 g, 3.47 mmol) was added, and the reaction was stirred for 4 hours at room temperature.",0.0,65968,US20180057448A1,1
8746,8746," The reaction was quenched with 10% aqueous HCl (40 mL), the organic layer was washed with a saturated NaHCO3 solution, and then brine, dried over anhydrous Na2SO4, concentrated, and purified by column chromatography (acetone:petroleum ether 1:6) to give 8e (704 mg, 72%).",0.0,66240,US20180057448A1,1
8750,8750,"Synthesis of methyl 4-benzyl-8-oxo-8-(phenylamino)octanoate (8f)
",0.0,66887,US20180057448A1,2
8751,8751,"The procedure was similar to that of 6b except the following reagents were used: 4 (500 mg, 3.52 mmol), dry THF (20 mL), copper(I)bromide dimethyl sulfide (2.17 g, 10.56 mmol), benzylmagnesium chloride (21.11 ml of a 1.0 M solution in methyl THF, 3.189 g, 21.12 mmol), chlorotrimethylsilane (3.44 g, 31.68 mmol), NaH (282 mg of 60% NaH in mineral oil, 7.04 mmol) and benzyl diethyl phosphonoacetate 5b (2.02 g, 7.04 mmol).",0.0,67309,US20180057448A1,1
8752,8752, The reaction was heated to reflux for 1 hour 45 minutes.,0.0,67366,US20180057448A1,1
8753,8753, The crude product was purified by silica gel flash chromatography (ethyl acetate:hexanes 1:9).,0.0,67461,US20180057448A1,1
8754,8754," The purified product was used in the following reaction.
",0.0,67519,US20180057448A1,1
8755,8755,"The procedure was similar to that of 7b except the following: 6f from prior reaction, Pd(OH)2 (247 mg of 20 wt.",0.0,67630,US20180057448A1,1
8756,8756," % Pd(OH)2 on carbon, 0.35 mmol).",0.0,67663,US20180057448A1,1
8757,8757," The reaction was stirred for 4.5 hours under hydrogen, then it was filtered, and the solvent was evaporated.",0.0,67772,US20180057448A1,1
8758,8758," The crude product was used in the following reaction.
",0.0,67827,US20180057448A1,1
8759,8759,"The procedure was similar to that of 8a except the following: crude 7f from prior reaction, DIPEA (464 mg, 3.59 mmol), TBTU (865 mg, 3.59 mmol), and aniline (250 mg, 2.69 mmol).",0.0,68004,US20180057448A1,1
8760,8760, The reaction was stirred for 4 hours 45 minutes.,0.0,68053,US20180057448A1,1
8761,8761, The combined organic extracts were dried over anhydrous Na2CO3.,0.0,68117,US20180057448A1,1
8762,8762," The product was purified by silica gel flash chromatography (ethyl acetate:hexanes 1:3) to afford 8f (340 mg, 27% over four steps).",0.0,68249,US20180057448A1,1
8767,8767,"Synthesis of N1-hydroxy-4-methyl-N8-phenyloctanediamide (1a)
",0.0,68906,US20180057448A1,2
8768,8768,"In an acid-washed flask, hydroxylamine HCl (1.09 g, 15.67 mmol) was dissolved in MeOH (10 mL).",0.0,69000,US20180057448A1,1
8769,8769," KOH (1.76 g, 31.33 mmol) was added at 0° C. and allowed to stir for 20 minutes.",0.0,69080,US20180057448A1,1
8770,8770," An alcoholic solution of 7a (434 mg, 1.57 mmol, in 10 mL MeOH) was added, and the reaction was stirred for 4.5 hours at 0° C. The pH of the reaction mixture was adjusted to 6 with concentrated aqueous HCl, followed by dilution with distilled de-ionized water (30 mL).",0.0,69348,US20180057448A1,1
8771,8771, The reaction was extracted with ethyl acetate (3×30 mL).,0.0,69405,US20180057448A1,1
8772,8772, The organic extracts were collected together and dried over anhydrous Na2SO4.,0.0,69483,US20180057448A1,1
8773,8773," The product was purified by silica gel flash chromatography (acetone:dichloromethane 1:3) using iron-free silica gel to afford 1a (312 mg, 72%).",0.0,69628,US20180057448A1,1
8779,8779,"Synthesis of 4-ethyl-N1-hydroxy-N8-phenyloctanediamide (1b)
",0.0,70244,US20180057448A1,2
8780,8780,"The procedure was similar to that of 1a except the following: hydroxylamine HCl (597 mg, 8.59 mmol), KOH (964 mg, 17.18 mmol), and 7b (250 mg, 0.86 mmol).",0.0,70398,US20180057448A1,1
8781,8781," The reaction was left to stir for 4 hours at 0° C., then at room temperature overnight.",0.0,70486,US20180057448A1,1
8782,8782," The product was purified by silica gel flash chromatography (ethyl acetate:hexanes 1:4 to 1:3) using iron-free silica gel to afford 1b (116 mg, 46%).",0.0,70636,US20180057448A1,1
8788,8788,"Synthesis of 4-butyl-N1-hydroxy-N8-phenyloctanediamide (1c)
",0.0,71262,US20180057448A1,2
8789,8789,"The procedure was similar to that of 1a except the following: hydroxylamine HCl (538 mg, 7.74 mmol), KOH (869 mg, 15.49 mmol), and 7c (247 mg, 0.77 mmol).",0.0,71416,US20180057448A1,1
8790,8790," The product was purified by silica gel flash chromatography (acetone:dichloromethane 1:4) using iron-free silica gel to afford 1c (167 mg, 67%) 1HNMR (400 MHz, CD3OD) δ (ppm): 0.90 (t, J=7.6 Hz, 31H), 1.33 (m, 9H), 1.60 and 1.69 (overlapped m and quintet, J=7.2 Hz, 4H), 2.08 (t, J=7.2 Hz, 2H), 2.35 (t, J=7.2 Hz, 2H), 7.07 (t, J=8.0 Hz, 1H), 7.29 (t, J=7.6 Hz, 2H), 7.53 (d, J=8.0 Hz, 2H).",0.0,71807,US20180057448A1,1
8795,8795,"Synthesis of 4-hexyl-N1-hydroxy-N8-phenyloctanediamide (1d)
",0.0,72206,US20180057448A1,2
8796,8796,"The procedure was similar to that of 1a except the following: hydroxylamine HCl (573 mg, 8.24 mmol), KOH (925 mg, 16.48 mmol), and 7d (286 mg, 0.82 mmol).",0.0,72360,US20180057448A1,1
8797,8797," The reaction was stirred for 2 hours at 0° C., then pre-incubated solution of hydroxylamine HCl (573 mg, 8.24 mmol) and KOH (925 mg, 16.48 mmol) was added followed by stirring for 1.5 hour at 0° C. The product was purified by sequential silica gel flash chromatography (acetone:dichloromrethane 1:3 and a second purification with acetone:dichloromethane 1:2) using iron-free silica gel.",0.0,72747,US20180057448A1,1
8798,8798," The compound was further purified by HPLC on a reverse phase HPLC semi-preparative column (YMC America, 250×10 mmI.D., 4 m, 8 nm) using a gradient of 60% to 10% of buffer A over 90 minutes (buffer A=0.1% HPLC grade TFA in water; buffer B=HPLC grade acetonitrile) at a flow rate of 3.0 mL/min at room temperature to yield 1d (49 mg, 17%).",0.0,73085,US20180057448A1,1
8804,8804,"Synthesis of 4-hexyl-N1-hydroxy-N8-phenyloctanediamide (1e)
",0.0,73740,US20180057448A1,2
8805,8805,"The procedure was similar to that of 1a except the following: hydroxylamine HCl (1.38 g, 19.91 mmol), MeOH (50 mL), KOH (2.23 g, 39.82 mmol), and 7e (675 mg, 1.99 mmol).",0.0,73909,US20180057448A1,1
8806,8806, The reaction was stirred overnight.,0.0,73945,US20180057448A1,1
8807,8807," The product was purified by silica gel flash chromatography (5% MeOH in dichloromethane) using iron-free silica gel, followed by crystallization from MeOH to afford 1e (350 mg, 52%).",0.0,74128,US20180057448A1,1
8813,8813,"Synthesis of 4-benzyl-N1-hydroxy-N8-phenyloctanediamide (1f)
",0.0,74719,US20180057448A1,2
8814,8814,"The procedure was similar to that of 1a except the following: hydroxylamine HCl (600 mg, 8.64 mmol), KOH (970 mg, 17.28 mmol), and 7f (305 mg, 0.86 mmol).",0.0,74873,US20180057448A1,1
8815,8815," The reaction was stirred for 2 hours at 0° C., then another premixed solution of hydroxylamine HCl (600 mg, 8.64 mmol) and KOH (970 mg, 17.28 mmol) was added followed by stirring for 1.5 hour at 0° C. The product was purified by silica gel flash chromatography (acetone:dichloromethane 1:2) using iron-free silica gel to afford 1f (158 mg, 51%).",0.0,75219,US20180057448A1,1
8822,8822," Synthesis Procedures for (R)-1f and (S)-1f
",0.0,75789,US20180057448A1,2
8823,8823,"Synthesis of (R)-4-benzyl-3-(pent-4-enoyl)oxazolidin-2-one ((R)-9)
",0.0,75856,US20180057448A1,1
8824,8824,"The compound was synthesized in a similar way to the reported procedure.58 Briefly, (R)-8 (1.0 g, 5.64 mmol) was dissolved in dry THF (25 mL) followed by the addition of n-butyl lithium (2.5 mL of 2.5 M solution, 5.64 mmol) drop wise under argon at −78° C. The reaction was stirred at −78° C. for 10 minutes, then 4-pentenoyl chloride (0.81 mL, 6.77 mmol) was added drop wise.",0.0,76232,US20180057448A1,1
8825,8825, Stirring was continued for 30 minutes at −78° C. Then the reaction temperature was raised gradually over 30 minutes to room temperature.,0.0,76369,US20180057448A1,1
8826,8826, The reaction was diluted by addition of saturated solution of ammonium chloride (30 mL) followed by a saturated solution of sodium carbonate (30 mL) and stirred for 15 minutes at room temperature.,0.0,76566,US20180057448A1,1
8827,8827, The solution was extracted with ethyl acetate (3×40 mL).,0.0,76623,US20180057448A1,1
8828,8828," The organic extracts were combined and evaporated, and the product was purified by flash silica-gel chromatography (ethyl acetate:hexanes 1:9-1:3) which yielded the product (R)-9 (954 mg, 65%).",0.0,76817,US20180057448A1,1
8832,8832,"Synthesis of (R)-4-benzyl-3-((S)-2-benzylpent-4-enoyl)oxazolidin-2-one ((RS)-10)
",0.0,77496,US20180057448A1,2
8833,8833,"To compound (R)-9 (951 mg, 3.67 mmol) was added dry THF (20 mL) followed by lowering of the temperature to −78° C. NaHMDS (2.0 mL of 2 M solution, 4.04 mmol) was added drop wise under Argon and the reaction was stirred at −78° C. for 30 minutes.",0.0,77741,US20180057448A1,1
8834,8834," Benzyl bromide (0.86 mL, 7.34 mmol) was then added drop wise, and the reaction was stirred at −78° C. for 5 hours.",0.0,77856,US20180057448A1,1
8835,8835, The reaction temperature was increased gradually to room temperature overnight.,0.0,77936,US20180057448A1,1
8836,8836, The reaction was then quenched with a saturated ammonium chloride solution (15 mL) and was left to stir at room temperature for 15 minutes.,0.0,78076,US20180057448A1,1
8837,8837, The reaction was extracted with ethyl acetate (2×30 mL).,0.0,78133,US20180057448A1,1
8838,8838," The extracts were combined and evaporated, and the product was purified by flash silica-gel chromatography (ethyl acetate:hexanes 1:15-1:10) which yielded (RS)-10 as a white solid (730 mg, 57%).",0.0,78328,US20180057448A1,1
8843,8843,"Synthesis of (R)-4-benzyl-3-(3-phenylpropanoyl)oxazolidin-2-one ((R)-12)
",0.0,79347,US20180057448A1,2
8844,8844,"The procedure was similar to that of (R)-9 except the following reagents were used: (R)-8 (1.5 g, 8.47 mmol), n-butyl lithium (4.1 mL of 2.5 M solution, 10.16 mmol), and 3-phenyl propanoyl chloride (1.64 mL, 11 mmol).",0.0,79564,US20180057448A1,1
8845,8845, The reaction gave (R)-12 in 90% yield (2.36 g).,0.0,79612,US20180057448A1,1
8849,8849,"Synthesis of (R)-4-benzyl-3-((R)-2-benzylpent-4-enoyl)oxazolidin-2-one ((RR-10)
",0.0,80186,US20180057448A1,2
8850,8850,"The procedure was similar to that of (RS)-10 except the following reagents were used: (R)-16 (2.35 g, 7.59 mmol), NaHMDS (4.18 mL of 2 M solution, 8.35 mmol), and allyl bromide (1.97 mL, 22.8 mmol).",0.0,80384,US20180057448A1,1
8851,8851," The product was purified by Flash silica-gel chromatography (ethyl acetate:hexanes 1:15) which yielded (RS)-10 as an oily product (1.84 g, 69%).",0.0,80529,US20180057448A1,1
8856,8856,"Synthesis of (S)-2-benzylpent-4-en-1-ol ((S)-11)
",0.0,81513,US20180057448A1,2
8857,8857,"A solution of (RS)-10 (901 mg, 2.58 mmol) in dry THF (7 mL) was cooled and stirred at 0° C. in ice bath for 15 minutes.",0.0,81632,US20180057448A1,1
8858,8858," Lithium aluminum hydride (295 mg, 7.77 mmol) was added portion wise and the reaction was stirred at 0° C. for 2 hours.",0.0,81751,US20180057448A1,1
8859,8859, The reaction was quenched by careful drop wise addition of 1M solution of NaOH until no effervescence was observed.,0.0,81867,US20180057448A1,1
8860,8860, The reaction was then diluted with water (3 mL).,0.0,81916,US20180057448A1,1
8861,8861, Extraction of the aqueous layer was done with ethyl acetate (3×40 mL).,0.0,81987,US20180057448A1,1
8862,8862," The organic extracts were combined and evaporated, and the product was purified by flash silica-gel chromatography (ethyl acetate:hexanes 1:15-1:10) which afforded (S)-11 (402 mg, 88%).",0.0,82173,US20180057448A1,1
8866,8866,"Synthesis of (R)-2-benzylpent-4-en-1-ol ((R)-11)
",0.0,82619,US20180057448A1,2
8867,8867,"The procedure was similar to that of (S)-11 except the following reagents were used: (RR)-10 (1.83 g, 5.23 mmol) in dry THF (25 mL), Lithium aluminum hydride (595 mg, 15.68 mmol).",0.0,82798,US20180057448A1,1
8868,8868, The reaction afforded (R)-11 in 70% yield (645 mg).,0.0,82850,US20180057448A1,1
8871,8871,"Synthesis of (S)-2-benzylpent-4-en-1-yl (R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate ((S)-11-(R)-MTPA)
",0.0,83264,US20180057448A1,2
8872,8872,"Alcohol (S)-11 (35 mg, 0.2 mmol) was dissolved in dry DCM (4 mL), followed by replacement of air with argon and addition of (R)-(+)-α-Methoxy-α-trifluoromethylphenylacetic acid ((R)-MTPA, 71 mg, 0.3 mmol), EDCI (116 mg, 0.6 mmol), and 4-(dimethylamino)pyridine (73 mg, 0.6 mmol).",0.0,83543,US20180057448A1,1
8873,8873, The reaction was stirred overnight at room temperature.,0.0,83599,US20180057448A1,1
8874,8874, Solvent was evaporated and the residue was suspended in 1N HCl (5 mL) and extracted with ethyl acetate (2×15 mL).,0.0,83713,US20180057448A1,1
8875,8875," The combined extracts were combined and evaporated, and purified by silica gel flash chromatography (ethyl acetate:hexanes 1:15) to afford (S)-11-(R)-MTPA (49 mg, 63%).",0.0,83882,US20180057448A1,1
8880,8880,"Synthesis of (R)-2-benzylpent-4-en-1-yl (R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoate ((R)-11-(R)-MTPA)
",0.0,84534,US20180057448A1,2
8881,8881,"The procedure was similar to that of (SR)-18 except the following reagents were used (R)-11 (15.8 mg, 0.09 mmol), (R)-(+)-α-Methoxy-α-trifluoromethylphenylacetic acid ((R)-MTPA, 46 mg, 0.2 mmol), EDCI (35 mg, 0.27 mmol), and 4-(dimethylamino)pyridine (33 mg, 0.27 mmol).",0.0,84804,US20180057448A1,1
8882,8882, The reaction was stirred at room temperature for 3 hours.,0.0,84862,US20180057448A1,1
8883,8883, The product was purified by silica gel flash chromatography (ethyl acetate:hexanes 1:50) and afforded (R)-11-(R)-MTPA in 89% yield (32 rag).,0.0,85003,US20180057448A1,1
8888,8888,"Synthesis of dimethyl (R)-2-(2-benzylpent-4-en-1-yl)malonate ((R)-13)
",0.0,85628,US20180057448A1,2
8889,8889,"A solution of (S)-11 (400 mg, 2.27 mmol) in dry DCM (10 mL) was cooled to 0° C. in ice bath, followed by addition of triethyl amine (265 μL, 3.41 mmol), and then methanesulfonyl chloride (476 μL, 3.41 mmol) drop wise.",0.0,85845,US20180057448A1,1
8890,8890," The reaction was stirred for 10 minutes at 0° C., then for 1 hour at room temperature.",0.0,85932,US20180057448A1,1
8891,8891," The reaction was diluted with water (10 mL), followed by concentration at reduced pressure.",0.0,86024,US20180057448A1,1
8892,8892, The aqueous layer was extracted with ethyl acetate (3×20 mL).,0.0,86086,US20180057448A1,1
8893,8893," The organic extracts were combined, dried over anhydrous sodium sulfate, and evaporated.",0.0,86175,US20180057448A1,1
8894,8894," The crude product was used in the following reaction without purification.
",0.0,86251,US20180057448A1,1
8895,8895,"In a 2-neck flame dried flask, air was purged with argon, NaH (273 mg of 60% NaH in mineral oil, 6.82 mmol) dissolved in dry THF (20 mL) was added.",0.0,86398,US20180057448A1,1
8896,8896," The reaction was then cooled to 0° C. and dimethyl malonate (0.78 mL, 6.82 mmol) was added drop wise with stirring.",0.0,86514,US20180057448A1,1
8897,8897," The reaction was allowed to stir for 15 minutes at 0° C., then the crude product from the previous reaction was added (in 10 mL dry THF).",0.0,86652,US20180057448A1,1
8898,8898," The reaction was heated under reflux for 20 hours, and then another solution of malonate anion (0.78 mL, 6.82 mmol, prepared in the same way as described above) was added to the reaction and reflux was continued for another 20 hours.",0.0,86886,US20180057448A1,1
8899,8899, The reaction was then quenched with a saturated ammonium chloride solution (20 mL) and extracted with ethyl acetate (3×30 mL).,0.0,87013,US20180057448A1,1
8900,8900," The extracts were combined and evaporated, and the product was purified by flash silica-gel chromatography (ethyl acetate:hexanes 1:9) which yielded (R)-13 in 49% yield (269 mg) over two steps.",0.0,87207,US20180057448A1,1
8904,8904,"Synthesis of dimethyl (S)-2-(2-benzylpent-4-en-1-yl)malonate ((S)-13)
",0.0,87794,US20180057448A1,2
8905,8905,"The procedure was similar to that of (S)-12 except the following reagents were used: (R)-11 (597 mg, 3.34 mmol), triethyl amine (710 μL, 5.09 mmol), methanesulfonyl chloride (394 μL, 5.09 mmol), and the reaction was stirred at room temperature for 3 hours.",0.0,88050,US20180057448A1,1
8906,8906," For the next reaction, the following reagents were used once only, NaH (407 mg of 60% NaH in mineral oil, 10.17 mmol), dimethyl malonate (1.16 mL, 10.17 mmol) and the reaction was refluxed for 20 hours.",0.0,88253,US20180057448A1,1
8907,8907, The reaction afforded (S)-13 in 66% yield (648 mg) over two steps.,0.0,88320,US20180057448A1,1
8911,8911,"Synthesis of methyl (S)-4-benzylhept-6-enoate ((S)-14)
",0.0,88941,US20180057448A1,2
8912,8912,"(R)-13 (269 mg, 0.93 mmol) was dissolved in DMSO (15 mL) followed by addition of LiCl (394 mg, 9.3 mmol) and water (167 μL, 9.3 mmol).",0.0,89075,US20180057448A1,1
8913,8913, The reaction was heated under reflux (150-160° C.) overnight.,0.0,89137,US20180057448A1,1
8914,8914, Water (20 mL) was added to the reaction and the product was extracted with ethyl acetate (2×30 mL).,0.0,89237,US20180057448A1,1
8915,8915," The organic layer was evaporated and the product was purified by flash silica-gel chromatography (ethyl acetate:hexanes 1:15), which yielded (S)-14 in 75% yield (162 mg).",0.0,89408,US20180057448A1,1
8919,8919,"Synthesis of methyl (R)-4-benzylhept-6-enoate ((R)-14)
",0.0,89943,US20180057448A1,2
8920,8920,"The procedure was similar to that of (S)-14 except the following reagents were used: (S)-13 (617 mg, 2.13 mmol), LiCl (270 mg, 6.38 mmol), and water (115 μL, 6.38 mmol).",0.0,90112,US20180057448A1,1
8921,8921, The reaction afforded (R)-14 in 65% yield (321 mg).,0.0,90164,US20180057448A1,1
8925,8925,"Synthesis of N-phenylacrylamide (15)
",0.0,90658,US20180057448A1,2
8926,8926,"The compound was synthesized similar to the reported procedure.62 Briefly, aniline (3.03 mL, 33.15 mmol) and triethyl amine (6 mL, 66.29 mmol) were dissolved in dry DCM (30 mL) and the temperature of the solution was lowered to 0° C. A solution of acryloyl chloride (2.69 mL, 33.15 mmol) in dry DCM (10 mL) was added drop wise.",0.0,90985,US20180057448A1,1
8927,8927, The reaction temperature was increased gradually from 0° C. to room temperature and stirring was continued overnight at room temperature.,0.0,91123,US20180057448A1,1
8928,8928, Solvent was evaporated and the residue was suspended in 10% HCl (20 mL) and then extracted with DCM (2×30 mL).,0.0,91234,US20180057448A1,1
8929,8929," The combined organic extracts were washed with saturated solution of sodium carbonate (20 mL), dried over anhydrous sodium sulfate, and evaporated to give the product as a yellow solid (4.44 g, 91%).",0.0,91434,US20180057448A1,1
8932,8932,"Synthesis of methyl (S,E)-4-benzyl-8-oxo-8-(phenylamino)oct-6-enoate ((S)-16)
",0.0,91912,US20180057448A1,2
8933,8933,"To a solution of (S)-14 (162 mg, 0.7 mmol) in dry DCM (20 mL) was added 15 (103 mg, 0.7 mmol), and then air was replaced with argon.",0.0,92044,US20180057448A1,1
8934,8934," Grubbs' second generation catalyst (35 mg, 5 mol %) was added and the reaction was heated to 50-60° C. for 20 hours.",0.0,92161,US20180057448A1,1
8935,8935," A second addition of Grubbs' second generation catalyst (35 mg, 5 mol %) was done and the reaction was heated to 50-60° C. for 28 hours.",0.0,92298,US20180057448A1,1
8936,8936," The solvent was evaporated and the product was purified by flash silica-gel chromatography (ethyl acetate:hexanes 1:15 followed by 1:7-1:3), which yielded (S)-16 in 46% yield (112 mg).",0.0,92483,US20180057448A1,1
8940,8940,"Synthesis of methyl (R,E)-4-benzyl-8-oxo-8-(phenylamino)oct-6-enoate ((R)-16)
",0.0,93260,US20180057448A1,2
8941,8941,"A similar to that of (S)-16 was followed except the following reagents were used (R)-14 (321 mg, 1.38 mmol), 15 (204 mg, 1.38 mmol), and Grubbs' second generation catalyst (59 mg, 5 mol %).",0.0,93449,US20180057448A1,1
8942,8942, The reaction afforded (R)-16 in 48% yield (233 mg).,0.0,93501,US20180057448A1,1
8946,8946,"Synthesis of (R)-4-benzyl-N1-hydroxy-N8-phenyloctanediamide ((R)-1f)
",0.0,94269,US20180057448A1,2
8947,8947,"(S)-16 (112 mg, 0.32 mmol) was dissolved in MeOH (15 mL), then Pd (30 mg of 20 wt.",0.0,94351,US20180057448A1,1
8948,8948, % Pd on carbon) was added to the solution.,0.0,94394,US20180057448A1,1
8949,8949," Air inside the flask was purged with argon (three times), then with hydrogen gas (three times).",0.0,94490,US20180057448A1,1
8950,8950, The reaction was stirred under hydrogen overnight.,0.0,94541,US20180057448A1,1
8951,8951," The reaction was filtered, and the solvent was evaporated.",0.0,94600,US20180057448A1,1
8952,8952," The crude product was used in the next reaction without purification.
",0.0,94671,US20180057448A1,1
8953,8953,"In an acid-washed flask, hydroxylamine HCl (222 mg, 3.19 mmol) was dissolved in MeOH (10 mL).",0.0,94764,US20180057448A1,1
8954,8954," KOH (358 rag, 6.38 mmol) was added at 0° C. and allowed to stir for 10 minutes.",0.0,94844,US20180057448A1,1
8955,8955," An alcoholic solution of the crude product from the previous reaction (in 5 mL MeOH) was added, and the reaction was stirred for 3.5 hours at 0° C. Then another premixed solution of hydroxylamine HCl (222 mg, 3.19 mmol) and KOH (358 mg, 6.38 mmol) was added, followed by stirring for 4 hour at 0° C. The pH of the reaction mixture was adjusted to 6 with concentrated aqueous HCl, followed by dilution with distilled de-ionized water (10 mL).",0.0,95286,US20180057448A1,1
8956,8956, The reaction was extracted with ethyl acetate (2×20 mL).,0.0,95343,US20180057448A1,1
8957,8957," The product was purified by silica gel flash chromatography (acetone:dichloromethane 1:4-1:2) using iron-free silica gel to afford (R)-1f (84 mg, 74% over two steps).",0.0,95510,US20180057448A1,1
8963,8963,"Synthesis of (S)-4-benzyl-N1-hydroxy-N8-phenyloctanediamide ((S)-1f)
",0.0,96182,US20180057448A1,2
8964,8964,"A procedure similar to that of (R)-1f was followed, except the following reagents were used: (R)-16 (283 mg, 0.8 mmol), Pd (58 mg of 20 wt.",0.0,96321,US20180057448A1,1
8965,8965, % Pd on carbon).,0.0,96338,US20180057448A1,1
8966,8966," Hydroxylamine HCl (557 mg, 8.02 mmol) and KOH (900 mg, 16.03 mmol) were added once only and the reaction was stirred for 3 hours at 0° C. The product was purified by silica gel flash chromatography (acetone:dichloromethane 1:4-1:2) using iron-free silica gel to afford (S)-1f (133 mg, 47% over two steps).",0.0,96644,US20180057448A1,1
9672,9672, Amine 8 was reacted with either the N-hydroxysuccinimidyl carbonate of trans-cyclooctene (NHS-TCO) to generate O-TCO-TMM (5) or fluorescein isothiocyanate (FITC) to generate O-FITC-TMM (6).,0.0,59569,US20180072767A1,2
9673,9673," Purification by C18 reverse-phase chromatography yielded 5 and 6 in 62% and 85% yield, respectively.",0.0,59670,US20180072767A1,1
9687,9687,"O-AlkTMM may also be prepared by direct acylation of trehalose, such that compounds can be formed in one step.",1.0,61620,US20180072767A1,0
9695,9695,"N-(6-heptynoyl)-6-amino-6-deoxy-α,α-D-trehalose (N-AlkTMM)
",2.0,62397,US20180072767A1,0
9707,9707,"1H NMR (300 MHz, D2O): δ 5.17 (d, J=4.2 Hz, 1H), 5.13 (d, J=3.6 Hz, 1H), 3.86-3.70 (m, 6H), 3.66-3.61 (m, 2H), 3.60 (dd, J=2.7, 10.5 Hz, 1H), 3.44-3.37 (m, 2H), 3.30 (t, J=9.3 Hz, 1H), 2.37 (t, J=2.4 Hz, 1H), 2.29 (t, J=7.5 Hz, 2H), 2.23 (dt, J=2.4, 6.9 Hz, 2H), 1.70 (pent, J=6.9 Hz, 2H), 1.52 (pent, J=7.5 Hz, 2H).",1.0,64299,US20180072767A1,0
9718,9718,"1H NMR for O-C7TMM (300 MHz, D2O): δ 5.16 (d, J=3.9 Hz, 1H), 5.14 (d, J=3.6 Hz, 1H), 4.43 (dd, J=2.4, 12.3 Hz, 1H), 4.29 (dd, J=4.8, 12.3 Hz, 1H), 4.03-3.98 (m, 1H), 3.89-3.60 (m, 7H), 3.48 (t, J=9.6 Hz, 1H), 3.43 (t, J=9.6 Hz, 1H) 2.42 (t, J=7.5 Hz, 2H), 1.61 (pent, J=6.9 Hz, 2H), 1.38-1.24 (m, 6H), 0.86 (t, J=6.6 Hz, 3H).",1.0,65588,US20180072767A1,0
9734,9734," 1H NMR (500 MHz, D2O): δ 5.16 (d, J=3.0 Hz, 1H, H-1'), 5.15 (d, J=3.5 Hz, 1H, H-1), 4.42 (dd, J=2.0, 12 Hz, 1H, H-6a' or 6b'), 4.35 (dd, J=5.0, 12 Hz, 1H, H-6a' or 6b'), 4.01 (ddd, J=2.0, 4.5, 10.5 Hz, 1H, H-5'), 3.85-3.78 (m, 4H, H-3, 3', 5, 6a or 6b), 3.73 (dd, J=5.0, 12 Hz, 1H, H-6a or 6b), 3.63 (t, J=11 Hz, 1H, H-2'), 3.62 (t, J=11.5 Hz, 1H, H-2), 3.51 (t, J=10 Hz, 1H, H-4'), 3.42 (t, J=9.0 Hz, 1H, H-4), 2.66 (t, J=7.0 Hz, 2H, α-CH2), 2.51 (dt, J=2.5, 7.0 Hz, 2H, propargylic CH2), 2.36 (t, J=2.5 Hz, 1H, terminal alkyne H).",1.0,67231,US20180072767A1,0
9744,9744," 1H NMR (500 MHz, CD3OD) δ 5.01 (d, J=3.0 Hz, 1H, H-1'), 4.98 (d, J=4.0 Hz, 1H, H-1), 4.27 (dd, J=2.0, 12 Hz, 1H, H-6a' or 6b'), 4.11 (dd, J=5.0, 12 Hz, 1H, H-6a' or 6b'), 3.93 (ddd, J=2.0, 5.0, 10 Hz, 1H, H-5'), 3.75-3.66 (m, 4H, H-3, 3', 5, 6a or 6b), 3.58 (dd, J=5.5, 12 Hz, 1H, H-6a or 6b), 3.39 (t, J=5.0 Hz, 1H, H-2'), 3.37 (t, J=4.0 Hz, 1H, H-2), 3.25 (t, J=9.5 Hz, 1H, H-4'), 3.23-3.18 (m, 1H, H-4), 2.25 (t, J=7.0 Hz, 2H, α-CH2), 2.09-2.05 (m, J=2 3, propargylic CH2 and terminal alkyne H), 1.53 (pent, J=7.5 Hz, 2H, (3-CH2), 1.41 (pent, J=7.0 Hz, 2H, homopropargylic CH2), 1.33-1.23 (m, 10H, CH2s).",1.0,68394,US20180072767A1,0
9753,9753,"1H NMR (500 MHz, CD3OD): δ 5.00 (d, J=3.5 Hz, 1H, H-1'), 4.98 (d, J=3.5 Hz, 1H, H-1), 4.29 (dd, J=2.0, 12 Hz, 1H, H-6a' or 6b'), 4.11 (dd, J=5.0, 11.5 Hz, 1H, H-6a' or 6b'), 3.93 (ddd, J=2.0, 5.0, 10 Hz, 1H, H-5'), 3.76-3.66 (m, 4H, H-3, 3', 5, 6a or 6b), 3.63 (dd, J=5.0, 7.0 Hz, 1H, H-6a or 6b), 3.39 (t, J=4.5 Hz, 1H, H-2'), 3.37 (t, J=4.5 Hz, 1H, H-2), 3.26-3.20 (m, 4H, H-4, 4', CH2-N3), 2.30 (t, J=7.0 Hz, 2H, α-CH2), 1.63-1.51 (m, 4H, CH2s).",1.0,69361,US20180072767A1,0
9761,9761," 1H NMR (500 MHz, CD3OD): δ 5.01 (d, J=4.0 Hz, 1H, H-1'), 4.98 (d, J=4.0, 1 H, H-1), 4.29 (dd, J=2.5, 12 Hz, 1H, H-6a' or 6b'), 4.11 (dd, J=4.5, 11.5 Hz, 1H, H-6a' or 6b'), 3.93 (ddd, J=2.0, 5.0, 10.5 Hz, 1H, H-5'), 3.75-3.68 (m, 4H, H-3, 3', 5, 6a or 6b), 3.60 (dd, J=5.5, 12 Hz, 1H, H-6a or 6b), 3.40 (t, J=4.0 Hz, 1H, H-2'), 3.38 (t, J=4.5 Hz, 1H, H-2), 3.27-3.17 (m, 4H, H-4, 4', CH2-N3), 2.26 (t, J=7.5 Hz, 2H, α-CH2), 1.55-1.47 (m, 4H, CH2s), 1.31-1.25 (m, 10H, CH2s).",1.0,70268,US20180072767A1,0
9771,9771," 1H NMR (500 MHz): δ 5.16 (d, J=4.0 Hz, 1H, H-1'), δ 5.14 (d, J=4.0 Hz, 1H, H-1), 4.42 (dd, J=2.0, 12 Hz, 1H, H-6'a or b), δ 4.30 (dd, J=5.0, 12 Hz, 1H, H-6'a or b), 4.01 (ddd, J=2.0, 5.0, 10 Hz, 1H, H-5'), 3.86-3.78 (m, 4H, H-3', 3, 5, 6a or 6b), 3.74 (dd, J=5.0, 12 Hz, 1H, H6a or b), 3.63 (dd, J=4.0, 9.5 Hz, 1H, H-2'), 3.61 (dd, J=4.0, 10 Hz, 1H, H-2), 3.48 (t, J=10 Hz, 1H, H-4'), 3.42 (t, J=10 Hz, 1H, H-4), 2.97 (t, J=8.0 Hz, 2H, CH2-NH2), 2.42 (t, J=7.5 Hz, 2H, α-CH2), 1.67-1.59 (m, 4H, CH2s), 1.38-1.26 (m, 10H, CH2s).",1.0,71604,US20180072767A1,0
9780,9780," 1H NMR (500 MHz, CD3OD) δ 5.57-5.35 (m, 2H, TCO vinyl-CH), 5.00 (d, J=3.5 Hz, 1H, H-1'), 4.98 (d, J=3.0 Hz, 1H, H-1), 4.27 (dd, J=2.0, 12 Hz, 1H, H-6a' or 6b'), 4.22-4.16 (m, 2H, TCO CH), 4.10 (dd, J=5.0, 12 Hz, 1H, H-6a' or 6b'), 3.95-3.89 (m, 1H, H-5'), 3.74-3.66 (m, 4H, H-3, 3', 5, 6a or 6b), 3.58 (dd, J=5.5, 11 Hz, 1H, H-6a or 6b), 3.40-3.35 (m, 2H, H-2, 2'), 3.27-3.20 (m, 2H, H-4, 4'), 2.96 (t, J=5.5 Hz, 2H, CH2-N), 2.27-2.19 (m, 4H, α-CH2, TCO allylic CH2), 1.92-1.77 (m, 4H, TCO CH2s), 1.61 (pent, J=12.5 Hz, 2H, TCO CH2), 1.56-1.46 (m, 4H, (3-CH2, TCO CH2), 1.37-1.35 (m, 2H, CH2), 1.26-1.16 (m, 10H, CH2s).",1.0,73149,US20180072767A1,0
9789,9789," 1H NMR (500 MHz, 10% CDCl3 in CD3OD) δ 8.18 (s, broad, 1H, FITC Ar-CH), 7.86 (dd, J=2.0, 8.5 Hz, 1H, FITC Ar-CH), 7.16 (d, J=8.5 Hz, 1H, FITC Ar-CH), 6.71-6.69 (m, 4H, FITC Ar-CH), 6.56 (dd, J=2.5, 9.0 Hz, 2H, FITC Ar-CH), 5.14 (d, J=4.0 Hz, 1H, H-1'), 5.11 (d, J=3.5 Hz, 1H, H-1), 4.38 (dd, J=2.0, 12 Hz, 1H, H-6a' or 6b'), 4.26 (dd, J=5.5, 12.5 Hz, 1H, H-6a' or 6b'), 4.03 (ddd, J=2.0, 4.5, 10 Hz, 1H, H-5'), 3.85-3.78 (m, 4H, H-3, 3', 5, 6a or 6b), 3.71 (dd, J=6.0, 12 Hz, 1H, H-6a or 6b), 3.67-3.60 (m, 2H, CH2-N), 3.55 (dd, J=3.5, 10 Hz, 1H, H-2'), 3.51 (dd, J=4.0, 10 Hz, 1H, H-2), 3.42-3.36 (m, 2H, H-4, 4'), 2.37 (t, J=7.5 Hz, 2H, α-CH2), 1.70-1.63 (m, 4H, CH2s), 1.44-1.30 (m, 10H, CH2s).",1.0,74821,US20180072767A1,0
10048,10048, 1H NMR (FIG.,1.0,111188,US20180072767A1,0
10057,10057, 1H NMR (FIG.,1.0,112317,US20180072767A1,0
10067,10067, 1H NMR (FIG.,1.0,113618,US20180072767A1,0
10077,10077, 1H NMR (FIG.,1.0,115277,US20180072767A1,0
10422,10422,"The molecular weight of Compound B measured by FAB-MS was 409.
",0.0,42897,US20180083209A1,1
10428,10428,"The molecular weight of the white solid compound, measured by FAB-MS was 743.",0.0,43582,US20180083209A1,1
10429,10429," Through the results, the white solid compound was identified as Compound 1.
",0.0,43659,US20180083209A1,1
10430,10430,2.,2.0,43661,US20180083209A1,0
10431,10431," Synthesis of Compound 3
",1.0,43686,US20180083209A1,0
10433,10433," The molecular weight of Compound 3 measured by FAB-MS was 819.
",0.0,43945,US20180083209A1,1
10442,10442,"The molecular weight of Compound E measured by FAB-MS was 472.
",0.0,44716,US20180083209A1,1
10446,10446," The molecular weight of Compound F measured by FAB-MS was 485.
",0.0,45029,US20180083209A1,1
10450,10450," The molecular weight of Compound 4 measured by FAB-MS was 895.
",0.0,45356,US20180083209A1,1
10466,10466,"The molecular weight of Compound E measured by FAB-MS was 540.
",0.0,46839,US20180083209A1,1
10470,10470," The molecular weight of Compound 6 measured by FAB-MS was 869.
",0.0,47153,US20180083209A1,1
10471,10471,"The measuring of the molecular weight by FAB-MS was conducted using JMS-700V manufactured by JEOL CO.
",0.0,47255,US20180083209A1,1
11289,11289, Perkin Trans.,1.0,94261,US20180092937A1,0
11290,11290," 1 1989, 1769-1774.
",1.0,94281,US20180092937A1,0
11291,11291,"Intermediate 1.2
",1.0,94298,US20180092937A1,2
11292,11292,"5'-DMT-imidazopyridazinon-β-D-ribofuranoside
",0.0,94343,US20180092937A1,1
11293,11293,"<img> id-US20180092937A1-20180405-C00016.TIF </img>
",0.0,94395,US20180092937A1,1
11294,11294,"Imidazopyridazinon-β-D-ribofuranoside (INTERMEDIATE 1.1, 4.00 g, 14.9 mmol) was azeotroped with anhydrous pyridine (3×20 mL), dried in vacuo and dissolved in anhydrous pyridine (25 mL).",0.0,94580,US20180092937A1,1
11295,11295," To this solution was added a solution of 4,4'-dimethoxytrityl chloride (5.05 g, 14.9 mmol) in anhydrous pyridine (15 mL) and the reaction mixture was stirred for 1 h at room temperature.",0.0,94767,US20180092937A1,1
11296,11296," The reaction mixture was evaporated under reduced pressure and the resulting residue was purified by preparative reversed phase HPLC (X-Bridge C18, acetonitrile/water/NH3)
",0.0,94940,US20180092937A1,1
11299,11299,"Intermediate 1.3-a and Intermediate 1.3-b
",0.0,95034,US20180092937A1,2
11300,11300,"5'-DMT-2'-TBS-imidazopyridazinon-β-D-ribofuranoside (Intermediate 1.3-a) and 5'-DMT-3'-TBS-imidazopyridazinon-β-D-ribofuranoside (Intermediate 1.3-b)
",0.0,95184,US20180092937A1,1
11301,11301,"<img> id-US20180092937A1-20180405-C00017.TIF </img>
",0.0,95236,US20180092937A1,1
11302,11302,"5'-DMT-imidazopyridazinon-β-D-ribofuranoside (INTERMEDIATE 1.2, 5.30 g, 9.29 mmol) was azeotroped with anhydrous pyridine (3×30 mL), dried in vacuo and dissolved in anhydrous pyridine (20 mL).",0.0,95428,US20180092937A1,1
11303,11303," To this solution was added imidazole (1.90 g, 27.9 mmol) and tert-butylchlorodimethylsilane (1.54 g, 10.2 mmol) and the reaction mixture was stirred for 6 h at room temperature.",0.0,95606,US20180092937A1,1
11304,11304, The reaction mixture was partitioned between dichloromethane and water.,0.0,95678,US20180092937A1,1
11305,11305, The organic layer was separated and the aqueous layer extracted with dichloromethane.,0.0,95764,US20180092937A1,1
11306,11306," The combined organic extracts were washed with brine, dried using a hydrophobic frit and evaporated under reduced pressure.",0.0,95888,US20180092937A1,1
11307,11307," The resulting residue was purified by mid-pressure column chromatography (silica gel, gradient of 5-20% acetone in dichloromethane).
",0.0,96022,US20180092937A1,1
11311,11311,"Intermediate 1.4
",0.0,96165,US20180092937A1,2
11312,11312,"5'-DMT-3'-TBS-2'-CEP-imidazopyridazinon-β-D-ribofuranoside
",0.0,96224,US20180092937A1,1
11313,11313,"<img> id-US20180092937A1-20180405-C00018.TIF </img>
",0.0,96276,US20180092937A1,1
11314,11314,"5'-DMT-3'-TBS-imidazopyridazinon-β-D-ribofuranoside (INTERMEDIATE 1.3-b, 1.75 g, 2.56 mmol) was azeotroped with anhydrous acetonitrile (3×25 mL), dried in vacuo and dissolved in anhydrous dichloromethane (45 mL).",0.0,96488,US20180092937A1,1
11315,11315," To this solution was added 2-cyanoethyl N,N,N',N'-tetraisopropylphosphorodiamidite (1.62 mL, 5.12 mmol) and tetrazole (5.69 mL of a 0.5 M solution in acetonitrile, 2.85 mmol) and the reaction mixture was stirred at room temperature for 4 h. The reaction mixture was diluted with dichloromethane and washed with aqueous sodium hydrogen carbonate solution.",0.0,96843,US20180092937A1,1
11316,11316, The organic layer was separated and the aqueous layer was extracted with dichloromethane.,0.0,96933,US20180092937A1,1
11317,11317, The combined organic extracts were dried using a hydrophobic frit and evaporated under reduced pressure.,0.0,97038,US20180092937A1,1
11318,11318," The resulting residue was purified by mid-pressure column chromatography (silica gel (deactivated with triethylamine in dichloromethane), gradient of 20-100% ethyl acetate (3% triethylamine) in cyclohexane).",0.0,97246,US20180092937A1,1
11319,11319," The product was obtained as a mixture of diastereoismers.
",0.0,97305,US20180092937A1,1
11323,11323,"Intermediate 1.5
",0.0,97429,US20180092937A1,2
11324,11324,"5'-OH-2'-TBS-3'-H-phosphonate-N6-Bz-adenosine
",0.0,97475,US20180092937A1,1
11325,11325,"<img> id-US20180092937A1-20180405-C00019.TIF </img>
",0.0,97527,US20180092937A1,1
11326,11326,"N6-Bz-5'-DMT-2'-TBS-3'-CEP-adenosine (obtained from ChemGenes, 0.890 g, 0.90 mmol) was dissolved in acetonitrile (15 mL) and water (0.033 mL, 1.83 mmol, 2 eq.)",0.0,97686,US20180092937A1,1
11327,11327, at room temperature.,0.0,97707,US20180092937A1,1
11328,11328," Pyridinium trifluoroacetate (0.210 g, 1.09 mmol, 1.2 eq.)",0.0,97765,US20180092937A1,1
11329,11329, was added and the reaction mixture was stirred at room temperature for 10 minutes.,0.0,97848,US20180092937A1,1
11330,11330," tert-Butylamine (10 mL, 95.7 mmol) was added and the reaction mixture was stirred at room temperature for 30 minutes.",0.0,97966,US20180092937A1,1
11331,11331," The reaction mixture was evaporated under reduced pressure, re-dissolved in anhydrous acetonitrile (25 mL) and evaporated under reduced pressure to yield a white to colorless foam.",0.0,98147,US20180092937A1,1
11332,11332," The residue was dissolved in dichloromethane (25 mL) and water (0.162 mL, 9 mmol, 10 eq.).",0.0,98238,US20180092937A1,1
11333,11333," Dichloroacetic acid (0.670 mL, 8.12 mmol, 9 eq.)",0.0,98287,US20180092937A1,1
11334,11334, in dichloromethane (25 mL) was added and the resulting orange solution was stirred at room temperature for 10 minutes.,0.0,98406,US20180092937A1,1
11335,11335," Pyridine (1.31 mL, 16.23 mmol, 18 eq.)",0.0,98445,US20180092937A1,1
11336,11336," was added and the reaction mixture was stirred at room temperature for 5 minutes.
",0.0,98528,US20180092937A1,1
11337,11337,"LC-MS analytics of the raw material confirmed the presence of INTERMEDIATE 1.5.
",0.0,98608,US20180092937A1,1
11338,11338,"LC-MS (system A):
",0.0,98626,US20180092937A1,1
11339,11339,"tRet=3.10 min; ESI-MS: 550 [M+H]+
",0.0,98660,US20180092937A1,1
11340,11340,"The flask was stoppered, carefully sealed and stored at +2° C. for 16 hours.",0.0,98736,US20180092937A1,1
11341,11341, The solvents were evaporated under reduced pressure and the residue was azeotroped with anhydrous acetonitrile (4×15 mL).,0.0,98858,US20180092937A1,1
11342,11342, During the last evaporation procedure the solution was concentrated to approximately 5 mL of final azeotrope.,0.0,98968,US20180092937A1,1
11343,11343," The resulting anhydrous solution of intermediate 1.5 was immediately used in the next sequence of reactions.
",0.0,99078,US20180092937A1,1
11344,11344,"Intermediate 1.6
",0.0,99095,US20180092937A1,2
11345,11345,"Linear Dimer 5'-OH-3'-TBS-imidazopyridazinon-β-D-ribofuranoside-(2'→5')-cyanoethyl-phosphorothioate-2'-TBS-3'-H-phosphonate-N6-Bz-adenosine
",0.0,99235,US20180092937A1,1
11346,11346,"<img> id-US20180092937A1-20180405-C00020.TIF </img>
",0.0,99287,US20180092937A1,1
11347,11347,"5'-DMT-3'-TBS-2'-CEP-imidazopyridazinon-β-D-ribofuranoside (INTERMEDIATE 1.4, 1.340 g, 1.51 mmol, 1.7 eq.)",0.0,99393,US20180092937A1,1
11348,11348, was azeotroped with anhydrous acetonitrile (4×10 mL).,0.0,99447,US20180092937A1,1
11349,11349, During the last evaporation procedure the solution was concentrated to approximately 3 mL of the final azeotrope.,0.0,99561,US20180092937A1,1
11350,11350," The resulting solution was added to 5'-OH-2'-TBS-3'-H-phosphonate-N6-Bz-adenosine (INTERMEDIATE 1.5) dissolved in approximately 5 mL anhydrous acetonitrile (theoretical amount of desired material: 0.495 g, 0.90 mmol) at room temperature.",0.0,99799,US20180092937A1,1
11351,11351, The reaction mixture was stirred at room temperature for 30 minutes.,0.0,99868,US20180092937A1,1
11352,11352," ((N,N-dimethylamino-methylidene)amino)-3H-1,2,4-dithiazoline-3-thione (DDTT) (0.203 g, 0.99 mmol, 1.1 eq.)",0.0,99975,US20180092937A1,1
11353,11353, was added and the reaction mixture was stirred at room temperature for 30 minutes.,0.0,100058,US20180092937A1,1
11354,11354," The volatiles were evaporated under reduced pressure and the residue was dissolved in dichloromethane (25 mL) and water (0.162 mL, 9 mmol, 10 eq.).",0.0,100206,US20180092937A1,1
11355,11355," Dichloroacetic acid (1.340 mL, 16.24 mmol, 18 eq.)",0.0,100257,US20180092937A1,1
11356,11356," in dichloromethane (25 mL), was added and the orange solution was stirred at room temperature for 20 minutes.",0.0,100367,US20180092937A1,1
11357,11357, Pyridine (10 mL) was added and the reaction mixture was stirred at room temperature for 5 minutes.,0.0,100466,US20180092937A1,1
11358,11358," LC-MS analytics of the raw material confirmed the presence of INTERMEDIATE 1.6 as a mixture of diastereoisomers.
",0.0,100580,US20180092937A1,1
11362,11362,"The flask was stoppered, carefully sealed and stored at +2° C. for 16 hours.",0.0,100790,US20180092937A1,1
11363,11363, The mixture was evaporated under reduced pressure and the residue was co-evaporated with anhydrous pyridine (2×20 mL) under reduced pressure.,0.0,100932,US20180092937A1,1
11364,11364, A further portion of 40 mL anhydrous pyridine was added and the residue was concentrated under reduced pressure to approximately 20 mL total volume.,0.0,101081,US20180092937A1,1
11365,11365," The resulting anhydrous solution of INTERMEDIATE 1.6 was immediately used in the next sequence of reactions.
",0.0,101191,US20180092937A1,1
11366,11366,"Intermediate 1.7
",0.0,101208,US20180092937A1,2
11367,11367,"Cyclic Dimer 3'-TBS-imidazopyridazinon-β-D-ribofuranoside-(2'→5')-cyanoethyl-phosphorothioate-2'-TBS-N6-Bz-adenosine-(3'→5')-phosphorothioate
",0.0,101350,US20180092937A1,1
11368,11368,"<img> id-US20180092937A1-20180405-C00021.TIF </img>
",0.0,101402,US20180092937A1,1
11369,11369,"2-Chloro-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (DMOCP) (0.581 g, 3.15 mmol, 3.5 eq.)",0.0,101494,US20180092937A1,1
11370,11370," was added to crude 5'-OH-3'-TBS-imidazopyridazinon-β-D-ribofuranoside-(2'→5')-CE-PS-2'-TBS-3'-H-phosphonate-N6-Bz-adenosine (INTERMEDIATE 1.6) (theoretical amount of desired material in crude preparation: 0.957 g, 0.90 mmol) in anhydrous pyridine in a total volume of approximately 20 mL.",0.0,101783,US20180092937A1,1
11371,11371, The resulting mixture was stirred at room temperature for 20 minutes.,0.0,101853,US20180092937A1,1
11372,11372," Water (0.570 mL, 31.6 mmol, 35.1 eq.)",0.0,101891,US20180092937A1,1
11373,11373," and 3H-1,2-benzodithiol-3-one (0.230 g, 1.37 mmol, 1.5 eq.)",0.0,101951,US20180092937A1,1
11374,11374, were added and stirring was continued at room temperature.,0.0,102010,US20180092937A1,1
11375,11375," After 20 minutes, the reaction mixture was poured into a solution of sodium hydrogen carbonate (4.500 g, 53.6 mmol) in 150 mL water and was shaken at room temperature for 5 minutes, followed by the addition of a mixture of ethyl acetate/methyl-tert-butylether (150 mL, 1:1).",0.0,102285,US20180092937A1,1
11376,11376," The organic phase was separated and the aqueous phase was further extracted two times with ethyl acetate/methyl-tert-butylether (2×75 mL, 1:1).",0.0,102429,US20180092937A1,1
11377,11377," The combined organic phases were dried with anhydrous magnesium sulfate, followed by evaporation of solvents under reduced pressure and a final co-evaporation with 100 mL anhydrous toluene.",0.0,102619,US20180092937A1,1
11378,11378," The raw material was purified by preparative flash chromatography (160 g silica gel, gradient of 0-12.5% MeOH in dichloromethane) to yield 0.78 g of purity enriched INTERMEDIATE 1.7 (mixture of diastereomers).
",0.0,102830,US20180092937A1,1
11383,11383,"Intermediate 1.8
",0.0,103052,US20180092937A1,2
11384,11384,"Cyclic Dimer 3'-TBS-imidazopyridazinon-β-D-ribofuranoside-(2'→5')-phosphorothioate-2'-TBS-adenosine-(3'→5')-phosphorothioate
",0.0,103177,US20180092937A1,1
11385,11385,"<img> id-US20180092937A1-20180405-C00022.TIF </img>
",0.0,103229,US20180092937A1,1
11386,11386,125 mL 33% methylamine in absolute ethanol was added to purity enriched 3'-TBS-imidazopyridazinon-β-D-ribofuranoside-(2'→5')-cyanoethyl-phosphorothioate-2'-TBS-N6-Bz-adenosine-(3'→5')-phosphorothioate (INTERMEDIATE 1.7; 0.780 g) and the resulting solution was stirred at room temperature for 4 hours.,0.0,103529,US20180092937A1,1
11387,11387," All volatiles were evaporated under reduced pressure and further dried in vacuo yielding 0.758 g crude INTERMEDIATE 1.8 (mixture of diastereomers), which was directly used in the next reaction.
",0.0,103724,US20180092937A1,1
11392,11392,"Intermediate 2.1
",0.0,103944,US20180092937A1,2
11393,11393,"5'-OH-2'-F-3'-H-phosphonate-N6-Bz-2'-deoxyadenosine
",0.0,103996,US20180092937A1,1
11394,11394,"<img> id-US20180092937A1-20180405-C00023.TIF </img>
",0.0,104048,US20180092937A1,1
11395,11395,"N6-Benzoyl-5'-DMT-2'-F-2'-deoxyadenosine-3'-CEP (obtained from Alfa Aesar) (1.05 g, 1.20 mmol) was dissolved in acetonitrile (6 mL) and water (0.043 mL, 2.40 mmol, 2 eq.)",0.0,104218,US20180092937A1,1
11396,11396, at room temperature.,0.0,104239,US20180092937A1,1
11397,11397," Pyridinium trifluoroacetate (278 mg, 1.44 mmol, 1.2 eq.)",0.0,104296,US20180092937A1,1
11398,11398, was added and the reaction mixture was stirred at room temperature for 5 minutes.,0.0,104378,US20180092937A1,1
11399,11399," Afterwards, tert-butylamine (6.0 mL, 57.1 mmol) was added and the reaction mixture was stirred at room temperature for 15 minutes.",0.0,104509,US20180092937A1,1
11400,11400," The reaction mixture was evaporated in vacuo, re-dissolved (2×) in anhydrous acetonitrile (12 mL) and again evaporated in vacuo to yield a white to colorless foam.",0.0,104673,US20180092937A1,1
11401,11401," The residue was dissolved in dichloromethane (14.4 mL) and water (0.22 mL, 12.0 mmol, 10 eq.).",0.0,104768,US20180092937A1,1
11402,11402," Dichloroacetic acid in dichloromethane (6%, 14.4 mL) was added and the resulting orange solution was stirred at room temperature for 10 minutes.",0.0,104913,US20180092937A1,1
11403,11403," Pyridine (1.64 mL, 20.3 mmol, 17 eq.)",0.0,104951,US20180092937A1,1
11404,11404, was added and the reaction mixture was evaporated in vacuo and azeotroped with anhydrous acetonitrile (3×11 mL).,0.0,105064,US20180092937A1,1
11405,11405," Finally the remaining crude product was dried in high vacuo for additional 30 min and used without further purification.
",0.0,105186,US20180092937A1,1
11406,11406,"LC-MS analytics of the raw material confirmed the presence of INTERMEDIATE 2.1.
",0.0,105266,US20180092937A1,1
11409,11409,"Intermediate 2.2
",0.0,105335,US20180092937A1,2
11410,11410,"Linear Dimer 5'-OH-3'-TBS-imidazopyridazinon-β-D-ribofuranoside-(2'→5')-cyanoethyl-phosphorothioate-2'-F-3'-H-phosphonate-N6-Bz-2'-deoxyadenosine
",0.0,105481,US20180092937A1,1
11411,11411,"<img> id-US20180092937A1-20180405-C00024.TIF </img>
",0.0,105533,US20180092937A1,1
11412,11412,"5'-DMT-3'-TBS-2'-CEP-imidazopyridazinon-β-D-ribofuranoside (INTERMEDIATE 1.4, 1.38 g, 1.56 mmol, 1.0 eq.)",0.0,105638,US20180092937A1,1
11413,11413, was dissolved in anhydrous acetonitrile (10 mL) and was azeotropically evaporated in vacuo.,0.0,105730,US20180092937A1,1
11414,11414, This operation was repeated another three times leaving about 5 mL of azeotrope in the flask at the last evaporation.,0.0,105848,US20180092937A1,1
11415,11415," 10 pieces of molecular sieve (3 Å) were added and the resulting mixture was added to 5'-OH-2'-F-3'-H-phosphonate-N6-Bz-2'-deoxyadenosine (INTERMEDIATE 2.1) dissolved in approximately 3 mL anhydrous acetonitrile (theoretical amount of desired material: 523 mg, 1.20 mmol) at room temperature.",0.0,106140,US20180092937A1,1
11416,11416, The reaction mixture was stirred at room temperature for 5 minutes.,0.0,106208,US20180092937A1,1
11417,11417," ((N,N-dimethylamino-methylidene)amino)-3H-1,2,4-dithiazoline-3-thione (DDTT) (275 mg, 1.34 mmol, 0.9 eq.)",0.0,106314,US20180092937A1,1
11418,11418, was added and the reaction mixture was stirred at room temperature for 30 minutes.,0.0,106397,US20180092937A1,1
11419,11419," The volatiles were evaporated in vacuo and the residue was dissolved in dichloromethane (20 mL) and water (0.216 mL, 12 mmol, 7.7 eq.).",0.0,106533,US20180092937A1,1
11420,11420," Dichloroacetic acid in dichloromethane (6%, 19.2 mL) was added and the resulting orange solution was stirred at room temperature for 10 minutes.",0.0,106678,US20180092937A1,1
11421,11421," After this period, pyridine (12 mL) was added and the reaction mixture was evaporated in vacuo.",0.0,106774,US20180092937A1,1
11422,11422," Finally the remaining crude product was dried in high vacuo for additional 30 min and used without further purification and characterization.
",0.0,106917,US20180092937A1,1
11423,11423,"Intermediate 2.3
",0.0,106934,US20180092937A1,2
11424,11424,"Cyclic Dimer 3'-TBS-imidazopyridazinon-β-D-ribofuranoside-(2'→5')-cyanoethyl-phosphorothioate-2'-F-N6-Bz-2'-deoxyadenosine-(3'→5')-phosphorothioate
",0.0,107082,US20180092937A1,2
11425,11425,"<img> id-US20180092937A1-20180405-C00025.TIF </img>
",0.0,107134,US20180092937A1,1
11426,11426,"Crude intermediate 2.2 (maximum theoretical amount of desired material: 1.48 g, 1.56 mmol) was dissolved in 36 mL anhydrous pyridine and reduced to approximately 20 mL in vacuo.",0.0,107311,US20180092937A1,1
11427,11427," 2-Chloro-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (DMOCP) (775 mg, 4.20 mmol, 2.7 eq.)",0.0,107403,US20180092937A1,1
11428,11428, was added and the resulting mixture was stirred at room temperature for 5 minutes.,0.0,107486,US20180092937A1,1
11429,11429," Water (0.75 mL, 41.3 mmol, 26.5 eq.)",0.0,107523,US20180092937A1,1
11430,11430," and 3H-1,2-Benzodithiol-3-one (0.302 g, 1.80 mmol, 1.15 eq.)",0.0,107584,US20180092937A1,1
11431,11431, were added and stirring was continued at room temperature.,0.0,107643,US20180092937A1,1
11432,11432," After 5 minutes, the reaction mixture was poured into a solution of sodium hydrogen carbonate (4.00 g, 47.6 mmol) in 140 mL water and was stirred at room temperature for 5 minutes, followed by the addition of a mixture of ethyl acetate/methyl-tert-butylether (140 mL, 1:1).",0.0,107917,US20180092937A1,1
11433,11433, The organic phase was separated and the aqueous phase was further extracted with ethyl acetate/methyl-tert-butylether (1:1).,0.0,108042,US20180092937A1,1
11434,11434," The organic phases were combined and the solvent was removed in vacuo.
",0.0,108114,US20180092937A1,1
11435,11435,"The remaining residue was dissolved in a minimum volume of dichloromethane and purified by preparative flash chromatography (silica gel, DCM/MeOH: 100/0→80/20).",0.0,108274,US20180092937A1,1
11436,11436, Fractions were analyzed by HPLC-MS. Product-containing fractions were combined and the solvent removed in vacuo to yield 900 mg of a mixture of diastereoisomers.,0.0,108436,US20180092937A1,1
11442,11442,"Intermediate 2.4
",0.0,108742,US20180092937A1,2
11443,11443,"Cyclic Dimer 3'-TBS-imidazopyridazinon-β-D-ribofuranoside-(2'→5')-phosphorothioate-2'-F-2'-deoxyadenosine-(3'→5')-phosphorothioate
",0.0,108873,US20180092937A1,1
11444,11444,"<img> id-US20180092937A1-20180405-C00026.TIF </img>
",0.0,108925,US20180092937A1,1
11445,11445,To 10 mL methanol and 10 mL aq.,0.0,108956,US20180092937A1,1
11446,11446, ammonia (30-33%) were added 300 mg (max.,0.0,108997,US20180092937A1,1
11447,11447, theoretical amount of desired material: 0.31 mmol) of INTERMEDIATE 2.3.,0.0,109069,US20180092937A1,1
11448,11448, The resulting mixture was stirred at 50° C. for 15 h. The reaction mixture was cooled to room temperature and nitrogen was bubbled through the mixture for 30 min.,0.0,109232,US20180092937A1,1
11449,11449," The solvent was removed in vacuo, the mixture re-dissolved in anhydrous acetonitrile (30 mL) and again evaporated in vacuo.",0.0,109356,US20180092937A1,1
11450,11450," The residue was triturated with anhydrous acetonitrile, filtered, washed with 5 ml ACN and dried over night at room temperature.",0.0,109485,US20180092937A1,1
11451,11451, The crude product was dissolved in DMF and purified by preparative HPLC (X-Bridge C-18; acetonitrile/H2O/NH3).,0.0,109596,US20180092937A1,1
11452,11452, Product-containing fractions were collected and the solvent was removed by lyophilization.,0.0,109687,US20180092937A1,1
11453,11453," By this method, all four diastereoisomers could be separated.
",0.0,109750,US20180092937A1,1
11459,11459,"Intermediate 3.1
",0.0,110055,US20180092937A1,2
11460,11460,"5'-OH-3'-H-phosphonate-N6-Bz-LNA-adenine
",0.0,110096,US20180092937A1,1
11461,11461,"<img> id-US20180092937A1-20180405-C00027.TIF </img>
",0.0,110148,US20180092937A1,1
11462,11462,"INTERMEDIATE 3.1 was prepared analogously to INTERMEDIATE 2.1 by using “LNA-A amidite” (EQ-0063-1000, obtained from Exiqon) as starting material.
",0.0,110294,US20180092937A1,1
11463,11463,"LC-MS analytics of the raw material confirmed the presence of INTERMEDIATE 3.1.
",0.0,110374,US20180092937A1,1
11466,11466,"Intermediate 3.2
",0.0,110443,US20180092937A1,2
11467,11467,"Linear Dimer 5'-OH-3'-TBS-imidazopyridazinon-β-D-ribofuranoside-(2'→5')-cyanoethyl-phosphorothioate-3'-H-phosphonate-N6-Bz-LNA-adenine
",0.0,110578,US20180092937A1,1
11468,11468,"<img> id-US20180092937A1-20180405-C00028.TIF </img>
",0.0,110630,US20180092937A1,1
11469,11469,"INTERMEDIATE 3.2 was prepared analogously to INTERMEDIATE 2.2 by using INTERMEDIATE 3.1 and INTERMEDIATE 1.4 as starting materials.
",0.0,110762,US20180092937A1,1
11488,11488,"Intermediate 4.1
",0.0,111971,US20180092937A1,2
11489,11489,"5'-OH-2'-TBS-3'-H-phosphonate-purine-β-D-ribofuranoside
",0.0,112027,US20180092937A1,1
11490,11490,"<img> id-US20180092937A1-20180405-C00031.TIF </img>
",0.0,112079,US20180092937A1,1
11491,11491,INTERMEDIATE 4.1 was prepared analogously to INTERMEDIATE 1.5 by using 5'-DMT-2'-TBS-3'-CEP-purine-β-D-ribofuranoside_as starting material which can be prepared as described in Fu et al.,0.0,112265,US20180092937A1,1
11492,11492," Biochemistry 1993, 32, 10629-10637.",0.0,112301,US20180092937A1,1
11493,11493," In contrast to INTERMEDIATE 1.5 this intermediate was not stored overnight but used immediately in the next sequence of reactions.
",0.0,112433,US20180092937A1,1
11494,11494,"LC-MS analytics of the raw material confirmed the presence of INTERMEDIATE 4.1.
",0.0,112513,US20180092937A1,1
11497,11497,"Intermediate 4.2
",0.0,112582,US20180092937A1,2
11498,11498,"Linear Dimer 5'-OH-3'-TBS-imidazopyridazinon-β-D-ribofuranoside-(2'→5')-cyanoethyl-phosphorothioate-2'-TBS-3'-H-phosphonate-purine-β-D-ribofuranoside
",0.0,112732,US20180092937A1,1
11499,11499,"<img> id-US20180092937A1-20180405-C00032.TIF </img>
",0.0,112784,US20180092937A1,1
11500,11500,"INTERMEDIATE 4.2 was prepared analogously to INTERMEDIATE 1.6 by using INTERMEDIATE 1.4 and the above described INTERMEDIATE 4.1 as starting materials.
",0.0,112936,US20180092937A1,1
11501,11501,"LC-MS analytics of the raw material confirmed the presence of INTERMEDIATE 4.2 as a mixture of diastereoisomers.
",0.0,113049,US20180092937A1,1
11505,11505,"Intermediate 4.3
",0.0,113201,US20180092937A1,2
11506,11506,"Cyclic Dimer 3'-TBS-imidazopyridazinon-β-D-ribofuranoside-(2'→5')-cyanoethyl-phosphoro-thioate-2'-TBS-purine-β-D-ribofuranoside-(3'→5')-phosphorothioate
",0.0,113354,US20180092937A1,1
11507,11507,"<img> id-US20180092937A1-20180405-C00033.TIF </img>
",0.0,113406,US20180092937A1,1
11508,11508,"INTERMEDIATE 4.3 (as mixture of diastereomers) was prepared analogously to INTERMEDIATE 1.7 by using INTERMEDIATE 4.2 as starting material.
",0.0,113546,US20180092937A1,1
11513,11513,"Intermediate 4.4
",0.0,113770,US20180092937A1,2
11514,11514,"Cyclic Dimer 3'-TBS-imidazopyridazinon-β-D-ribofuranoside-(2'→5')-phosphorothioate-2'-TBS-purine-β-D-ribofuranoside-(3'→5')-phosphorothioate
",0.0,113911,US20180092937A1,1
11515,11515,"<img> id-US20180092937A1-20180405-C00034.TIF </img>
",0.0,113963,US20180092937A1,1
11516,11516,"INTERMEDIATE 4.4 (as mixture of diastereomers) was prepared analogously to INTERMEDIATE 1.8 by using INTERMEDIATE 4.3 as starting material.
",0.0,114103,US20180092937A1,1
11528,11528,"Cyclic (imidazopyridazinon-β-D-ribofuranoside-(2'→5')-phosphorothioate-adenosine-(3'→5')-phosphorothioate)
",0.0,114776,US20180092937A1,1
11529,11529,"<img> id-US20180092937A1-20180405-C00035.TIF </img>
",0.0,114828,US20180092937A1,1
11530,11530,30 mL anhydrous pyridine and 15 mL anhydrous triethylamine were added to crude 3'-TBS-imidazopyridazinon-3-D-ribofuranoside-(2'→5')-phosphorothioate-2'-TBS-adenosine-(3'→5')-phosphorothioate (INTERMEDIATE 1.8; 0.76 g).,0.0,115046,US20180092937A1,1
11531,11531," The resulting solution was concentrated under reduced pressure to approximately 5 mL total volume, followed by simultaneous addition of triethylamine trihydrofluoride (3.590 mL, 21.7 mmol) and 11 mL anhydrous triethylamine.",0.0,115270,US20180092937A1,1
11532,11532, This solution was stirred at 50° C. for 3.5 hours.,0.0,115321,US20180092937A1,1
11533,11533," After cooling to room temperature, the reaction was quenched with methoxytrimethylsilane (10 mL, 72.4 mmol) and further stirred at room temperature to consume any excess of HF.",0.0,115498,US20180092937A1,1
11534,11534," After 30 minutes, all volatile components were evaporated under reduced pressure, followed by a final co-evaporation with 50 mL anhydrous toluene under reduced pressure.",0.0,115668,US20180092937A1,1
11535,11535," The residue was further dried in vacuo to yield the raw mixture containing Example 1.1 and Example 1.2.
",0.0,115773,US20180092937A1,1
11536,11536,65 mL water was added and the resulting suspension was placed in an ultrasonic bath at room temperature.,0.0,115877,US20180092937A1,1
11537,11537," After 15 minutes, this suspension was poured into 60 mL chloroform and the organic phase was separated.",0.0,115981,US20180092937A1,1
11538,11538, This extraction was repeated another two times with chloroform.,0.0,116045,US20180092937A1,1
11547,11547,"Preparation of Example 1.1, Sodium Salt (“Fourth Eluting Diastereomer”)
",0.0,117416,US20180092937A1,2
11548,11548,"Desalting of EXAMPLE 1.1, TEA-salt was performed by preparative reversed phase medium pressure liquid chromatography (MPLC).",0.0,117540,US20180092937A1,1
11549,11549," The product solution (˜40 mL) was applied to a Merck LiChroprep®RP-18 column (15-25 μm; 450×25 mm; ˜220 mL), previously equilibrated with water.",0.0,117685,US20180092937A1,1
11550,11550, The column was washed with water to remove excess TEAF buffer.,0.0,117748,US20180092937A1,1
11551,11551," Afterwards, 2% 2-propanol in water was used to elute the desalted EXAMPLE 1.1.",0.0,117827,US20180092937A1,1
11552,11552," Product-containing fractions were partially concentrated under reduced pressure and subsequently applied to a SP Sepharose™ Fast Flow cation exchange column (45-165 μm; 125×35 mm; 120 mL) Na+-form, previously regenerated with 2 M sodium chloride and washed with water.",0.0,118096,US20180092937A1,1
11553,11553, The column was washed with water until no UV-absorbance was detectable anymore (detection wavelength 254 nm).,0.0,118206,US20180092937A1,1
11554,11554," Product-containing fractions were carefully evaporated under reduced pressure and additionally dried in vacuo to yield EXAMPLE 1.1 as disodium salt.
",0.0,118356,US20180092937A1,1
11565,11565,"Example 2.1 and Example 2.2
",0.0,119486,US20180092937A1,2
11566,11566,"Cyclic (imidazopyridazinon-β-D-ribofuranoside-(2'→5')-phosphorothioate-2'-F-2'-deoxyadenosine-(3'→5')-phosphorothioate
",0.0,119605,US20180092937A1,1
11567,11567,"<img> id-US20180092937A1-20180405-C00036.TIF </img>
",0.0,119657,US20180092937A1,1
11568,11568,16 mg (19 μmol) of INTERMEDIATE 2.4-d were added to 1 mL anhydrous pyridine and 4 mL anhydrous acetonitrile and the solvent was azeotropically evaporated in vacuo.,0.0,119820,US20180092937A1,1
11569,11569, The residue was twice re-suspended in 10 mL anhydrous acetonitrile and again azeotropically evaporated in vacuo.,0.0,119933,US20180092937A1,1
11570,11570, 80.7 μL (1.0 mmol) anhydrous pyridine and 168 μL (1.2 μmol) TEA were added to the residue before 103 μL (0.63 mmol) TEA*3HF were cautiously added via a syringe.,0.0,120094,US20180092937A1,1
11571,11571, The resulting mixture was stirred at 50° C. for 90 min.,0.0,120150,US20180092937A1,1
11572,11572," After cooling to room temperature, the reaction was quenched by the addition of 20 mL of an aq.",0.0,120246,US20180092937A1,1
11573,11573, solution of triethylammonium carbonate (conc.=1 mol/L).,0.0,120302,US20180092937A1,1
11574,11574, The resulting mixture was stirred for further 15 min at room temperature.,0.0,120376,US20180092937A1,1
11575,11575," The mixture was carefully loaded on a Water Sep Pak C18© cartridge (5 g C18-material, preconditioned with first 25 mL acetonitrile and afterwards with 25 mL water) and washed with 60 mL of water.",0.0,120572,US20180092937A1,1
11576,11576, Afterwards the product was eluted from the cartridge by using 100 mL of a acetonitrile/triethylammonium acetat/water mixture (prepared by adding 1 mL of an aq.,0.0,120732,US20180092937A1,1
11577,11577, triethylammonium acetat solution (conc=1 mol/L) to 100 mL water and 25 mL acetonitrile).,0.0,120821,US20180092937A1,1
11578,11578, Fractions containing product were combined and the solvent was removed by lyophilization.,0.0,120911,US20180092937A1,1
11579,11579, The resulting product was further purified by prep.,0.0,120963,US20180092937A1,1
11580,11580, HPLC (Atlantis C18; 20 mM aq.,0.0,120993,US20180092937A1,1
11581,11581, NH4OAc/acetonitrile=98/2→80/20.).,0.0,121027,US20180092937A1,1
11582,11582," After the solvent were removed by freeze drying the product was dissolved in 2 mL water and poured on a Bio-Rad Spin column (filled with 250 mg BT AG 50W-2 resin 100-200 Mesh hydrogen Form, conditioned with 3 mL 1M aq.",0.0,121246,US20180092937A1,1
11583,11583, NaOH and afterwards washed with 6 mL water resulting in pH˜7)) and eluted with 12 mL water.,0.0,121338,US20180092937A1,1
11584,11584," Fractions containing the final product were combined and the solvent was removed by freeze drying.
",0.0,121438,US20180092937A1,1
11590,11590,"Example 2.2
",0.0,121879,US20180092937A1,2
11591,11591,"EXAMPLE 2.2 was prepared analogously to EXAMPLE 2.1 by using INTERMEDIATE 2.4-c as starting material.
",0.0,121981,US20180092937A1,1
11596,11596,"Example 3.1 and Example 3.2
",0.0,122450,US20180092937A1,2
11597,11597,"Cyclic (imidazopyridazinon-β-D-ribofuranoside-(2'→5')-phosphorothioate-LNA-adenine-(3'→5')-phosphorothioate), Sodium Salt
",0.0,122572,US20180092937A1,1
11598,11598,"<img> id-US20180092937A1-20180405-C00037.TIF </img>
",0.0,122624,US20180092937A1,1
11608,11608,"Example 4.1 and Example 4.2
",0.0,123766,US20180092937A1,2
11609,11609,"Cyclic (imidazopyridazinon-β-D-ribofuranoside-(2'→5')-phosphorothioate-purine-β-D ribofuranoside-(3'→5')-phosphorothioate), Sodium Salt
",0.0,123902,US20180092937A1,1
11610,11610,"<img> id-US20180092937A1-20180405-C00038.TIF </img>
",0.0,123954,US20180092937A1,1
11611,11611,EXAMPLES 4.1 and 4.2 were prepared analogously to EXAMPLE 1.1 and 1.2 by using INTERMEDIATE 4.4-d and INTERMEDIATE 4.4-c as starting material.,0.0,124096,US20180092937A1,1
11612,11612," In addition to the procedure described for EXAMPLES 1.1 and 1.2, before starting the reaction the starting material was once azeotroped by using a 2:1 mixture of anhydrous pyridine and anhydrous triethylamine.
",0.0,124307,US20180092937A1,1
12203,12203,"Synthesis of Intermediate Compound (iii)
",1.0,177867,US20180105741A1,2
13016,13016,"2 & <img> id-US20200031833A1_00044.PNG </img> & 3-(1,3-dimethyl-1H- indazol-5-yl)-2,6- dimethyl-N-((6- methylpyridin-3- yl)methyl)imidazo[1,2- b]pyridazin-8-amine
",0.0,57887,US20200031833A1,2
13017,13017,"3 & <img> id-US20200031833A1_00045.PNG </img> & N-(4-chlorobenzyl)- 3-(1,3-dimethyl-1H- indazol-5-yl)-2,6- dimethylimidazo[1,2- b]pyridazin-8-amine
",0.0,58035,US20200031833A1,2
13018,13018,"4 & <img> id-US20200031833A1_00046.PNG </img> & 3-(1,3-dimethyl-1H- indazol-5-yl)-N-((6- methoxypyridin-3- yl)methyl)-2,6- dimethylimidazo[1,2- b]pyridazin-8-amine
",0.0,58199,US20200031833A1,2
13019,13019,"5 & <img> id-US20200031833A1_00047.PNG </img> & 3-(1,3-dimethyl-1H- indazol-5-yl)-2,6- dimethyl-N-(thiophen- 2-ylmethyl)imidazo[1,2- b]pyridazin-8-amine
",0.0,58352,US20200031833A1,2
13020,13020,"6 & <img> id-US20200031833A1_00048.PNG </img> & 3-(1,3-dimethyl-1H- indazol-5-yl)-N-(4- methoxybenzyl)-2,6- dimethylimidazo[1,2- b]pyridazin-8-amine
",0.0,58501,US20200031833A1,2
13021,13021,"7 & <img> id-US20200031833A1_00049.PNG </img> & 3-(1,3-dimethyl-1H- indazol-5-yl)-2,6- dimethyl-N-(4- (methylsulfonyl) benzyl)imidazo[1,2- b]pyridazin-8-amine
",0.0,58660,US20200031833A1,2
13022,13022,"8 & <img> id-US20200031833A1_00050.PNG </img> & 3-(1,3-dimethyl-1H- indazol-5-yl)-2,5- dimethyl-N-(pyridin-4- ylmethyl)pyrazolo[1,5- a]pyrimidin-7-amine
",0.0,58813,US20200031833A1,2
13023,13023,"9 & <img> id-US20200031833A1_00051.PNG </img> & 3-(1,3-dimethyl-1H- indazol-5-yl)-2,5- dimethyl-N-((6- methylpyridin-3- yl)methyl)pyrazolo [1,5-a]pyrimidin-7- amine
",0.0,58978,US20200031833A1,2
13024,13024,"10 & <img> id-US20200031833A1_00052.PNG </img> & 3-(1,3-dimethyl-1H- indazol-5-yl)-N-(4- methoxybenzyl)-2,5- dimethylpyrazolo[1,5- a]pyrimidin-7-amine
",0.0,59129,US20200031833A1,2
13025,13025,"11 & <img> id-US20200031833A1_00053.PNG </img> & N-(4-chlorobenzyl)-3- (1,3-dimethyl-1H- indazol-5-yl)-2,5- dimethylpyrazolo[1,5- a]pyrimidin-7-amine
",0.0,59279,US20200031833A1,2
13026,13026,"12 & <img> id-US20200031833A1_00054.PNG </img> & 3-(1,3-dimethyl-1H- indazol-5-yl)-2,5- dimethyl-N-(4- (methylsulfonyl) benzyl)pyrazolo[1,5- a]pyrimidin-7-amine
",0.0,59440,US20200031833A1,2
13027,13027,"13 & <img> id-US20200031833A1_00055.PNG </img> & 4-(((3-(1,3-dimethyl- 1H-indazol-5-yl)-2,5- dimethylpyrazolo[1,5- a]pyrimidin-7- yl)amino)methyl) benzenesulfonamide
",0.0,59606,US20200031833A1,2
13028,13028,"14 & <img> id-US20200031833A1_00056.PNG </img> & 3-(1,3-dimethyl-1H- indazol-5-yl)-N-((6- methoxypyridin-3- yl)methyl)-2,5- dimethylpyrazolo[1,5- a]pyrimidin-7-amine
",0.0,59772,US20200031833A1,2
13029,13029,"15 & <img> id-US20200031833A1_00057.PNG </img> & 3-(1,3-dimethyl-1H- indazol-5-yl)-2,5- dimethyl-N- (thiophen-2- ylmethyl)pyrazolo [1,5-a]pyrimidin-7- amine
",0.0,59929,US20200031833A1,2
13030,13030,"16 & <img> id-US20200031833A1_00058.PNG </img> & N-(4-(((3-(1,3- dimethyl-1H- indazol-5-yl)-2,5- dimethylpyrazolo [1,5-a]pyrimidin-7- yl)amino)methyl)phenyl) methanesulfonamide
",0.0,60106,US20200031833A1,2
13031,13031,"17 & <img> id-US20200031833A1_00059.PNG </img> & 3-(1,3-dimethyl-1H- indazol-5-yl)-2,5- dimethyl-N-((6- trifluoromethylpyridin- 3-yl)methyl)pyrazolo [1,5-a]pyrimidin-7-amine
",0.0,60280,US20200031833A1,2
13032,13032,"18 & <img> id-US20200031833A1_00060.PNG </img> & N-(benzyl)-3-(1,3- dimethyl-1H-indazol- 5-yl)-2,5- dimethylpyrazolo [1,5-a]pyrimidin- 7-amine
",0.0,60423,US20200031833A1,2
13033,13033,"19 & <img> id-US20200031833A1_00061.PNG </img> & N-(4-fluorobenzyl)- 3-(1,3-dimethyl-1H- indazol-5-yl)-2,5- dimethylpyrazolo[1,5- a]pyrimidin-7-amine
",0.0,60573,US20200031833A1,2
13034,13034,"20 & <img> id-US20200031833A1_00062.PNG </img> & 8-(1,3-dimethyl-1H- indazol-5-yl)-2,7- dimethyl-N-(pyridin-4- ylmethyl)pyrazolo[1,5- a][1,3,5]triazin-4-amine
",0.0,60732,US20200031833A1,2
13035,13035,"21 & <img> id-US20200031833A1_00063.PNG </img> & 8-(1,3-dimethyl-1H- indazol-5-yl)-N-(4- methoxybenzyl)-2,7- dimethylpyrazolo[1,5- a][1,3,5]triazin-4-amine
",0.0,60888,US20200031833A1,2
13036,13036,"22 & <img> id-US20200031833A1_00064.PNG </img> & 8-(1,3-dimethyl-1H- indazol-5-yl)-2,7- dimethyl-N-((6- methylpyridin-3- yl)methyl)pyrazolo [1,5-a][1,3,5]triazin- 4-amine
",0.0,61059,US20200031833A1,2
13037,13037,"23 & <img> id-US20200031833A1_00065.PNG </img> & 4-(((8-(1,3-dimethyl- 1H-indazol-5-yl)-2,7- dimethylpyrazolo[1,5- a][1,3,5]triazin-4- yl)amino)methyl) benzenesulfonamide
",0.0,61230,US20200031833A1,2
13038,13038,"24 & <img> id-US20200031833A1_00066.PNG </img> & N-(4-chlorobenzyl)- 8-(1,3-dimethyl-1H- indazol-5-yl)-2,7- dimethylpyrazolo[1,5- a][1,3,5]triazin-4-amine
",0.0,61385,US20200031833A1,2
13039,13039,"25 & <img> id-US20200031833A1_00067.PNG </img> & 8-(1,3-dimethyl-1H- indazol-5-yl)-2,7- dimethyl-N-(4- (methylsulfonyl) benzyl)pyrazolo[1,5- a][1,3,5]triazin-4-amine
",0.0,61551,US20200031833A1,2
13040,13040,"26 & <img> id-US20200031833A1_00068.PNG </img> & N-(4-(((8-(1,3-dimethyl- 1H-indazol-5-yl)- 2,7-dimethylpyrazolo [1,5-a][1,3,5]triazin-4- yl)amino)methyl)phenyl) methanesulfonamide
",0.0,61732,US20200031833A1,2
13041,13041,"27 & <img> id-US20200031833A1_00069.PNG </img> & 8-(1,3-dimethyl-1H- indazol-5-yl)-2,7- dimethyl-N-(thiophen- 2-ylmethyl)pyrazolo [1,5-a][1,3,5]triazin-4- amine
",0.0,61893,US20200031833A1,2
13042,13042,"28 & <img> id-US20200031833A1_00070.PNG </img> & 8-(1,3-dimethyl-1H- indazol-5-yl)-N-((6- methoxypyridin-3- yl)methyl)-2,7- dimethylpyrazolo [1,5-a][1,3,5]triazin- 4-amine
",0.0,62065,US20200031833A1,2
13068,13068,"Step 2
",1.0,64666,US20200031833A1,2
13069,13069,"To a stirred solution of 5-bromo-1,3-dimethyl-1H-indazole (5.4 g, 0.023 mol) and 4,4,5,5,4′,4′,5′,5′-octamethyl-[2,2′]bi[[1,3,2]dioxaborolanyl] (7.3 g. 0.0287 mol) in dioxane (54 mL, 10 V) were added potassium acetate (7.05 g, 0.0719 mol) and palladium tetrakis (1.38 g, 0.0011 mol) under room temperature.",0.0,64972,US20200031833A1,1
13070,13070, The resulting reaction mass was stirred at 100° C. over a period of 3 hours.,0.0,65049,US20200031833A1,1
13071,13071, The reaction was monitored by TLC.,0.0,65084,US20200031833A1,1
13072,13072, The reaction mass was diluted with ethyl acetate (200 mL) and filtered through a celite pad.,0.0,65177,US20200031833A1,1
13073,13073," The organic layer was washed with water (500 mL), brine (250 mL), dried over anhydrous sodium sulphate and concentrated.",0.0,65298,US20200031833A1,1
13074,13074," The crude product obtained was purified by silica gel (230-400) column chromatography (15% ethyl acetate in hexane) to obtain tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole as an off-white solid (5.2 g, 80%).
",0.0,65511,US20200031833A1,1
13075,13075,"General Procedure 1: Synthesis of Imidazopyridazine Derivatives (Scheme 1)
",0.0,65586,US20200031833A1,2
13076,13076,"<img> id-US20200031833A1_00073.PNG </img>
",0.0,65628,US20200031833A1,1
13077,13077,"Step 1
",0.0,65635,US20200031833A1,2
13078,13078,"To a solution of 6-methyl-pyridazin-3-ylamine, A (2.0 g, 0.018 mol) in acetonitrile (60 mL, 30 V) was added N-bromo succinamide (3.92 g, 0.022 mol) under room temperature.",0.0,65806,US20200031833A1,1
13079,13079, The reaction mass was stirred at room temperature for 2 hours.,0.0,65869,US20200031833A1,1
13080,13080, The reaction was monitored by TLC.,0.0,65904,US20200031833A1,1
13081,13081," The crude reaction mass obtained upon evaporation of the volatiles was purified by silica gel (60-120) column chromatography (3% methanol in dichloromethane) to obtain 4-bromo-6-methyl-pyridazin-3-ylamine, B, (0.6 g, 30%) as a dark brown solid.
",0.0,66150,US20200031833A1,1
13082,13082,"Step 2
",0.0,66157,US20200031833A1,2
13083,13083,"To a solution of B (0.6 g, 3.1 mmol) in ethanol (6 mL, 10 V) was added chloro acetone (0.4 mL, 4.4 mmol) under room temperature.",0.0,66285,US20200031833A1,1
13084,13084, The resulting reaction mass was stirred at reflux temperature for 16 hours.,0.0,66361,US20200031833A1,1
13085,13085, The reaction was monitored by TLC.,0.0,66396,US20200031833A1,1
13086,13086, The crude reaction mass obtained upon evaporation of the volatiles was basified with saturated sodium bicarbonate and extracted with dichloromethane (100 mL).,0.0,66555,US20200031833A1,1
13087,13087," The organic layer was separated, dried over anhydrous sodium sulphate and concentrated under reduced pressure.",0.0,66666,US20200031833A1,1
13088,13088," The crude product obtained was purified by silica gel (230-400) column chromatography (1.5% methanol in dichloromethane) to obtain 8-bromo-2,6-dimethyl-imidazo[1,2-b]pyridazine, C, (0.15 g, 20%) as a pale yellow solid.
",0.0,66886,US20200031833A1,1
13089,13089,"Step 3
",0.0,66893,US20200031833A1,2
13090,13090,"To a solution of C (0.33 g, 1.4 mmol) and amine RANH2 (0.0027 mol, 1.3 eq) in toluene (10 mL, 30 V) under argon atmosphere in a sealed tube were added cesium carbonate (1.0 g, 2.9 mmol) and BINAP (46 mg, 0.07 mmol) at room temperature.",0.0,67128,US20200031833A1,1
13091,13091," The resulting reaction mass was degassed for 5 minutes, palladium acetate (17 mg, 0.07 mmol) was added and stirring was continued at 100° C. for a period of 16 hours.",0.0,67295,US20200031833A1,1
13092,13092, The resulting reaction mass was diluted with ethyl acetate (100 mL) and filtered through celite pad.,0.0,67396,US20200031833A1,1
13093,13093, The ethyl acetate layer was washed with water (50 mL) and brine (50 mL).,0.0,67469,US20200031833A1,1
13094,13094," The organic layer was dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure.",0.0,67579,US20200031833A1,1
13095,13095," The crude product obtained was purified by silica gel (230-400) column chromatography (3% methanol in dichloromethane) to obtain compound D.
",0.0,67721,US20200031833A1,1
13096,13096,"Step 4
",0.0,67728,US20200031833A1,2
13097,13097,"To a stirred solution of compound D (1.0 eq) in acetonitrile (10 mL, 10 V) was added N-iodo succinamide (0.9 eq) under ice temperature.",0.0,67863,US20200031833A1,1
13098,13098, The resulting reaction mass was stirred at ice temperature over a period of 10 minutes.,0.0,67951,US20200031833A1,1
13099,13099, The reaction was monitored by TLC.,0.0,67986,US20200031833A1,1
13100,13100," The crude product obtained upon evaporation of the volatiles was purified by silica gel (230-400) column chromatography (3% methanol in dichloromethane) to obtain compound E.
",0.0,68162,US20200031833A1,1
13101,13101,"Step 5
",0.0,68169,US20200031833A1,2
13102,13102,"To a stirred solution of compound E (1.0 eq) and 1,3-dimethyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole (1.3 eq) in dioxane:water (6 mL, 30 V) were added potassium carbonate (2.5 eq) and PdCl2(dppf)DCM (0.1 eq) under room temperature.",0.0,68422,US20200031833A1,1
13103,13103, The resulting reaction mass was stirred at 90° C. over a period of 6 hours.,0.0,68498,US20200031833A1,1
13104,13104, The reaction was monitored by TLC.,0.0,68533,US20200031833A1,1
13105,13105, The reaction mass was diluted with ethyl acetate (200 mL) and filtered through celite pad.,0.0,68624,US20200031833A1,1
13106,13106," The organic layer was washed with water (100 mL), brine (50 mL), dried over anhydrous sodium sulphate and concentrated.",0.0,68744,US20200031833A1,1
13107,13107," The crude product obtained was purified by silica gel (230-400) column chromatography (6% methanol in dichloromethane) to obtain a compound of formula (Ie).
",0.0,68902,US20200031833A1,1
13148,13148,"Step 1
",0.0,71199,US20200031833A1,2
13149,13149,"To a stirred solution of 5-methyl-1H-pyrazol-3-ylamine, F, (7.0 g, 0.0720 mol), and 3-oxo-butyric acid ethyl ester (11.26 mL, 0.0804 mol) in dioxane (70 mL, 10 V) was added acetic acid (2.1 mL, 0.3 V) under room temperature.",0.0,71423,US20200031833A1,1
13150,13150, The resulting reaction mass was stirred at room temperature for 16 hours.,0.0,71497,US20200031833A1,1
13151,13151, The reaction was monitored by TLC.,0.0,71532,US20200031833A1,1
13152,13152," After complete consumption of the starting material, the reaction mass was filtered, and the residue obtained was suspended in diethyl ether (70 mL) and filtered.",0.0,71695,US20200031833A1,1
13153,13153," The product was dried under high vacuum to obtain 2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-ol, G, as a white solid (8.2 g, 69.7%)
",0.0,71825,US20200031833A1,1
13154,13154,"Step 2
",0.0,71832,US20200031833A1,2
13155,13155,"To a stirred suspension of compound G (4.0 g, 0.0245 mol), in acetonitrile (40 mL, 10 V) was added phosphorous oxy chloride (4.7 mL, 0.049 mol) at room temperature.",0.0,71996,US20200031833A1,1
13156,13156, The resulting reaction mass was stirred at 90° C. over a period of 16 hours.,0.0,72073,US20200031833A1,1
13157,13157, Starting material consumption was monitored by TLC.,0.0,72125,US20200031833A1,1
13158,13158," The reaction mass was added to ice cold water (50 mL), basified with saturated sodium bicarbonate solution, and extracted with ethyl acetate (200 mL*2).",0.0,72278,US20200031833A1,1
13159,13159," The combined organics were dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure.",0.0,72393,US20200031833A1,1
13160,13160," The crude product was purified by silica gel (230-400) column chromatography (3% methanol in dichloromethane) to obtain 7-chloro-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine, H, as an off-white solid (3.0 g, 68%).
",0.0,72602,US20200031833A1,1
13161,13161,"Step 3
",0.0,72609,US20200031833A1,2
13162,13162,"To a stirred suspension of compound H (1.5 g, 0.008 mol) in acetonitrile (15 mL, 10 V) was added N-iodo succinamide (1.85 g, 0.008 mol) under ice temperature.",0.0,72767,US20200031833A1,1
13163,13163, The resulting reaction mass was stirred at ice temperature over a period of 10 minutes.,0.0,72855,US20200031833A1,1
13164,13164, The reaction was monitored by TLC.,0.0,72890,US20200031833A1,1
13165,13165," The crude reaction mass was concentrated and purified by silica gel (230-400) column chromatography (3% methanol in dichloromethane) to obtain 7-chloro-3-iodo-2,5-dimethyl-pyrazolo[1,5-a]pyrimidine, I, as an off-white solid (2.3 g, 92%).
",0.0,73129,US20200031833A1,1
13166,13166,"Step 4
",0.0,73136,US20200031833A1,2
13167,13167,"To a stirred solution of compound I (0.6 g, 1.9 mmol) in ethanol (12 mL, 20 V) were added N,N-diisopropyl ethylamine (0.72 mL, 3.9 mmol) and the amine RANH2 (1.3 eq) at RT.",0.0,73308,US20200031833A1,1
13168,13168, The reaction mass was stirred at 70° C. for 16 hours.,0.0,73362,US20200031833A1,1
13169,13169, Starting material consumption was monitored by TLC.,0.0,73414,US20200031833A1,1
13170,13170," After complete evaporation of the volatiles the crude product was diluted with ethyl acetate (200 mL), washed with water (100 mL), dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure.",0.0,73633,US20200031833A1,1
13171,13171," The crude product was purified by silica gel (230-400) column chromatography (3% methanol in dichloromethane) to obtain the compound J.
",0.0,73770,US20200031833A1,1
13172,13172,"Step 5
",0.0,73777,US20200031833A1,2
13173,13173,"To a stirred solution of compound J (1.0 eq) and 1,3-dimethyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole (1.3 eq) in dioxane:water (10 mL, 20 V) were added potassium carbonate (2.5 eq) and PdCl2(dppf)DCM (0.1 eq) under room temperature.",0.0,74031,US20200031833A1,1
13174,13174, The resulting reaction mass was stirred at 90° C. over a period of 16 hours.,0.0,74108,US20200031833A1,1
13175,13175, The reaction was monitored by TLC.,0.0,74143,US20200031833A1,1
13176,13176, The reaction mass was diluted with ethyl acetate (200 mL) and filtered through celite pad.,0.0,74234,US20200031833A1,1
13177,13177," The organic layer was washed with water (100 mL), brine (50 mL), dried over anhydrous sodium sulphate and concentrated.",0.0,74354,US20200031833A1,1
13178,13178," The crude product was purified by silica gel (230-400) column chromatography (6% methanol in dichloromethane) to obtain a compound of formula (If).
",0.0,74503,US20200031833A1,1
13232,13232,"Step 1
",0.0,78014,US20200031833A1,2
13233,13233,"A suspension of 5-methyl-1H-pyrazol-3-ylamine, F, (2.0 g, 0.02 mol) in acetonitrile (50 mL, 25 V) was basified with diisopropylethylamine until the reaction mass showed pH 9-10.",0.0,78191,US20200031833A1,1
13234,13234," To the reaction mixture, ethylacetamidate hydrochloride (3.8 g, 0.03 mol) was added at RT under nitrogen atmosphere and the mixture was stirred for 15 minutes, whereafter the reaction mass was again basified with diisopropylethylamine (pH 9-10).",0.0,78437,US20200031833A1,1
13235,13235," Acetic acid (1.13 mL, 0.02 mol) was added to the suspension and stirred for 16 h. The reaction was monitored by TLC.",0.0,78554,US20200031833A1,1
13236,13236," After completion, the reaction mass was diluted with diethyl ether (25 mL), and the solid was filtered and washed with diethyl ether.",0.0,78688,US20200031833A1,1
13237,13237," The filtered solid was dried under high vacuum at 50-55° C. to get pure N-(5-methyl-2H-pyrazol-3-yl)-acetamidine, N, (2.4 g, 72%) as a white solid.
",0.0,78837,US20200031833A1,1
13238,13238,"Step 2
",0.0,78844,US20200031833A1,2
13239,13239,"To a solution of sodium metal (2.74 g, 0.12 mol) in ethanol (23 mL, 30 V) under nitrogen atmosphere was added N (3.3 g, 0.02 mol) and diethyl carbonate (23 mL, 0.2 mol) at room temperature.",0.0,79033,US20200031833A1,1
13240,13240, The resulting reaction mass was refluxed for 16 h. The progress of the reaction was monitored by TLC.,0.0,79135,US20200031833A1,1
13241,13241," After completion, the reaction mass was cooled to room temperature and resultant mass was concentrated under reduced pressure at 50-55° C. to remove ethanol.",0.0,79293,US20200031833A1,1
13242,13242, The crude product obtained upon evaporation of the volatiles were diluted with water and acidified with acetic acid (pH: 4-5).,0.0,79420,US20200031833A1,1
13243,13243," The aqueous layer was extracted with dichloromethane (400 mL*3), the organic layers were combined, dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure.",0.0,79607,US20200031833A1,1
13244,13244," The solid product was washed with minimum volumes of acetonitrile, filtered and dried to get pure 2,7-dimethyl-3H-pyrazolo[1,5-a][1,3,5]triazin-4-one, L, (1.6 g, 40%) as an off-white solid.
",0.0,79798,US20200031833A1,1
13245,13245,"Step 3
",0.0,79805,US20200031833A1,2
13246,13246,"To a stirred solution of compound L (1.0 g, 0.006 mol) in acetonitrile (10 mL, 10 V) was added N-bromo succinamide (1.3 g, 0.007 mol) under ice temperature.",0.0,79961,US20200031833A1,1
13247,13247, The resulting reaction mass was stirred at ice temperature over a period of 1 hour.,0.0,80045,US20200031833A1,1
13248,13248, The reaction was monitored by TLC.,0.0,80080,US20200031833A1,1
13249,13249," The precipitate formed was filtered through buchner funnel, washed with minimum amount of acetonitrile and dried to obtain 8-bromo-2,7-dimethyl-3H-pyrazolo[1,5-a][1,3,5]triazin-4-one, M, (0.7 g, 50%) as a white solid.
",0.0,80299,US20200031833A1,1
13250,13250,"Step 4
",0.0,80306,US20200031833A1,2
13251,13251,"To a solution of compound M (0.2 g, 0.8 mmol) in toluene (5 mL, 25 V) were added diisopropylethylamine (0.3 mL, 1.6 mmol) and phosphorous oxy chloride (2.0 mL, 0.02 mol) at room temperature.",0.0,80496,US20200031833A1,1
13252,13252, The resulting reaction mass was stirred at reflux temperature for 16 hours.,0.0,80572,US20200031833A1,1
13253,13253," The crude product obtained upon evaporation of the volatiles was stripped with toluene (10 mL*2) and the 8-bromo-4-chloro-2,7-dimethyl-pyrazolo[1,5-a][1,3,5]triazine, N, obtained was taken to next step without further purification and characterization.
",0.0,80826,US20200031833A1,1
13254,13254,"Step 5
",0.0,80833,US20200031833A1,2
13255,13255,"The crude compound N (0.2 g, 0.7 mmol), obtained upon evaporation of volatiles, was dissolved in THF (5 mL, 25 V).",0.0,80947,US20200031833A1,1
13256,13256," Diisopropylethylamine (0.3 mL, 1.5 mmol) and the amine RANH2 (1.2 eq) were added at ice temperature, and the resulting reaction mass was stirred at room temperature for 1 hour.",0.0,81124,US20200031833A1,1
13257,13257, The reaction was monitored by TLC.,0.0,81159,US20200031833A1,1
13258,13258," The reaction mass was diluted with dichloromethane (100 mL), washed with water (50 mL*2) and brine solution (50 mL*2).",0.0,81278,US20200031833A1,1
13259,13259," The organic layer was separated, dried over anhydrous sodium sulphate, filtered and concentrated under reduced pressure.",0.0,81399,US20200031833A1,1
13260,13260," The crude product was purified by silica gel (230-400) column chromatography (10% ethyl acetate in hexane) to obtain compound O (120 mg, 43%).
",0.0,81543,US20200031833A1,1
13261,13261,"Step 6
",0.0,81550,US20200031833A1,2
13262,13262,"To a stirred solution of compound O (1.0 eq) and 1,3-dimethyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole (1.3 eq) in dioxane:water (14 mL, 20 V) were added potassium carbonate (2.5 eq) and PdCl2(dppf)DCM (0.1 eq) at RT.",0.0,81787,US20200031833A1,1
13263,13263, The resulting reaction mass was stirred at 90° C. for 6 hours.,0.0,81850,US20200031833A1,1
13264,13264, The reaction was monitored by TLC.,0.0,81885,US20200031833A1,1
13265,13265, The reaction mass was diluted with ethyl acetate (200 mL) and filtered through celite pad.,0.0,81976,US20200031833A1,1
13266,13266," The organic layer was washed with water (100 mL), brine (50 mL), dried over anhydrous sodium sulphate and concentrated.",0.0,82096,US20200031833A1,1
13267,13267," The crude product was purified by silica gel (230-400) column chromatography (6% methanol in dichloromethane) to obtain a compound of formula (Ig).
",0.0,82245,US20200031833A1,1
14120,14120,"Synthesis of 3-Bis(2-Pyridylimino)Benz(f)Isoindoline (Benz(f)BPI)
",1.0,70701,US20200048291A1,2
14121,14121,"<img> id-US20200048291A1_00032.PNG </img>
",0.0,70743,US20200048291A1,1
14122,14122,"A mixture of naphthalene-2,3-dicarbonitrile (1.39 g, 7.81 mmol), 2-aminopyridine (1.47 g, 15.62 mmol), and CaCl2 (78.6 mg, 0.7 mmol) in 1-butanol (50 mL) was refluxed for 5 days.",0.0,70921,US20200048291A1,1
14123,14123," After cooling to room temperature, the resulting pale yellow precipitate was extracted to dichloromethane layer.",0.0,71034,US20200048291A1,1
14124,14124," Then, the crude product was purified by chromatography on a silica gel column using hexane: ethyl acetate (5:1, v/v) as the eluent.",0.0,71166,US20200048291A1,1
14125,14125, Yield: 43%.,0.0,71178,US20200048291A1,1
14127,14127,"Synthesis of Pt(BPI)Cl (1i)
",0.0,71362,US20200048291A1,2
14128,14128,"<img> id-US20200048291A1_00033.PNG </img>
",0.0,71404,US20200048291A1,1
14129,14129,"Silver triflate (0.138 g, 0.54 mmol) was added dropwise into Pt(COD)Cl2 (0.1 g, 0.26 mmol) in methanol (15 mL).",0.0,71515,US20200048291A1,1
14130,14130," After stirring for 15 min, the mixture was filtered off and added into extend-BPI (101 mg, 0.29 mmol) in methanol (15 mL).",0.0,71638,US20200048291A1,1
14131,14131," Then, triethylamine (27 mg, 0.26 mmol) was added into reaction mixture and it was heated to 50° C. for 24 h. After cooling to room temperature, the crude product was extracted into dichloromethane layer.",0.0,71842,US20200048291A1,1
14132,14132," Finally, the yellow solid was washed with ether.",0.0,71891,US20200048291A1,1
14133,14133, Yield: 64%.,0.0,71903,US20200048291A1,1
14135,14135,"Synthesis of Pt (N{circumflex over ( )}N{circumflex over ( )}N) Cl
",0.0,72095,US20200048291A1,2
14136,14136,"<img> id-US20200048291A1_00034.PNG </img>
",0.0,72137,US20200048291A1,1
14137,14137,"Silver triflate (0.138 g, 0.54 mmol) was added dropwise into Pt(COD)Cl2 (0.1 g, 0.26 mmol) in methanol (15 mL).",0.0,72248,US20200048291A1,1
14138,14138," After stirring for 15 min, the mixture was filtered off and added into BPI (88 mg, 0.29 mmol) in methanol (15 mL).",0.0,72363,US20200048291A1,1
14139,14139," Then, triethylamine (27 mg, 0.26 mmol) was added into reaction mixture and it was heated to 50° C. for 24 h. After cooling to room temperature, the crude product was extracted into dichloromethane layer.",0.0,72567,US20200048291A1,1
14140,14140," Finally, the red solid was washed with ether.",0.0,72613,US20200048291A1,1
14141,14141, Yield: 42%.,0.0,72625,US20200048291A1,1
14143,14143,"Synthesis of 1a
",0.0,72780,US20200048291A1,2
14144,14144,"<img> id-US20200048291A1_00035.PNG </img>
",0.0,72822,US20200048291A1,1
14145,14145,"A mixture of [Pt(BPI)Cl] (50 mg, 0.095 mmol), potassium tert-butoxide (10.6 mg, 0.095 mmol) and 1,3-dimethyl-1H-imidazol-3-ium iodide (23.4 mg, 0.104 mmol) in acetonitrile (15 mL) was heated to reflux for 12 hours.",0.0,73036,US20200048291A1,1
14146,14146," After cooling to room temperature, silver trifluoromethanesulfonate (84 mg, 0.33 mmol) was added into reaction mixture and stirred for 30 min.",0.0,73179,US20200048291A1,1
14147,14147," After extracting the crude product into dichloromethane layer, it was purified by column chromatography on silica gel with CH3CN/CH2Cl2 (3:1, v/v) as eluent, and yellow powder was obtained.
",0.0,73370,US20200048291A1,1
14148,14148,"Yield 52%; 1H NMR (400 MHz, CD3CN): 8=8.17-8.15 (m, 2H), 8.02 (t, 2H, J=8.0 Hz), 7.80-7.82 (d, 2H, J=4.0 Hz), 7.70-7.72 (m, 2H), 7.60 (s, 2H), 7.42-7.40 (d, 2H, J=4.0 Hz), 7.02 (t, 2H, J=8.0 Hz), 3.98 (s, 6H); MS (FAB, +ve): m/z 589 [M-OTf]+; Elemental analysis calcd (%) for C24H20F3N7O3PtS: C, 39.03, H, 2.73, N, 13.27; found: C, 38.75, H, 2.80, N, 13.22.
",0.0,73728,US20200048291A1,1
14149,14149,"Synthesis of 1b
",0.0,73744,US20200048291A1,2
14150,14150,"<img> id-US20200048291A1_00036.PNG </img>
",0.0,73786,US20200048291A1,1
14151,14151,"The procedure is similar to that for 1a.
",0.0,73827,US20200048291A1,1
14152,14152,"Yield 61%; 1H NMR (400 MHz, CDCl3): δ=8.17-8.16 (m, 2H), 8.06-8.02 (m, 2H), 7.84-7.82 (m, 2H), 7.74-7.72 (m, 2H), 7.62-7.61 (m, 2H), 7.44-7.42 (m, 2H), 7.04-7.00 (m, 2H), 4.38 (t, 4H, J=8.0 Hz), 1.76-1.68 (m, 4H), 1.31-1.22 (m, 4H), 0.77-0.72 (m, 6H); MS (FAB, +ve): m/z 673 [M-OTf]+; Elemental analysis calcd (%) for C30H32F3N7O3PtS: C, 43.79, H, 3.92, N, 11.92; found: C, 43.64, H, 4.05, N, 11.82.
",0.0,74227,US20200048291A1,1
14153,14153,"Synthesis of 1c
",0.0,74243,US20200048291A1,2
14154,14154,"<img> id-US20200048291A1_00037.PNG </img>
",0.0,74285,US20200048291A1,1
14155,14155,"The procedure is similar to that for 1a.
",0.0,74326,US20200048291A1,1
14156,14156,"Yield 49%; 1H NMR (400 MHz, CDCl3): δ=8.20-8.14 (m, 2H), 8.08-8.02 (m, 2H), 7.88-7.82 (m, 2H), 7.78-7.72 (m, 2H), 7.62-7.60 (m, 2H), 7.42-7.38 (m, 2H), 7.02-6.96 (m, 2H), 4.35 (t, 4H, J=8.0 Hz), 1.78-1.66 (m, 4H), 1.28-1.16 (m, 4H), 1.14-1.04 (m, 8H), 0.78-0.70 (m, 6H); MS (FAB, +ve): m/z 729 [M-OTf]+; Elemental analysis calcd (%) for C35H43F3N7O3PtS.0.5H2O: C, 46.56, H, 4.91, N, 10.86; found: C, 46.38, H, 4.71, N, 11.00.
",0.0,74752,US20200048291A1,1
14157,14157,"Synthesis of 1d
",0.0,74768,US20200048291A1,2
14158,14158,"<img> id-US20200048291A1_00038.PNG </img>
",0.0,74810,US20200048291A1,1
14159,14159,"The procedure is similar to that for 1a.
",0.0,74851,US20200048291A1,1
14160,14160,"Yield 51%; 1H NMR (500 MHz, CDCl3): δ=8.17-8.15 (m, 2H), 8.04-8.00 (m, 2H), 7.86-7.80 (m, 2H), 7.74-7.72 (m, 3H), 7.46-7.43 (m, 3H), 7.04-7.01 (m, 2H), 4.28 (t, 2H, J=4.0 Hz), 4.06 (s, 3H), 1.16-1.07 (m, 12H), 0.77 (t, 3H, J=8.0 Hz); MS (FAB, +ve): m/z 687 [M-OTf]+; Elemental analysis calcd (%) for C30H36F3N7O3PtS: C, 43.58, H, 4.39, N, 11.86; found: C, 43.79, H, 4.15, N, 11.53.
",0.0,75233,US20200048291A1,1
14161,14161,"Synthesis of 1e
",0.0,75249,US20200048291A1,2
14162,14162,"<img> id-US20200048291A1_00039.PNG </img>
",0.0,75291,US20200048291A1,1
14163,14163,"The procedure is similar to that for 1a.
",0.0,75332,US20200048291A1,1
14164,14164,"Yield 44%; 1H NMR (300 MHz, CDCl3): δ=8.20-8.14 (m, 2H), 8.06-7.96 (m, 2H), 7.86-7.78 (m, 2H), 7.76-7.70 (m, 3H), 7.48-7.42 (m, 3H), 7.06-7.00 (m, 2H), 4.28 (t, 2H, J=6.0 Hz), 4.06 (s, 3H), 1.35-1.04 (m, 28H), 0.88 (t, 3H, J=6.0 Hz).",0.0,75565,US20200048291A1,1
14166,14166,"Synthesis of 1f
",0.0,75730,US20200048291A1,2
14167,14167,"<img> id-US20200048291A1_00040.PNG </img>
",0.0,75772,US20200048291A1,1
14168,14168,"The procedure is similar to that for 1a.
",0.0,75813,US20200048291A1,1
14169,14169,"Yield 45%; 1H NMR (400 MHz, CD3CN): 8=8.16-8.14 (m, 2H), 7.93-7.91 (m, 2H), 7.81-7.79 (m, 2H), 7.68-7.66 (m, 4H), 7.26-7.24 (m, 4H), 7.06-6.98 (m, 8H), 6.60-6.54 (m, 2H), 5.42 (s, 4H); MS (FAB, +ve): m/z 741[M-OTf]+; Elemental analysis calcd (%) for C36H28F3N7O3PtS.CHCl3: C, 43.99, H, 2.89, N, 9.71; found: C, 44.07, H, 2.97, N, 9.89.
",0.0,76149,US20200048291A1,1
14170,14170,"Synthesis of 1 g
",0.0,76166,US20200048291A1,2
14171,14171,"<img> id-US20200048291A1_00041.PNG </img>
",0.0,76208,US20200048291A1,1
14172,14172,"The procedure is similar to that for 1a.
",0.0,76249,US20200048291A1,1
14173,14173,"Yield 49%; 1H NMR (400 MHz, CDCl3): δ=8.17-8.12 (m, 2H), 8.08-8.02 (m, 2H), 7.80-7.78 (m, 2H), 7.74-7.73 (m, 2H), 7.65-7.62 (m, 1H), 7.54-7.53 (m, 1H), 7.27-7.25 (m, 2H), 7.17-7.15 (m, 2H), 7.04-6.99 (m, 3H), 6.77-6.74 (m, 2H), 5.44-5.42 (m, 2H), 4.33-4.29 (m, 2H), 1.74-1.62 (m, 2H), 1.24-1.15 (m, 2H), 0.72-0.68 (m, 3H); MS (FAB, +ve): m/z 707 [M-OTf]+; Elemental analysis calcd (%) for C33H30F3N7O3PtS: C, 46.26, H, 3.53, N, 11.44; found: C, 46.17, H, 3.55, N, 11.14.
",0.0,76720,US20200048291A1,1
14174,14174,"Synthesis of 1h
",0.0,76736,US20200048291A1,2
14175,14175,"<img> id-US20200048291A1_00042.PNG </img>
",0.0,76778,US20200048291A1,1
14176,14176,"Silver trifluoromethanesulfonate (24.4 mg, 0.095 mmol) was added into a mixture of [Pt(BPI)Cl] (50 mg, 0.095 mmol) and triphenylphosphine (30 mg, 0.114 mmol) in dichloromethane: acetonitrile (20 mL; 1:1, v/v).",0.0,76987,US20200048291A1,1
14177,14177," The reaction mixture was stirred at room temperature for 5 hours.
",0.0,77054,US20200048291A1,1
14178,14178,"After extracting the crude product into dichloromethane layer, it was purified by recrystallization by diffusing diethyl ether into acetonitrile.",0.0,77199,US20200048291A1,1
14179,14179," Reddish yellow crystal was obtained.
",0.0,77237,US20200048291A1,1
14180,14180,"Yield 39%; 1H NMR (400 MHz, CDCl3): δ=8.71-8.69 (m, 2H), 8.16-8.15 (m, 2H), 7.86-7.78 (m, 9H), 7.58-7.52 (m, 6H), 7.48-7.46 (m, 6H), 6.62-6.58 (m, 2H).",0.0,77388,US20200048291A1,1
14787,14787,"Embodiment 1
",2.0,21731,US20200055807A1,0
14788,14788,"a1 (87.5 mg, 0.2 mmol), potassium acetate (19.6 mg, 0.2 mmol), absolute ethanol (2.0 mL, water ≤0.01 wt %), and methyl glycidyl ether b1 (52.9 mg, 0.6 mmol) are sequentially added to a 25 mL dry clean Schlenck tube with a magnetic stirrer to form a reaction system.",1.0,21996,US20200055807A1,0
14789,14789," The Schlenck tube is heated in a 90° C. oil bath for 35 hours, and TLC shows that the raw material is completely reacted to obtain a product system.",1.0,22145,US20200055807A1,0
14790,14790," The product system is stopped heating and cooled to a room temperature, and the solvent is removed under reduced pressure to give a residue, and then 2.0 mL of purified water is added to the residue to form a mixture; the mixture is stirred, adjusted to pH 4 with 3M hydrochloric acid, and then extracted with n-hexane (3 mL×3) to obtain an organic phase; the combined organic phase is dried with anhydrous sodium sulfate, filtered after drying; the filtrate is concentrated to obtain 45.5 mg of pure product, with a yield of 92%.
",1.0,22677,US20200055807A1,0
14791,14791,"The chemical reaction of the above alcoholysis process is as follows:
",1.0,22747,US20200055807A1,0
14792,14792,"<img> id-US20200055807A1_00017.PNG </img>
",1.0,22789,US20200055807A1,0
14796,14796,"Embodiment 2
",2.0,23152,US20200055807A1,0
14797,14797,"It differs from Embodiment 1 in that after the amount of each material in Embodiment 1 is increased by 100 times, an alcoholysis reaction is carried out by using a 500 mL pressure reactor, and the filtrate is concentrated to obtain a pure product of 4.648 g, with a yield of 94%.",1.0,23431,US20200055807A1,0
14798,14798," The yield of Embodiment 2 is higher than that of Embodiment 1, because the adhesion loss is large in the operation of small-amount reaction of Embodiment 1, and the yield in large-amount reaction is more accurate.
",1.0,23646,US20200055807A1,0
14799,14799,"Embodiment 3
",2.0,23659,US20200055807A1,0
14800,14800,"It differs from Embodiment 1 in that the molar ratio of methyl glycidyl ether b1 to a1 is 5:1, and the yield is 93%.
",1.0,23776,US20200055807A1,0
14801,14801,"Embodiment 4
",2.0,23789,US20200055807A1,0
14802,14802,"It differs from Embodiment 1 in that the molar ratio of methyl glycidyl ether b1 to a1 is 1:1, and the yield is 69%.
",1.0,23906,US20200055807A1,0
14803,14803,"Embodiment 5
",2.0,23919,US20200055807A1,0
14804,14804,"It differs from Embodiment 1 in that the molar ratio of methyl glycidyl ether b1 to a1 is 8:1, and the yield is 94%.
",1.0,24036,US20200055807A1,0
14805,14805,"Embodiment 6
",2.0,24049,US20200055807A1,0
14806,14806,"It differs from Embodiment 1 in that the Schlenck tube is heated in an oil bath at 80° C. for 35 hours, and the product yield is 84%.
",1.0,24183,US20200055807A1,0
14807,14807,"Embodiment 7
",2.0,24196,US20200055807A1,0
14808,14808,"It differs from Embodiment 1 in that the Schlenck tube is heated in an oil bath at 100° C. for 35 hours, and the product yield is 91%.
",1.0,24331,US20200055807A1,0
14809,14809,"Embodiment 8
",2.0,24344,US20200055807A1,0
14810,14810,"It differs from Embodiment 1 in that the Schlenck tube is heated in an oil bath at 150° C. for 35 hours, and the product yield is 82%.
",1.0,24479,US20200055807A1,0
14811,14811,"Embodiment 9
",2.0,24492,US20200055807A1,0
14812,14812,"It differs from Embodiment 1 in that the Schlenck tube is heated in an oil bath at 50° C. for 35 hours, and the product yield is 48%.
",1.0,24626,US20200055807A1,0
14813,14813,"Embodiment 10
",2.0,24640,US20200055807A1,0
14814,14814,"It differs from Embodiment 1 in that the Schlenck tube is heated in an oil bath at 165° C. for 35 hours, and the product yield is 74%.
",1.0,24775,US20200055807A1,0
14815,14815,"Embodiment 11
",2.0,24789,US20200055807A1,0
14816,14816,"It differs from Embodiment 1 in that the pH adjuster used is CF3CO2K, and the product yield is 93%.
",1.0,24889,US20200055807A1,0
14817,14817,"Embodiment 12
",2.0,24903,US20200055807A1,0
14818,14818,"It differs from Embodiment 1 in that the pH adjuster used is KHCO3, and the product yield is 74%.
",1.0,25001,US20200055807A1,0
14819,14819,"Embodiment 13
",2.0,25015,US20200055807A1,0
14820,14820,"It differs from Embodiment 1 in that the pH adjuster used is K2HPO4, and the product yield is 51%.
",1.0,25114,US20200055807A1,0
14821,14821,"Embodiment 14
",2.0,25128,US20200055807A1,0
14822,14822,"It differs from Embodiment 1 in that the pH adjuster used is K2CO3, and the product yield is 22%.
",1.0,25226,US20200055807A1,0
14823,14823,"Embodiment 15
",2.0,25240,US20200055807A1,0
14824,14824,"a1 (87.5 mg, 0.2 mmol), NaHCO3 (16.8 mg, 0.2 mmol), absolute ethanol (2.0 mL, water ≤0.01 wt %), and methyl glycidyl ether b1 (52.9 mg, 0.6 mmol) are sequentially added to a 25 mL dry clean Schlenck tube with a magnetic stirrer to form a reaction system.",1.0,25494,US20200055807A1,0
14825,14825," The Schlenck tube is heated in a 90° C. oil bath for 35 hours, and TLC shows that the raw material is completely reacted to obtain a product system.",1.0,25643,US20200055807A1,0
14826,14826," The product system is stopped heating and cooled to a room temperature, and the solvent is removed under reduced pressure to give a residue, the residue is purified by silica gel column chromatography (hexane/EA=15/1) to obtain a pure product of 36.1 mg, with a yield of 73%.
",1.0,25920,US20200055807A1,0
14827,14827,"Embodiment 16
",2.0,25934,US20200055807A1,0
14828,14828,"a1 (86.8 mg, 0.2 mmol), LiOH (4.8 mg, 0.2 mmol), absolute ethanol (2.0 mL, water ≤0.01 wt %), and methyl glycidyl ether b1 (52.9 mg, 0.6 mmol) are sequentially added to a 25 mL dry clean Schlenck tube with a magnetic stirrer to form a reaction system.",1.0,26185,US20200055807A1,0
14829,14829," The Schlenck tube is heated in a 90° C. oil bath for 35 hours, and TLC shows that the raw material is completely reacted to obtain a product system.",1.0,26334,US20200055807A1,0
14830,14830," The product system is stopped heating and cooled to a room temperature, and the solvent is removed under reduced pressure to give a residue, the residue is purified by silica gel column chromatography (hexane/EA=15/1) to obtain a pure product of 32.1 mg, with a yield of 65%.",1.0,26610,US20200055807A1,0
14831,14831," The pH adjuster used in this embodiment is LiOH, which is a strong base, not only adjusts pH value in the reaction, but also acts as a metal ion for complexation activation.
",1.0,26785,US20200055807A1,0
14832,14832,"Embodiment 17
",2.0,26799,US20200055807A1,0
14833,14833,"a1 (86.8 mg, 0.2 mmol), NaOAc (16.4 mg, 0.2 mmol), absolute ethanol (2.0 mL, water ≤0.01 wt %), and methyl glycidyl ether b1 (52.9 mg, 0.6 mmol) are sequentially added to a 25 mL dry clean Schlenck tube with a magnetic stirrer to form a reaction system.",1.0,27052,US20200055807A1,0
14834,14834," The Schlenck tube is heated in a 90° C. oil bath for 35 hours, and TLC shows that the raw material is completely reacted to obtain a product system.",1.0,27201,US20200055807A1,0
14835,14835," The product system is stopped heating and cooled to a room temperature, and the solvent is removed under reduced pressure to give a residue, the residue is purified by silica gel column chromatography (hexane/EA=15/1) to obtain a pure product of 43.0 mg, with a yield of 87%.
",1.0,27478,US20200055807A1,0
14836,14836,"Embodiment 18
",2.0,27492,US20200055807A1,0
14837,14837,"a1 (86.8 mg, 0.2 mmol), KCl (14.9 mg, 0.2 mmol), absolute ethanol (2.0 mL, water ≤0.01 wt %), and methyl glycidyl ether b1 (52.9 mg, 0.6 mmol) are sequentially added to a 25 mL dry clean Schlenck tube with a magnetic stirrer to form a reaction system.",1.0,27743,US20200055807A1,0
14838,14838," The Schlenck tube is heated in a 90° C. oil bath for 35 hours, and TLC shows that the raw material is completely reacted to obtain a product system.",1.0,27892,US20200055807A1,0
14839,14839," The product system is stopped heating and cooled to a room temperature, and the solvent is removed under reduced pressure to give a residue, the residue is purified by silica gel column chromatography (hexane/EA=15/1) to obtain a pure product of 15.3 mg, with a yield of 31%.
",1.0,28169,US20200055807A1,0
14840,14840,"Embodiment 19
",2.0,28183,US20200055807A1,0
14841,14841,"a1 (86.8 mg, 0.2 mmol), sodium trifluoroacetate (27.2 mg, 0.2 mmol), absolute ethanol (2.0 mL, water ≤0.01 wt %), and methyl glycidyl ether b1 (52.9 mg, 0.6 mmol) are sequentially added to a 25 mL dry clean Schlenck tube with a magnetic stirrer to form a reaction system.",1.0,28454,US20200055807A1,0
14842,14842," The Schlenck tube is heated in a 90° C. oil bath for 45 hours, and TLC shows that the raw material is completely reacted to obtain a product system.",1.0,28603,US20200055807A1,0
14843,14843," The product system is stopped heating and cooled to a room temperature, and the solvent is removed under reduced pressure to give a residue, the residue is purified by silica gel column chromatography (hexane/EA=15/1) to obtain a pure product of 46.0 mg, with a yield of 93%.
",1.0,28880,US20200055807A1,0
14848,14848," Although the yield is slightly increased, the reaction time is prolonged, and the potassium trifluoroacetate is more expensive than potassium acetate.
",1.0,29745,US20200055807A1,0
14869,14869,"Embodiment 26
",2.0,32903,US20200055807A1,0
14870,14870,"It differs from Embodiment 1 in that the solvent used is isopropanol, and the product yield is 95%.
",1.0,33003,US20200055807A1,0
14873,14873,"Embodiment 27
",2.0,33273,US20200055807A1,0
14874,14874,"It differs from Embodiment 1 in that the solvent used is isobutanol, and the product yield is 92%.
",1.0,33372,US20200055807A1,0
14877,14877,"Embodiment 28
",2.0,33653,US20200055807A1,0
14878,14878,"It differs from Embodiment 1 in that the solvent used is isoamyl alcohol, and the product yield is 87%.
",1.0,33757,US20200055807A1,0
14881,14881,"Embodiment 29
",2.0,34053,US20200055807A1,0
14882,14882,"It differs from Embodiment 1 in that the product system is stopped heating and cooled to a room temperature, and the solvent is removed under reduced pressure to give a residue, and then 2.0 mL of purified water is added to the residue to form a mixture; the mixture is stirred, adjusted to pH 3.5 with 3M hydrochloric acid, and then extracted with n-hexane (3 mL×3) to obtain an organic phase; the combined organic phase is dried with anhydrous sodium sulfate, filtered after drying, with a yield of 91%.
",1.0,34559,US20200055807A1,0
14883,14883,"Embodiment 30
",2.0,34573,US20200055807A1,0
14884,14884,"It differs from Embodiment 1 in that the product system is stopped heating and cooled to a room temperature, and the solvent is removed under reduced pressure to give a residue, and then 2.0 mL of purified water is added to the residue to form a mixture; the mixture is stirred, adjusted to pH 4.5 with 3M hydrochloric acid, and then extracted with n-hexane (3 mL×3) to obtain an organic phase; the combined organic phase is dried with anhydrous sodium sulfate, filtered after drying, with a yield of 89%.
",1.0,35079,US20200055807A1,0
14885,14885,"Embodiment 31
",2.0,35093,US20200055807A1,0
14886,14886,"It differs from Embodiment 1 in that the product system is stopped heating and cooled to a room temperature, and the solvent is removed under reduced pressure to give a residue, and then 2.0 mL of purified water is added to the residue to form a mixture; the mixture is stirred, adjusted to pH 5 with 3M hydrochloric acid, and then extracted with n-hexane (3 mL×3) to obtain an organic phase; the combined organic phase is dried with anhydrous sodium sulfate, filtered after drying, with a yield of 84%.
",1.0,35597,US20200055807A1,0
14887,14887,"Embodiment 32
",2.0,35611,US20200055807A1,0
14888,14888,"It differs from Embodiment 1 in that the amide compound used is a2, and the yield is 96%.
",1.0,35701,US20200055807A1,0
14891,14891,"Embodiment 33
",2.0,35945,US20200055807A1,0
14892,14892,"It differs from Embodiment 1 in that the amide compound used is a3, and the yield is 41%.
",1.0,36035,US20200055807A1,0
14893,14893,"Embodiment 34
",2.0,36049,US20200055807A1,0
14894,14894,"It differs from Embodiment 1 in that the amide compound used is a4, and the yield is 97%.
",1.0,36139,US20200055807A1,0
14895,14895,"Embodiment 35
",2.0,36153,US20200055807A1,0
14896,14896,"It differs from Embodiment 1 in that the amide compound used is a5, and the yield is 96%.
",1.0,36243,US20200055807A1,0
14897,14897,"Embodiment 36
",2.0,36257,US20200055807A1,0
14898,14898,"It differs from Embodiment 1 in that the amide compound used is a6, and the yield is 93%.
",1.0,36347,US20200055807A1,0
14899,14899,"Embodiment 37
",2.0,36361,US20200055807A1,0
14900,14900,"It differs from Embodiment 1 in that the amide compound used is a7, and the yield is 90%.
",1.0,36451,US20200055807A1,0
14901,14901,"Embodiment 38
",2.0,36465,US20200055807A1,0
14902,14902,"It differs from Embodiment 1 in that the amide compound used is a8, and the yield is 62%.
",1.0,36555,US20200055807A1,0
14905,14905,"Embodiment 39
",2.0,36761,US20200055807A1,0
14906,14906,"It differs from Embodiment 1 in that the amide compound used is a9, and the yield is 91%.
",1.0,36851,US20200055807A1,0
14909,14909,"Embodiment 40
",2.0,37083,US20200055807A1,0
14910,14910,"It differs from Embodiment 1 in that the amide compound used is a10, and the yield is 97%.
",1.0,37174,US20200055807A1,0
14911,14911,"Embodiment 41
",2.0,37188,US20200055807A1,0
14912,14912,"It differs from Embodiment 1 in that the amide compound used is all, and the yield is 94%.
",1.0,37279,US20200055807A1,0
15033,15033,"Embodiment 60
",2.0,57534,US20200055807A1,0
15034,15034,"It differs from Embodiment 1 in that the epoxy compound used is b2, and the yield is 92%.
",1.0,57624,US20200055807A1,0
15035,15035,"Embodiment 61
",2.0,57638,US20200055807A1,0
15036,15036,"It differs from Embodiment 1 in that the epoxy compound used is b3, and the yield is 69%.
",1.0,57728,US20200055807A1,0
15037,15037,"Embodiment 62
",2.0,57742,US20200055807A1,0
15038,15038,"It differs from Embodiment 1 in that the epoxy compound used is b4, and the yield is 21%.
",1.0,57832,US20200055807A1,0
15039,15039,"Embodiment 63
",2.0,57846,US20200055807A1,0
15040,15040,"It differs from Embodiment 1 in that the epoxy compound used is b5, and the yield is 68%.
",1.0,57936,US20200055807A1,0
15041,15041,"Embodiment 64
",2.0,57950,US20200055807A1,0
15042,15042,"It differs from Embodiment 1 in that the epoxy compound used is b6, and the yield is 87%.
",1.0,58040,US20200055807A1,0
15043,15043,"Embodiment 65
",2.0,58054,US20200055807A1,0
15044,15044,"It differs from Embodiment 1 in that the epoxy compound used is b7, and the yield is 89%.
",1.0,58144,US20200055807A1,0
15045,15045,"Embodiment 66
",2.0,58158,US20200055807A1,0
15046,15046,"It differs from Embodiment 1 in that the epoxy compound used is b8, and the yield is 47%.
",1.0,58248,US20200055807A1,0
15608,15608,"Example 1a: Analytical Data
",1.0,45421,US20200121691A1,0
15620,15620,"Example 1b
",1.0,46127,US20200121691A1,0
15630,15630,"Example 2a
",1.0,46692,US20200121691A1,0
15637,15637,"Example 2b
",1.0,47051,US20200121691A1,0
15644,15644,"Example 2c
",1.0,47402,US20200121691A1,0
15646,15646,"Example 2d
",2.0,47470,US20200121691A1,0
15647,15647,"<img> id-US20200121691A1_00015.PNG </img>
",1.0,47512,US20200121691A1,0
15651,15651,"Example 2d
",1.0,47757,US20200121691A1,0
15658,15658,"Example 2e
",1.0,48118,US20200121691A1,0
15666,15666,"Example 2f
",1.0,48510,US20200121691A1,0
15673,15673,"Example 2g
",1.0,48852,US20200121691A1,0
15681,15681,"Example 2h
",1.0,49247,US20200121691A1,0
15688,15688,"Example 2i
",1.0,49591,US20200121691A1,0
15695,15695,"Example 2k
",1.0,49935,US20200121691A1,0
15703,15703,"Example 2j
",1.0,50316,US20200121691A1,0
15710,15710,"Example 2l
",1.0,50665,US20200121691A1,0
15717,15717,"Example 2m
",1.0,51020,US20200121691A1,0
15725,15725,"Example 3a
",1.0,51754,US20200121691A1,0
15732,15732,"Example 3b
",1.0,52007,US20200121691A1,0
15739,15739,"Example 3c
",1.0,52271,US20200121691A1,0
15741,15741,"Example 3d
",2.0,52332,US20200121691A1,0
15742,15742,"<img> id-US20200121691A1_00028.PNG </img>
",1.0,52374,US20200121691A1,0
15743,15743,Example 3d was prepared in analogy to Example 3a.,1.0,52423,US20200121691A1,0
15746,15746,"Example 3d
",1.0,52528,US20200121691A1,0
15753,15753,"Example 3e
",1.0,52785,US20200121691A1,0
15761,15761,"Example 3f
",1.0,53093,US20200121691A1,0
15768,15768,"Example 3g
",1.0,53356,US20200121691A1,0
15776,15776,"Example 3h
",1.0,53663,US20200121691A1,0
15783,15783,"Example 3i
",1.0,53927,US20200121691A1,0
15790,15790,"Example 3k
",1.0,54190,US20200121691A1,0
15799,15799,"Example 3j
",1.0,54609,US20200121691A1,0
15807,15807,"Example 3l
",1.0,54984,US20200121691A1,2
15815,15815,"Example 3m
",1.0,55357,US20200121691A1,0
15824,15824,"Example 4a
",1.0,55968,US20200121691A1,0
15831,15831,"Example 4b
",1.0,56250,US20200121691A1,0
15838,15838,"Example 4c
",1.0,56559,US20200121691A1,0
15845,15845,"Example 4d
",1.0,56864,US20200121691A1,0
15852,15852,"Example 4e
",1.0,57169,US20200121691A1,0
15859,15859,"Example 4f
",1.0,57519,US20200121691A1,0
15866,15866,"Example 4g
",1.0,57824,US20200121691A1,0
15873,15873,"Example 4h
",1.0,58174,US20200121691A1,0
15880,15880,"Example 4i
",1.0,58479,US20200121691A1,0
15887,15887,"Example 4k
",1.0,58784,US20200121691A1,0
15896,15896,"Example 4j
",1.0,59187,US20200121691A1,0
15904,15904,"Example 4l
",1.0,59523,US20200121691A1,0
15911,15911,"Example 4m
",1.0,59845,US20200121691A1,0
15920,15920,"Example 1
",1.0,60374,US20200121691A1,0
15931,15931,"Example 2
",1.0,60988,US20200121691A1,0
15942,15942,"Example 3
",1.0,61646,US20200121691A1,0
15953,15953,"Example 4
",1.0,62298,US20200121691A1,0
15964,15964,"Example 5
",1.0,62949,US20200121691A1,0
15975,15975,"Example 6
",1.0,63634,US20200121691A1,0
15986,15986,"Example 7
",1.0,64298,US20200121691A1,0
15997,15997,"Example 8
",1.0,64986,US20200121691A1,0
16008,16008,"Example 9
",1.0,65684,US20200121691A1,0
16019,16019,"Example 18
",1.0,66310,US20200121691A1,0
16029,16029,"Example 30
",1.0,67016,US20200121691A1,0
16040,16040,"Example 3l
",1.0,67680,US20200121691A1,0
16051,16051,"Example 33
",1.0,68358,US20200121691A1,2
16052,16052,"HPLC-MS; Method: Z003_S05; Rt [min]: 0.96 MS: 377 and 379 (M+H)+: isotopic pattern for 1 Cl observed
",0.0,68459,US20200121691A1,1
16062,16062,"Example 34
",1.0,69150,US20200121691A1,0
16073,16073,"Example 35
",1.0,69806,US20200121691A1,0
16084,16084,"Example 36
",1.0,70462,US20200121691A1,0
16257,16257, 1 and 2.,0.0,25518,US20200123187A1,2
16258,16258," As three types of a butane-1,2,3,4-tetraol-based maltoside (BTM) stereoisomer, A-BTM (α-BTM), B-BTM (β-BTM) and M-BTM (meso-BTM) were synthesized according to the following synthesis methods of Examples <1-1> to <1-4>, each of which was performed in triplicate to synthesize a total of 9 compounds.",0.0,25817,US20200123187A1,1
16259,16259, The compounds are shown in FIG.,0.0,25849,US20200123187A1,1
16260,16260," 3.
",0.0,25853,US20200123187A1,1
16261,16261,<1-1> Typical Synthesis Procedure for Dialkylation (Step a in FIG.,2.0,25919,US20200123187A1,1
16264,16264,"(E)-but-2-ene-1,4-diol or (Z)-but-2-ene-1,4-diol (1 equiv.",1.0,25992,US20200123187A1,2
16271,16271,<1-2> Typical Synthesis Procedure for Sharpless Asymmetric Dihydroxylation (Steps b and c in FIG.,2.0,26763,US20200123187A1,1
16311,16311,<1-4> Typical Synthesis Procedure for Deprotection Reaction (Step e in FIG.,2.0,30303,US20200123187A1,1
16312,16312, 1 and Step d in FIG.,1.0,30324,US20200123187A1,0
16313,16313," 2)
",1.0,30328,US20200123187A1,0
16314,16314,"In this procedure, de-O-benzoylation or de-O-acetylation was performed under Zemplen's conditions according to the synthesis method by P. R. Ashton, et al.",1.0,30483,US20200123187A1,0
16315,16315, (Chem.,1.0,30490,US20200123187A1,0
16316,16316, Eur.,1.0,30495,US20200123187A1,0
16317,16317, J.,1.0,30498,US20200123187A1,0
16318,16318," 1996, 2, 1115-1128.).",1.0,30520,US20200123187A1,0
16319,16319," Specifically, the O-protected compound D, E or J was dissolved in MeOH, and NaOMe, which was a 0.5 M methanolic solution, was added thereto so that the final concentration of NaOMe reached 0.05 M. The reaction mixture was stirred at room temperature for 14 hours, and then neutralized with an Amberlite IR-120 (H+ form) resin.",1.0,30847,US20200123187A1,0
16323,16323,"<Preparative Example 1> Synthesis of B-BTM-C9
",0.0,31486,US20200123187A1,2
16336,16336, The 1H NMR spectrum is shown in FIG.,0.0,33644,US20200123187A1,1
16337,16337, 4A.,0.0,33648,US20200123187A1,1
16340,16340,"<Preparative Example 2> Synthesis of B-BTM-C10
",0.0,34128,US20200123187A1,2
16352,16352,B-BTM-C10 was synthesized with a yield of 92% according to the typical synthesis procedure for a deprotection reaction as described in Example 1-4.,1.0,36268,US20200123187A1,2
16355,16355,"<Preparative Example 3> Synthesis of B-BTM-C11
",0.0,36744,US20200123187A1,2
16356,16356,"<3-1> Synthesis of Compound 3
",2.0,36774,US20200123187A1,1
16370,16370,"<Preparative Example 4> Synthesis of A-BTM-C9
",0.0,39346,US20200123187A1,2
16371,16371,"<4-1> Synthesis of Compound 1
",2.0,39376,US20200123187A1,1
16383,16383, The 1H NMR spectrum is shown in FIG.,0.0,41281,US20200123187A1,1
16387,16387,"<Preparative Example 5> Synthesis of A-BTM-C10
",0.0,41753,US20200123187A1,2
16388,16388,"<5-1> Synthesis of Compound 2
",2.0,41783,US20200123187A1,1
16402,16402,"<Preparative Example 6> Synthesis of A-BTM-C11
",0.0,44131,US20200123187A1,2
16403,16403,"<6-1> Synthesis of Compound 3
",2.0,44161,US20200123187A1,1
16419,16419,"<Preparative Example 7> Synthesis of M-BTM-C9
",0.0,46505,US20200123187A1,2
16420,16420,"<7-1> Synthesis of Compound 16
",2.0,46536,US20200123187A1,1
16436,16436,"<Preparative Example 8> Synthesis of M-BTM-C10
",0.0,49263,US20200123187A1,2
16437,16437,"<8-1> Synthesis of Compound 17
",2.0,49294,US20200123187A1,1
16451,16451,"<Preparative Example 9> Synthesis of M-BTM-C11
",0.0,51975,US20200123187A1,2
16452,16452,"<9-1> Synthesis of Compound 18
",2.0,52006,US20200123187A1,1
17361,17361,"The compound thus obtained was confirmed to be a target compound from the following analysis results: MS (ESI) (m/z): 449 (M+H), Elemental analysis values: CHN measurement values (82.90%, 7.33%, 6.22%); theoretical values (82.81%, 7.40%, 6.23%)
",0.0,129930,US20200148885A1,1
17362,17362,"<img> id-US20200148885A1_00032.PNG </img>
",0.0,129972,US20200148885A1,2
17365,17365,"The compound thus obtained was confirmed to be a target compound from the following analysis results: MS (ESI) (m/z): 477 (M+H), Elemental analysis values: CHN measurement values (83.23%, 7.55%, 5.84%); theoretical values (83.15%, 7.61%, 5.88%)
",0.0,130506,US20200148885A1,1
17366,17366,"<img> id-US20200148885A1_00033.PNG </img>
",0.0,130548,US20200148885A1,2
17369,17369,"The compound thus obtained was confirmed to be a target compound from the following analysis results: MS (ESI) (m/z): 505 (M+H), Elemental analysis values: CHN measurement values (83.39%, 7.91%, 5.54%); theoretical values (83.29%, 7.99%, 5.55%)
",0.0,131085,US20200148885A1,1
17370,17370,"<img> id-US20200148885A1_00034.PNG </img>
",0.0,131127,US20200148885A1,2
17373,17373,"The compound thus obtained was confirmed to be a target compound from the following analysis results: MS (ESI) (m/z): 461 (M+H), Elemental analysis values: CHN measurement values (80.89%, 9.60%, 6.05%); theoretical values (80.82%, 9.63%, 6.08%)
",0.0,131665,US20200148885A1,1
17374,17374,"<img> id-US20200148885A1_00035.PNG </img>
",0.0,131707,US20200148885A1,2
17376,17376,"First, 2.47 g (6.08 mmol) of the intermediate A-4 obtained in Synthesis Example 4, 6.00 g (13.4 mmol) of the intermediate B-1 obtained in Synthesis Example 5, and 10 mL of chlorobenzene were mixed and stirred at 45° C. to 50° C. Then, 2.06 g (13.4 mmol) of phosphorus oxychloride (manufactured by Wako Pure Chemical Industries, Ltd.) was added thereto in a dropwise manner.",1.0,132127,US20200148885A1,2
17381,17381,"The compound thus obtained was confirmed to be a target compound from the following analysis results: MS (ESI) (m/z): 635 (+), divalent Elemental analysis values: CHN measurement values (81.59%, 6.85%, 5.25%); theoretical values (81.53%, 6.92%, 5.29%)
",0.0,132886,US20200148885A1,1
17382,17382,"<img> id-US20200148885A1_00036.PNG </img>
",0.0,132928,US20200148885A1,2
17385,17385,"The compound thus obtained was confirmed to be a target compound from the following analysis results: MS (ESI) (m/z): 663(+), divalent Elemental analysis values: CHN measurement values (81.75%, 7.17%, 5.99%); theoretical values (81.69%, 7.22%, 6.02%)
",0.0,133421,US20200148885A1,1
17386,17386,"<img> id-US20200148885A1_00037.PNG </img>
",0.0,133463,US20200148885A1,2
17389,17389,"The compound thus obtained was confirmed to be a target compound from the following analysis results:
",0.0,133807,US20200148885A1,1
17395,17395,"The compound thus obtained was confirmed to be a target compound from the following analysis results: MS (ESI) (m/z): 538(+), divalent Elemental analysis values: CHN measurement values (73.51%, 8.02%, 7.28%); theoretical values (78.43%, 8.07%, 7.32%)
",0.0,134625,US20200148885A1,1
17396,17396,"<img> id-US20200148885A1_00039.PNG </img>
",0.0,134667,US20200148885A1,2
17399,17399,"The compound thus obtained was confirmed to be a target compound from the following analysis results: MS (ESI) (m/z): 552(+), divalent Elemental analysis values: CHN measurement values (78.68%, 8.17%, 7.10%); theoretical values (78.61%, 8.22%, 7.14%)
",0.0,135294,US20200148885A1,1
17400,17400,"<img> id-US20200148885A1_00040.PNG </img>
",0.0,135336,US20200148885A1,2
17407,17407,"The compound thus obtained was confirmed to be a target compound from the following analysis results: MS (ESI) (m/z): 691(+), divalent Elemental analysis values: CHN measurement values (81.90%, 7.44%, 5.74%); theoretical values (81.84%, 7.49%, 5.78%)
",0.0,136454,US20200148885A1,1
17411,17411,"The compound thus obtained was confirmed to be a target compound from the following analysis results: MS (ESI) (m/z): 719(+), divalent Elemental analysis values: CHN measurement values (81.97%, 7.55%, 5.65%); theoretical values (81.91%, 7.62%, 5.67%)
",0.0,137080,US20200148885A1,1
17412,17412,"<img> id-US20200148885A1_00043.PNG </img>
",0.0,137122,US20200148885A1,2
17415,17415,"The compound thus obtained was confirmed to be a target compound from the following analysis results: MS (ESI) (m/z): 675(+), divalent Elemental analysis values: CHN measurement values (80.38%, 8.73%, 5.85%); theoretical values (80.30%, 8.80%, 5.91%)
",0.0,137706,US20200148885A1,1
17416,17416,"<img> id-US20200148885A1_00044.PNG </img>
",0.0,137748,US20200148885A1,2
17425,17425,"The compound thus obtained was confirmed to be a target compound from the following analysis results: MS (ESI) (m/z): 511(+), divalent Elemental analysis values: CHN measurement values (78.13%, 7.48%, 7.78%); theoretical values (78.06%, 7.75%, 7.69%)
",0.0,139086,US20200148885A1,1
17426,17426,"<img> id-US20200148885A1_00045.PNG </img>
",0.0,139128,US20200148885A1,2
17432,17432,"The compound thus obtained was confirmed to be a target compound from the following analysis results: 31P NMR (d-dmso, ppm) δ-15.15 MS (MALDI) (m/z): 1270 (M+), 2879 (MH2 −) Elemental analysis values: CHN measurement values (35.01%, 2.88%, 2.59%); theoretical values (34.29%, 2.91%, 2.64%) Fluorescent X-ray analysis: Mo/W measurement values (0%, 100%); theoretical values (0%, 100%)
",0.0,140088,US20200148885A1,1
17433,17433,"<img> id-US20200148885A1_00046.PNG </img>
",0.0,140130,US20200148885A1,2
17436,17436,"The compound thus obtained was confirmed to be a target compound from the following analysis results: 31P NMR (d-dmso, ppm) δ-15.15 MS (MALDI) (m/z): 1326 (M+), 2879 (MH2 −) Elemental analysis values: CHN measurement values (35.28%, 3.15%, 2.63%); theoretical values (35.18%, 3.11%, 2.59%) Fluorescent X-ray analysis: Mo/W measurement values (0%, 100%); theoretical values (0%, 100%)
",0.0,140726,US20200148885A1,1
17437,17437,"<img> id-US20200148885A1_00047.PNG </img>
",0.0,140768,US20200148885A1,2
17444,17444,"The compound thus obtained was confirmed to be a target compound from the following analysis results: 31P NMR (d-dmso, ppm) δ-15.15 MS (MALDI) (m/z): 1078 (M+), 2879 (MH2 −) Elemental analysis values: CHN measurement values (30.20%, 3.14%, 2.86%); theoretical values (30.070, 3.10%, 2.81%) Fluorescent X-ray analysis: Mo/W measurement values (0%, 100%); theoretical values (0%, 100%)
",0.0,142002,US20200148885A1,1
17445,17445,"<img> id-US20200148885A1_00049.PNG </img>
",0.0,142044,US20200148885A1,2
17448,17448,"The compound thus obtained was confirmed to be a target compound from the following analysis results: 31P NMR (d-dmso, ppm) δ-15.15 MS (MALDI) (m/z): 1106 (M+), 2879 (MH2 −) Elemental analysis values: CHN measurement values (30.63%, 3.18%, 2.75%); theoretical values (30.59%, 3.20%, 2.78%) Fluorescent X-ray analysis: Mo/W measurement values (0%, 100%); theoretical values (0%, 100%)
",0.0,142640,US20200148885A1,1
17449,17449,"<img> id-US20200148885A1_00050.PNG </img>
",0.0,142682,US20200148885A1,2
17452,17452,"The compound thus obtained was confirmed to be a target compound from the following analysis results: 31P NMR (d-dmso, ppm) δ-15.15 MS (MALDI) (m/z): 1383 (M+), 2879 (MH2 −) Elemental analysis values: CHN measurement values (36.25%, 3.33%, 2.54%); theoretical values (36.04%, 3.30%, 2.55%) Fluorescent X-ray analysis: Mo/W measurement values (0%, 100%); theoretical values (0%, 100%)
",0.0,143278,US20200148885A1,1
17453,17453,"<img> id-US20200148885A1_00051.PNG </img>
",0.0,143320,US20200148885A1,2
17456,17456,"The compound thus obtained was confirmed to be a target compound from the following analysis results: 31P NMR (d-dmso, ppm) δ-15.15 MS (MALDI) (m/z): 1383 (M+), 2879 (MH2 −) Elemental analysis values: CHN measurement values (36.25%, 3.33%, 2.54%); theoretical values (36.04%, 3.30%, 2.55%) Fluorescent X-ray analysis: Mo/W measurement values (0%, 100%); theoretical values (0%, 100%)
",0.0,143916,US20200148885A1,1
17457,17457,"<img> id-US20200148885A1_00052.PNG </img>
",0.0,143958,US20200148885A1,2
17460,17460,"The compound thus obtained was confirmed to be a target compound from the following analysis results: 31P NMR (d-dmso, ppm) δ-15.15 MS (MALDI) (m/z): 1440 (M+), 2879 (MH2 −) Elemental analysis values: CHN measurement values (36.88%, 3.49%, 2.51%); theoretical values (36.87%, 3.48%, 2.50%) Fluorescent X-ray analysis: Mo/W measurement values (0%, 100%); theoretical values (0%, 100%)
",0.0,144554,US20200148885A1,1
17461,17461,"<img> id-US20200148885A1_00053.PNG </img>
",0.0,144596,US20200148885A1,2
17485,17485,"(1) Synthesis of Block Copolymer B
",0.0,148848,US20200148885A1,2
17486,17486,"First, 100 parts by mass of dehydrated tetrahydrofuran and 3.00 parts by mass of dimethylketene methyl trimethylsilyl acetal were put in a reactor equipped with a cooling tube, an addition funnel, a nitrogen inlet, a mechanical stirrer and a digital thermometer.",0.0,149110,US20200148885A1,1
17487,17487, Nitrogen substitution was sufficiently carried out thereon.,0.0,149170,US20200148885A1,1
17488,17488," Next, 0.25 part by mass of a 1 M solution of tetrabutylammonium m-chlorobenzoate in acetonitrile, was injected into the reactor by a syringe.",0.0,149312,US20200148885A1,1
17489,17489," Then, a mixed solution of 50.0 parts by mass of methyl methacrylate, 30.0 parts by mass of n-butyl methacrylate and 20.0 parts by mass of benzyl methacrylate was added in a dropwise manner for 60 minutes.",0.0,149517,US20200148885A1,1
17490,17490," The reactor was cooled in an ice bath to keep the temperature at less than 40° C. After one hour passed, 25.0 parts by mass of glycidyl methacrylate was added in a dropwise manner for 20 minutes.",0.0,149713,US20200148885A1,1
17491,17491," After the mixture was reacted for one hour, 1 part by mass of methanol was added to stop the reaction.",0.0,149816,US20200148885A1,1
17492,17492," To the thus-obtained solution of the block copolymer B in THF, 188.0 parts by mass of PGMEA was added.",0.0,149919,US20200148885A1,1
17493,17493," Solvent substitution was carried out thereon by evaporation, thereby obtaining a solution of the block copolymer B in 40.0% by mass PGMEA.
",0.0,150059,US20200148885A1,1
17494,17494,"The thus-obtained block copolymer B had a mass average molecular weight (Mw) of 9470, a number average molecular weight (Mn) of 7880, and a molecular weight distribution (Mw/Mn) of 1.20.
",0.0,150246,US20200148885A1,1
17495,17495,"(2) Production of Phosphorus-Based Block Copolymer Solution
",0.0,150306,US20200148885A1,2
17496,17496,"First, 100.0 parts by mass of the block copolymer B, 86.70 parts by mass of PGMEA, and 8.90 parts by mass of phenylphosphonic acid (PPA) were put in a reactor and stirred for two hours at 90° C., thereby obtaining a phosphorus-based block copolymer B solution (solid content 25% by mass).",0.0,150594,US20200148885A1,1
17497,17497, The progress of an esterification reaction between the PPA and a glycidyl group (a constitutional unit derived from the glycidyl methacrylate of the block copolymer B) was confirmed by acid value measurement and 1H-NMR measurement.,0.0,150826,US20200148885A1,1
17498,17498," The thus-obtained phosphorus-based block copolymer B had an acid value of 65 mgKOH/g.
",0.0,150913,US20200148885A1,1
17500,17500,"(1) Synthesis of Phosphate Triester Compound A
",0.0,151019,US20200148885A1,2
17501,17501,"First, 70 parts by mass of chloroform, 20.89 parts by mass of hydroxyethyl acrylate and 12.14 parts by mass of triethylamine were put in a reactor equipped with a cooling tube, an addition funnel, a nitrogen inlet, a mechanical stirrer and a digital thermometer.",0.0,151281,US20200148885A1,1
17502,17502," With stirring the mixed solution under a nitrogen atmosphere, the solution temperature was cooled to about 5° C. by use of an ice bath.",0.0,151417,US20200148885A1,1
17503,17503," Then, a solution obtained by diluting 6.13 parts by mass of phosphoryl chloride with 10 parts by mass of chloroform, was continuously added in a dropwise manner for 15 minutes, while controlling the solution temperature so as not to exceed 30° C. After the dropwise addition was completed, the ice bath was taken out, and the solution was stirred for three hours at room temperature.",0.0,151801,US20200148885A1,1
17504,17504," Then, 30 parts by mass of pure water was added thereto, and the mixed solution was stirred for 30 minutes.",0.0,151908,US20200148885A1,1
17505,17505," Then, the resulting reacted solution was taken out therefrom and washed three times with saturated brine.",0.0,152014,US20200148885A1,1
17506,17506," An organic layer thus formed was dehydrated with magnesium sulfate, filtered, and then mixed with 0.015 g of p-methoxyphenol.",0.0,152140,US20200148885A1,1
17507,17507," Then, the solvent was removed from the mixture, thereby obtaining 14.09 g (yield 90%) of a phosphate triester compound A represented by the following chemical formula (A).",0.0,152312,US20200148885A1,1
17508,17508, The thus-obtained compound had an acid value of 5 mgKOH/g.,0.0,152371,US20200148885A1,1
18046,18046," Consecutively, Fmoc-Lys(Tfa)-OH, Fmoc-8-aminocaprylic acid, Fmoc-Phe-OH, Fmoc-Phe-OH and Fmoc-8-aminocaprylic acid were attached to the growing peptide chain in sequence as mentioned before.",0.0,53800,US20200164075A1,2
18047,18047," After deprotection of Fmoc group from the last amino acid, Fmoc-8-aminocaprylic acid, tris-tert butyl protected AAPT ligand 16a (0.040 g, 0.079 mmol), PyBOP (0.068 g, 0.1312 mmol) and DIPEA (0.091 mL, 0.525 mmol) in DMF (0.5 mL) was added to the resin beads and mixed for 6 h. The completion of coupling reaction was confirmed by performing the Kaiser test.",0.0,54158,US20200164075A1,1
18272,18272, The crude products 1-3 were washed (3×5 mL) with ether to remove excess trifluoroacetic acid and other non-polar impurities.,1.0,90688,US20200164075A1,0
18273,18273," The products 1-3 were purified through Buchi Reveleris preparative high-performance liquid chromatography using RP-PFP column (XSelect CSH Prep Fluorophenyl 5 μm OBD, 19 mm×150 mm).",1.0,90870,US20200164075A1,0
18274,18274, The purity of the products 1-3 was confirmed by analytical high-performance liquid chromatography and LC-MS.,1.0,90979,US20200164075A1,0
18275,18275," The purified inhibitors 1-3 were used for NAALADase or PSMA enzyme inhibition assay to determine the IC50.
",1.0,91087,US20200164075A1,0
19056,19056,"<img> id-US20200165244A1_00022.PNG </img>
",1.0,111155,US20200165244A1,0
19061,19061,"<img> id-US20200165244A1_00023.PNG </img>
",1.0,111751,US20200165244A1,0
19066,19066,"<img> id-US20200165244A1_00024.PNG </img>
",1.0,112337,US20200165244A1,0
19073,19073,"<img> id-US20200165244A1_00025.PNG </img>
",1.0,113161,US20200165244A1,0
19080,19080,"<img> id-US20200165244A1_00026.PNG </img>
",1.0,114028,US20200165244A1,0
19100,19100," & A2 & NBoc2
",2.0,114701,US20200165244A1,0
19101,19101," & A4 & NHC(O)OMe
",2.0,114719,US20200165244A1,0
19103,19103," & A8 & <img> id-US20200165244A1_00028.PNG </img>
",2.0,114773,US20200165244A1,0
19105,19105," & A9 & <img> id-US20200165244A1_00029.PNG </img>
",2.0,114827,US20200165244A1,0
19117,19117,"<img> id-US20200165244A1_00030.PNG </img>
",1.0,116399,US20200165244A1,0
19137,19137," & A4 & C(O)OMe & H
",2.0,117116,US20200165244A1,0
19138,19138," & A6 & C(O)OPr & H
",2.0,117136,US20200165244A1,0
19147,19147,"<img> id-US20200165244A1_00032.PNG </img>
",1.0,118036,US20200165244A1,0
19149,19149,"Preparation Example 11
",2.0,118290,US20200165244A1,0
19150,19150,"The compound A5 which was prepared according to the method described in Preparation Example 10 and physical property value thereof is shown below.
",1.0,118437,US20200165244A1,0
19151,19151,"<img> id-US20200165244A1_00033.PNG </img>
",1.0,118479,US20200165244A1,0
19163,19163,"<img> id-US20200165244A1_00035.PNG </img>
",1.0,119931,US20200165244A1,0
19183,19183," & C2 & H & C(O)Ot-Bu
",2.0,120743,US20200165244A1,0
19184,19184," & C3 & H & C(O)OMe
",2.0,120763,US20200165244A1,0
19776,19776,"<Synthesis of Intermediate 1>
",2.0,64518,US20200181061A1,1
19779,19779,"<Synthesis of Intermediate 2>
",2.0,64674,US20200181061A1,1
19782,19782,"<Synthesis of Intermediate 3>
",2.0,64848,US20200181061A1,1
19785,19785,"<Synthesis of Intermediate 4>
",2.0,65020,US20200181061A1,1
19788,19788,"<Synthesis of Intermediate 5>
",2.0,65192,US20200181061A1,1
19791,19791,"<Synthesis of Intermediate 6>
",2.0,65364,US20200181061A1,1
19796,19796,"<Synthesis of Intermediate 7>
",2.0,66123,US20200181061A1,1
19801,19801,"<Synthesis of Intermediate 8>
",2.0,66732,US20200181061A1,1
19804,19804,"<Synthesis of Intermediate 9>
",2.0,66945,US20200181061A1,1
19810,19810,"<Synthesis of Intermediate 10>
",2.0,67678,US20200181061A1,1
19815,19815,"<Synthesis of Intermediate 11>
",2.0,68361,US20200181061A1,1
19822,19822,"<Synthesis of Intermediate 12>
",2.0,69087,US20200181061A1,1
19828,19828,"<Synthesis of Intermediate 13>
",2.0,69796,US20200181061A1,1
19831,19831,"<Synthesis of Intermediate 14>
",2.0,70017,US20200181061A1,1
19834,19834,"<Synthesis of Intermediate 15>
",2.0,70234,US20200181061A1,1
19837,19837,"<Synthesis of Compound 1>
",2.0,70447,US20200181061A1,1
19877,19877," The 1H-NMR data of the compound 36 was as follows.
",1.0,76345,US20200181061A1,0
20197,20197,"Example 1-1
",2.0,40503,US20200270285A1,0
20198,20198,"Synthesis of Organic Silicon Compound 1
",1.0,40543,US20200270285A1,2
20202,20202,"The obtained organic silicon compound 1 was a pale yellow transparent liquid having a viscosity of 13 mm2/s and a weight average molecular weight of 480, and was a compound having the following formula (9).
",0.0,41809,US20200270285A1,1
20203,20203,"<img> id-US20200270285A1_00024.PNG </img>
",0.0,41851,US20200270285A1,1
20209,20209,"The obtained organic silicon compound 2 was a yellow transparent liquid having a viscosity of 15 mm2/s and a weight average molecular weight of 490, and was a compound having the following formula (11).
",0.0,43162,US20200270285A1,1
20211,20211,"Example 1-3
",2.0,43216,US20200270285A1,0
20212,20212,"Synthesis of Organic Silicon Compound 3
",1.0,43256,US20200270285A1,0
20213,20213,"Synthesis was performed by a similar procedure as in Example 1-1 except that the 65.0 g of an amine compound having an alkenyl group of the above formula (7) was changed to 74.9 g of an amine compound having an alkenyl group of the following formula (12), and 156 g of the corresponding organic silicon compound 3 was obtained.
",1.0,43584,US20200270285A1,0
20216,20216,"Example 1-4
",2.0,43841,US20200270285A1,0
20217,20217,"Synthesis of Organic Silicon Compound 4
",1.0,43881,US20200270285A1,0
20218,20218,"Synthesis was performed by a similar procedure as in Example 1-1 except that the 65.0 g of an amine compound having an alkenyl group of the above formula (7) was changed to 69.3 g of an amine compound having an alkenyl group of the following formula (14), and 151 g of the corresponding organic silicon compound 4 was obtained.
",1.0,44209,US20200270285A1,0
20221,20221,"Example 1-5
",2.0,44465,US20200270285A1,0
20222,20222,"Synthesis of Organic Silicon Compound 5
",1.0,44505,US20200270285A1,0
20223,20223,"Synthesis was performed by a similar procedure as in Example 1-1 except that the 65.0 g of an amine compound having an alkenyl group of the above formula (7) was changed to 92.8 g of an amine compound having an alkenyl group of the following formula (16), and 175 g of the corresponding organic silicon compound 5 was obtained.
",1.0,44833,US20200270285A1,2
20226,20226,"Example 1-6
",2.0,45095,US20200270285A1,0
20227,20227,"Synthesis of Organic Silicon Compound 6
",1.0,45135,US20200270285A1,0
20228,20228,"Synthesis was performed by a similar procedure as in Example 1-2 except that the 83.8 g of a silane compound having an organosiloxane structure of the above formula (8) was changed to 108.8 g of a silane compound having an organosiloxane structure of the following formula (18), and 177 g of the corresponding organic silicon compound 6 was obtained.
",1.0,45486,US20200270285A1,0
20231,20231,"Example 1-7
",2.0,45748,US20200270285A1,0
20232,20232,"Synthesis of Organic Silicon Compound 7
",1.0,45788,US20200270285A1,0
20233,20233,"Synthesis was performed by a similar procedure as in Example 1-2 except that the 83.8 g of a silane compound having an organosiloxane structure of the above formula (8) was changed to 96.3 g of a silane compound having an organosiloxane structure of the following formula (20), and 164 g of the corresponding organic silicon compound 7 was obtained.
",1.0,46138,US20200270285A1,0
20236,20236,"Example 1-8
",2.0,46395,US20200270285A1,0
20237,20237,"Synthesis of Organic Silicon Compound 8
",1.0,46435,US20200270285A1,0
20238,20238,"Synthesis was performed by a similar procedure as in Example 1-2 except that the 83.8 g of a silane compound having an organosiloxane structure of the above formula (8) was changed to 79.1 g of a silane compound having an organosiloxane structure of the following formula (22), and 147 g of the corresponding organic silicon compound 8 was obtained.
",1.0,46785,US20200270285A1,0
20241,20241,"Example 1-9
",2.0,47047,US20200270285A1,0
20242,20242,"Synthesis of Organic Silicon Compound 9
",1.0,47087,US20200270285A1,0
20243,20243,"Synthesis was performed by a similar procedure as in Example 1-2 except that the 83.8 g of a silane compound having an organosiloxane structure of the above formula (8) was changed to 124.2 g of a silane compound having an organopolysiloxane structure of the following average structural formula (24), and 192 g of the corresponding organic silicon compound 9 was obtained.
",1.0,47461,US20200270285A1,0
20246,20246,"Example 1-10
",2.0,47743,US20200270285A1,0
20247,20247,"Synthesis of Organic Silicon Compound 10
",1.0,47784,US20200270285A1,0
20248,20248,"Synthesis was performed by a similar procedure as in Example 1-2 except that the 83.8 g of a silane compound having an organosiloxane structure of the above formula (8) was changed to 136.7 g of a silane compound having an organopolysiloxane structure of the following average structural formula (26), and 204 g of the corresponding organic silicon compound 10 was obtained.
",1.0,48159,US20200270285A1,0
20251,20251,"Example 1-11
",2.0,48437,US20200270285A1,0
20252,20252,"Synthesis of Organic Silicon Compound 11
",1.0,48478,US20200270285A1,0
20253,20253,"Synthesis was performed by a similar procedure as in Example 1-2 except that the 83.8 g of a silane compound having an organosiloxane structure of the above formula (8) was changed to 119.5 g of a silane compound having an organopolysiloxane structure of the following average structural formula (28), and 187 g of the corresponding organic silicon compound 11 was obtained.
",1.0,48853,US20200270285A1,0
20256,20256,"Example 1-12
",2.0,49131,US20200270285A1,0
20257,20257,"Synthesis of Organic Silicon Compound 12
",1.0,49172,US20200270285A1,0
20258,20258,"Synthesis was performed by a similar procedure as in Example 1-2 except that the 83.8 g of a silane compound having an organosiloxane structure of the above formula (8) was changed to 190.2 g of a silane compound having an organopolysiloxane structure of the following average structural formula (30), and 257 g of the corresponding organic silicon compound 12 was obtained.
",1.0,49547,US20200270285A1,0
20261,20261,"Example 1-13
",2.0,49830,US20200270285A1,0
20262,20262,"Synthesis of Organic Silicon Compound 13
",1.0,49871,US20200270285A1,0
20263,20263,"Synthesis was performed by a similar procedure as in Example 1-2 except that the 83.8 g of a silane compound having an organosiloxane structure of the above formula (8) was changed to 256.1 g of a silane compound having an organopolysiloxane structure of the following average structural formula (32), and the 300 mL separable flask was changed to a 500 mL separable flask, and 323 g of the corresponding organic silicon compound 13 was obtained.
",1.0,50318,US20200270285A1,0
20266,20266,"Example 1-14
",2.0,50603,US20200270285A1,0
20267,20267,"Synthesis of Organic Silicon Compound 14
",1.0,50644,US20200270285A1,0
20268,20268,"Synthesis was performed by a similar procedure as in Example 1-2 except that the 83.8 g of a silane compound having an organosiloxane structure of the above formula (8) was changed to 717.9 g of a silane compound having an organopolysiloxane structure of the following average structural formula (34), and the 300 mL separable flask was changed to a 1 L separable flask, and 780 g of the corresponding organic silicon compound 14 was obtained.
",1.0,51088,US20200270285A1,0
20271,20271,"Example 1-15
",2.0,51374,US20200270285A1,0
20272,20272,"Synthesis of Organic Silicon Compound 15
",1.0,51415,US20200270285A1,0
20273,20273,"Synthesis was performed by a similar procedure as in Example 1-2 except that the 83.8 g of a silane compound having an organosiloxane structure of the above formula (8) was changed to 2,235.3 g of a silane compound having an organopolysiloxane structure of the following average structural formula (36), and the 300 mL separable flask was changed to a 3 L separable flask, and 2,282 g of the corresponding organic silicon compound 15 was obtained.
",1.0,51863,US20200270285A1,0
20276,20276,"Example 1-16
",2.0,52149,US20200270285A1,0
20277,20277,"Synthesis of Organic Silicon Compound 16
",1.0,52190,US20200270285A1,0
20278,20278,"Synthesis was performed by a similar procedure as in Example 1-2 except that the 83.8 g of a silane compound having an organosiloxane structure of the above formula (8) was changed to 83.8 g of a silane compound having an organopolysiloxane structure of the following average structural formula (38), and 150 g of the corresponding organic silicon compound 16 was obtained.
",1.0,52564,US20200270285A1,0
20284,20284,"Example 1-17
",2.0,53041,US20200270285A1,0
20285,20285,"Synthesis of Organic Silicon Compound 17
",1.0,53082,US20200270285A1,0
20286,20286,"Synthesis was performed by a similar procedure as in Example 1-2 except that the 83.8 g of a silane compound having an organosiloxane structure of the above formula (8) was changed to 33.5 g of a silane compound having an organopolysiloxane structure of the following average structural formula (40), and 102 g of the corresponding organic silicon compound 17 was obtained.
",1.0,53456,US20200270285A1,0
21219,21219,"<First Step>
",2.0,71969,US20200377536A1,0
21226,21226,"<Second Step>
",2.0,72841,US20200377536A1,1
21274,21274,"Example 4
",2.0,79675,US20200377536A1,0
21275,21275,"<img> id-US20200377536A1_00029.PNG </img>
",1.0,79717,US20200377536A1,0
21276,21276,"wherein R1 represents a tert-butyl group, and R2 represents an adamantyl group.
",1.0,79797,US20200377536A1,0
21277,21277,"A phosphine-borane (3d) was used instead of the phosphine-borane (3a) in the first step to obtain a phosphinopyrazine derivative (4d) in the second step.
",1.0,79951,US20200377536A1,0
21278,21278,"Then, in the third step and the fourth step, reactions and purification were performed as in Example 1 except that the optically active phosphine-borane in the (R) form (5b) (0.495 mmol, 97.1 mg, >99% ee) was used instead of the optically active phosphine-borane (5a) to form an optically active phosphinopyrazine-borane derivative (10d) (0.3 mmol, 92.6 mg).",1.0,80309,US20200377536A1,0
21279,21279," Thus, an optically active 2,3-bisphosphinopyrazine derivative in the S form (1d) (hereinafter referred to as “(S)-Quniox-AdCF”) (0.26 mmol, 119 mg, yield 87%) was obtained.
",1.0,80483,US20200377536A1,0
21287,21287,"Example 5
",2.0,81318,US20200377536A1,0
21288,21288,"<img> id-US20200377536A1_00030.PNG </img>
",1.0,81360,US20200377536A1,0
21289,21289,"wherein R1 represents a tert-butyl group, and R2 represents a 1,1,3,3-tetramethylbutyl group.
",1.0,81454,US20200377536A1,0
21300,21300,"Comparative Example 1
",2.0,83080,US20200377536A1,0
21301,21301,"<img> id-US20200377536A1_00031.PNG </img>
",1.0,83122,US20200377536A1,0
21302,21302,"wherein R1 and R2 represent a tert-butyl group.
",1.0,83170,US20200377536A1,0
21303,21303,"The phosphine-borane (3d) was used instead of the phosphine-borane (3a) in the first step to obtain the phosphinopyrazine derivative (4d).
",1.0,83309,US20200377536A1,0
21304,21304,"Then, reactions and purification were performed as in Example 1 except that in the third step, an optically active phosphinopyrazine-borane derivative (10f) was obtained.",1.0,83479,US20200377536A1,0
21305,21305," Thus, an optically active 2,3-bisphosphinopyrazine derivative in the R form (1f) (hereinafter referred to as “(R)-Quinox-TCF)”) (yield 95%) was obtained.
",1.0,83634,US20200377536A1,0
21308,21308,"Example 6
",2.0,84313,US20200377536A1,0
21309,21309,"Enantioselective Markovnikov Hydroboration Reaction
",1.0,84365,US20200377536A1,0
21310,21310,"<img> id-US20200377536A1_00032.PNG </img>
",1.0,84407,US20200377536A1,0
21311,21311,"CuBF4(MeCN)4 (4.7 mg, 0.015 mmol), (S)-Quinox-tODAd (8.8 mg, 0.015 mmol), and bispinacolatodiboron (2) (152.4 mg, 0.6 mmol) were placed in a dried reaction container.",1.0,84573,US20200377536A1,0
21312,21312," The container was hermetically sealed with a Teflon (registered trademark)-coated septum, and pressure reduction and nitrogen sealing were performed three times to place the interior of the reaction container under a nitrogen atmosphere.",1.0,84811,US20200377536A1,0
21313,21313," Next, THF (0.4 mL) and a K(O-t-Bu) (t-butoxypotassium)/THF solution (1.0 mol/L, 0.6 mL, 0.6 mmol) were injected by a syringe, and the mixture was stirred at −40° C. for 30 min.",1.0,84988,US20200377536A1,0
21314,21314," Then, an alkene compound 1a (66.1 mg, 0.5 mmol) and methanol (40.4 μL, 1.0 mmol) were each dropped into the reaction solution using a syringe.",1.0,85131,US20200377536A1,0
21315,21315," The reaction solution was stirred at −40° C. for 24 h, and then the reaction solution was passed through a column (diameter: 10 mm, height: 30 mm) packed with a small amount of silica gel, and washed with diethyl ether.",1.0,85351,US20200377536A1,0
21316,21316," The solvent was removed by an evaporator, and the obtained material was purified using flash column chromatography (SiO2, Et2O/hexane, volume ratio 0:100-4:96), and thus the target hydroboration product (S)-3a was obtained as a colorless transparent liquid with a yield of 94%, 3a/4a=92:8, and 98% ee (122.0 mg, 0.47 mmol).",1.0,85675,US20200377536A1,0
21317,21317," Ph in the above reaction formula means a phenyl group.
",1.0,85731,US20200377536A1,0
21341,21341,"Example 6 & (S) -Quinox-tODAd & 94 & 92:8 & 98
",2.0,86790,US20200377536A1,0
21342,21342,"Example 7 & (R) -Quinox-CFDAd & 40 & 84:16 & −91
",2.0,86839,US20200377536A1,0
21343,21343,"Example 8 & (S) -Quinox-TAd & 85 & 86:14 & 97
",2.0,86885,US20200377536A1,0
21344,21344,"Example 9 & (S) -Quinox-AdDCF & 69 & 82:18 & 91
",2.0,86933,US20200377536A1,0
21345,21345,"Example 10 & (S) -Quinox-tODCF & 37 & 80:20 & 93
",2.0,86982,US20200377536A1,0
21346,21346,"Comparative & (R) -Quinox-TCF & 39 & 78:22 & −87
",2.0,87031,US20200377536A1,0
21347,21347,"Example 1
",1.0,87041,US20200377536A1,0
21377,21377,"Example 11 & CH3—(CH2)7— & 64 & 90:10 & 96
",2.0,88031,US20200377536A1,0
21378,21378,"Example 12 & Ph—(CH2)— & 88 & 85:15 & 99
",2.0,88072,US20200377536A1,0
21379,21379,"Example 13 & Cl—(CH2)4— & 89 & 86:14 & 98
",2.0,88114,US20200377536A1,0
21380,21380,"Example 14 & Ph2MeSiO—(CH2)3— & 52 & 89:11 & 97
",2.0,88162,US20200377536A1,0
21381,21381,"Example 15 & BnO—(CH2)4— & 60 & 88:12 & 95
",2.0,88205,US20200377536A1,0
21390,21390,"<Ath Step>
",2.0,88593,US20200377536A1,1
21513,21513," 2,5-diphenyl-1H-pyrrole (5f), vii.",0.0,12897,US20200384451A1,2
21514,21514," 2-benzyl-5-phenyl-1H-pyrrole (5g), viii.",0.0,12938,US20200384451A1,2
21515,21515," 2-isopropyl-5-p-tolyl-1H-pyrrole (5h), ix.",0.0,12981,US20200384451A1,2
21516,21516," 2-(4-chlorophenyl)-5-isopropyl-1H-pyrrole (5i), x.",0.0,13032,US20200384451A1,1
21517,21517," 2-isopropyl-5-(4-methoxyphenyl)-1H-pyrrole (5j), xi.",0.0,13085,US20200384451A1,1
21518,21518," 4-(5-isopropyl-1H-pyrrol-2-yl)aniline (5k), xii.",0.0,13134,US20200384451A1,2
21519,21519," 2-isopropyl-5-m-tolyl-1H-pyrrole (5l), xiii.",0.0,13179,US20200384451A1,2
21520,21520," 2-isopropyl-5-(naphthalen-1-yl)-1H-pyrrole (5m), xiv.",0.0,13233,US20200384451A1,1
21521,21521," 2-isopropyl-5-octyl-1H-pyrrole (5n), xv.",0.0,13274,US20200384451A1,2
21522,21522," 2-isobutyl-5-(naphthalen-2-yl)-1H-pyrrole (5o), xvi.",0.0,13327,US20200384451A1,1
21523,21523," 2-phenyl pyridine (7a), xvii.",0.0,13357,US20200384451A1,2
21524,21524," 2-p-tolyl pyridine (7b), xviii.",0.0,13389,US20200384451A1,2
21525,21525," 2-(4-methoxyphenyl) pyridine (7c), xix.",0.0,13429,US20200384451A1,1
21526,21526," 2-m-tolylpyridine (7d), xx.",0.0,13457,US20200384451A1,1
21527,21527," 2-octyl pyridine (7e), xxi.",0.0,13485,US20200384451A1,1
21528,21528," 2-decyl pyridine (7f), xxii.",0.0,13514,US20200384451A1,1
21529,21529," 2-phenyl quinoline (7g), xxiii.",0.0,13546,US20200384451A1,1
21530,21530," 2-(3-methoxyphenyl) quinoline (7h), xxiv.",0.0,13588,US20200384451A1,2
21531,21531," 2-(4-fluorophenyl)quinoline (7i), xxv.",0.0,13627,US20200384451A1,2
21532,21532, 2-(4-(trifluoromethyl)phenyl)quinoline (7j) or xxvi.,0.0,13680,US20200384451A1,1
21533,21533," 2-(naphthalen-2-yl)quinoline (7k).
",0.0,13716,US20200384451A1,1
21648,21648,"a) Reaction with Different Solventa
",2.0,29288,US20200384451A1,0
21649,21649,"<img> id-US20200384451A1_00012.PNG </img>
",1.0,29330,US20200384451A1,0
21650,21650,"<table>
",1.0,29338,US20200384451A1,0
21651,21651,"<header>
",1.0,29347,US20200384451A1,0
21652,21652,"TABLE 1
",1.0,29355,US20200384451A1,0
21653,21653,"</header>
",1.0,29365,US20200384451A1,0
21654,21654,"<header>
",1.0,29374,US20200384451A1,0
21655,21655,"</header>
",1.0,29384,US20200384451A1,0
21656,21656,"<header>
",1.0,29393,US20200384451A1,0
21657,21657,"Entry & Solvent & Yield (%)b
",1.0,29422,US20200384451A1,0
21658,21658,"</header>
",1.0,29432,US20200384451A1,0
21659,21659,"<header>
",1.0,29441,US20200384451A1,0
21660,21660,"</header>
",1.0,29451,US20200384451A1,0
21661,21661,"1 & Toluene & 47
",1.0,29468,US20200384451A1,0
21662,21662,"2 & m-xylene & 77
",1.0,29486,US20200384451A1,0
21663,21663,"3 & Mesitylene & 57
",1.0,29506,US20200384451A1,0
21664,21664,"4 & n-octane & 52
",1.0,29524,US20200384451A1,2
21669,21669,"</table>
",1.0,29780,US20200384451A1,0
21670,21670,"b) Reaction with Different Catalysta
",1.0,29817,US20200384451A1,0
21762,21762,"1 & 1/1 & 69
",0.0,32356,US20200384451A1,2
21763,21763,"2 & 1/1 (cat 2) & 67
",0.0,32377,US20200384451A1,1
21764,21764,"3 & 1.5/1 & 71
",0.0,32392,US20200384451A1,1
21765,21765,"4 & 2/1 & 77
",0.0,32405,US20200384451A1,1
21766,21766,"5 & 3/1 & 65
",0.0,32418,US20200384451A1,1
21767,21767,"aReactions performed using amino alcohol 3c (0.125 mmol), 1-Phenyl ethanol 4a (0.15 mmol), catalyst (2.5 mol %), KOtBu (equiv.)",0.0,32545,US20200384451A1,1
21768,21768," reflux at 150° C. to 180° C.
",0.0,32575,US20200384451A1,1
21769,21769,"bYield determined by GC using 1,4-dibromo butane as an internal standard.
",0.0,32649,US20200384451A1,1
21773,21773,"(a) General Procedure for the Synthesis of 1H-Pyrroles
",0.0,32801,US20200384451A1,2
21774,21774,"To an oven-dried 15 mL ace pressure tube, 1,2 amino alcohol 3 (0.25 mmol), secondary alcohol 4 (0.5 mmol), Co-complex 1 (2.5 mol %) and m-xylene (2 mL) were added under a gentle stream of argon.",0.0,32995,US20200384451A1,1
21775,21775, The mixture was of heated at 150° C. to 180° C. for 24 h followed by cooling to room temperature.,0.0,33093,US20200384451A1,1
21776,21776, The reaction mixture was diluted with water (4 mL) and extracted with dichloromethane (3×5 mL).,0.0,33189,US20200384451A1,1
21777,21777, The resultant organic layer was dried over anhydrous Na2SO4 and the solvent was evaporated under reduced pressure.,0.0,33304,US20200384451A1,1
21778,21778," The crude mixture was purified by silica gel column chromatography (230-400 mesh size) using petroleum-ether/ethyl acetate as an eluting system.
",0.0,33450,US20200384451A1,1
21779,21779,i.,0.0,33452,US20200384451A1,2
21780,21780," 2-methyl-5-phenyl-1H-pyrrole (5a)
",0.0,33487,US20200384451A1,2
21781,21781,"To an oven-dried 15 mL ace pressure tube, 2-aminopropan-1-ol (0.25 mmol), 1-phenylethanol (0.5 mmol), Co-complex 1 (2.5 mol %) and m-xylene (2 mL) were added under a gentle stream of argon.",0.0,33676,US20200384451A1,1
21782,21782, The mixture was of heated at 150° C. to 180° C. for 24 h followed by cooling to room temperature.,0.0,33774,US20200384451A1,1
21783,21783, The reaction mixture was diluted with water (4 mL) and extracted with dichloromethane (3×5 mL).,0.0,33870,US20200384451A1,1
21784,21784, The resultant organic layer was dried over anhydrous Na2SO4 and the solvent was evaporated under reduced pressure.,0.0,33985,US20200384451A1,1
21785,21785," The crude mixture was purified by silica gel column chromatography (230-400 mesh size) using petroleum-ether/ethyl acetate as an eluting system.
",0.0,34131,US20200384451A1,1
21786,21786,Colorless oil.,0.0,34145,US20200384451A1,1
21787,21787, Yield: 77%.,0.0,34157,US20200384451A1,1
21791,21791,ii.,0.0,34491,US20200384451A1,2
21792,21792," 2-ethyl-5-phenyl-1H-pyrrole (5b)
",0.0,34525,US20200384451A1,2
21793,21793,Colorless oil.,0.0,34539,US20200384451A1,1
21794,21794, Yield: 81%.,0.0,34551,US20200384451A1,1
21798,21798,iii.,0.0,34935,US20200384451A1,2
21799,21799," 2-isopropyl-5-phenyl-1H-pyrrole (5c)
",0.0,34973,US20200384451A1,2
21800,21800,Colorless oil.,0.0,34987,US20200384451A1,1
21801,21801, Yield: 73%.,0.0,34999,US20200384451A1,1
21805,21805,iv.,0.0,35377,US20200384451A1,2
21806,21806," 2-isobutyl-5-phenyl-1H-pyrrole (5d)
",0.0,35414,US20200384451A1,2
21807,21807,Colorless oil.,0.0,35428,US20200384451A1,1
21808,21808, Yield: 86%.,0.0,35440,US20200384451A1,1
21812,21812,"v. 2-sec-butyl-5-phenyl-1H-pyrrole (5e)
",0.0,35886,US20200384451A1,2
21813,21813,Colorless oil.,0.0,35900,US20200384451A1,1
21814,21814, Yield: 78%.,0.0,35912,US20200384451A1,1
21818,21818,vi.,0.0,36366,US20200384451A1,2
21819,21819," 2,5-diphenyl-1H-pyrrole (5f)
",0.0,36396,US20200384451A1,1
21820,21820,Brown liquid.,0.0,36409,US20200384451A1,1
21821,21821, Yield: 58%.,0.0,36421,US20200384451A1,1
21828,21828," 2-benzyl-5-phenyl-1H-pyrrole (5g)
",0.0,36742,US20200384451A1,2
21829,21829,Light brown oil.,0.0,36758,US20200384451A1,1
21830,21830, Yield: 70%.,0.0,36770,US20200384451A1,1
21837,21837," 2-isopropyl-5-p-tolyl-1H-pyrrole (5h)
",0.0,37133,US20200384451A1,2
21838,21838,Colorless oil.,0.0,37147,US20200384451A1,1
21839,21839, Yield: 85%.,0.0,37159,US20200384451A1,1
21843,21843,ix.,0.0,37534,US20200384451A1,2
21844,21844," 2-(4-chlorophenyl)-5-isopropyl-1H-pyrrole (5i)
",0.0,37582,US20200384451A1,2
21845,21845,Colorless oil.,0.0,37596,US20200384451A1,1
21846,21846, Yield: 70%.,0.0,37608,US20200384451A1,1
21850,21850,x.,0.0,37963,US20200384451A1,2
21851,21851," 2-isopropyl-5-(4-methoxyphenyl)-1H-pyrrole (5j)
",0.0,38012,US20200384451A1,1
21852,21852,White solid.,0.0,38024,US20200384451A1,1
21853,21853, Yield: 89%.,0.0,38036,US20200384451A1,1
21858,21858," 4-(5-isopropyl-1H-pyrrol-2-yl)aniline (5k)
",0.0,38448,US20200384451A1,2
21859,21859,Light brown liquid.,0.0,38467,US20200384451A1,1
21860,21860, Yield: 67%.,0.0,38479,US20200384451A1,1
21865,21865," 2-isopropyl-5-m-tolyl-1H-pyrrole (5l)
",0.0,38893,US20200384451A1,2
21866,21866,Colorless oil.,0.0,38907,US20200384451A1,1
21867,21867, Yield: 70%.,0.0,38919,US20200384451A1,1
21871,21871,xiii.,0.0,39316,US20200384451A1,2
21872,21872," 2-isopropyl-5-(naphthalen-1-yl)-1H-pyrrole (5m)
",0.0,39365,US20200384451A1,1
21873,21873,Light yellow sticky liquid.,0.0,39392,US20200384451A1,1
21874,21874, Yield: 61%.,0.0,39404,US20200384451A1,1
21875,21875," 1H NMR (500 MHz, CHLOROFORM-d) δ=8.39-8.38 (m, 1H), 8.16 (s, br, 1H), 7.90-7.89 (m, 1H), 7.80-7.79 (m, 1H), 7.51 (m, 4H), 6.44 (s, 1H), 6.12 (s, 1H), 3.11-3.03 (m, 1H), 3.37 (d, J=6.5 Hz, 6H).",0.0,39597,US20200384451A1,1
21878,21878,xiv.,0.0,39822,US20200384451A1,2
21879,21879," 2-isopropyl-5-octyl-1H-pyrrole (5n)
",0.0,39859,US20200384451A1,2
21880,21880,Ration of alcohol/amino alcohol=1.5/1 has taken under the identical reaction condition.,0.0,39946,US20200384451A1,1
21881,21881, Colorless oil.,0.0,39961,US20200384451A1,1
21882,21882, Yield: 45%.,0.0,39973,US20200384451A1,1
21888,21888,Light yellow sticky liquid.,0.0,40396,US20200384451A1,1
21889,21889, Yield: 74%.,0.0,40408,US20200384451A1,1
21893,21893,"b) General Procedure for the Synthesis Pyridine Derivatives
",0.0,40925,US20200384451A1,2
21894,21894,"To an oven-dried 15 mL ace pressure tube, 1,2 amino alcohol 6 (0.25 mmol), secondary alcohol 4 (0.5 mmol), Co-complex 1 (2.5 mol %) and m-xylene (1 mL) were added under a gentle stream of argon.",0.0,41119,US20200384451A1,1
21895,21895, The mixture was heated at 150° C. to 180° C. for 24 h followed by cooling to room temperature.,0.0,41214,US20200384451A1,1
21896,21896, The reaction mixture was diluted with water (4 mL) and extracted with dichloromethane (3×5 mL).,0.0,41310,US20200384451A1,1
21897,21897, The resultant organic layer was dried over anhydrous Na2SO4 and the solvent was evaporated under reduced pressure.,0.0,41425,US20200384451A1,1
21898,21898," The crude mixture was purified by silica gel column chromatography (230-400 mesh size) using petroleum-ether/ethyl acetate as an eluting system.
",0.0,41571,US20200384451A1,1
21899,21899,i.,0.0,41573,US20200384451A1,2
21900,21900," 2-Phenyl Pyridine (7a)
",0.0,41597,US20200384451A1,2
21901,21901,"To an oven-dried 15 mL ace pressure tube, (2-aminophenyl)methanol 6 (0.25 mmol), 1-phenylethan-1-ol 4 (0.5 mmol), Co-complex 1 (2.5 mol %) and m-xylene (1 mL) were added under a gentle stream of argon.",0.0,41798,US20200384451A1,1
21902,21902, The mixture was heated at 150° C. to 180° C. for 24 h followed by cooling to room temperature.,0.0,41893,US20200384451A1,1
21903,21903, The reaction mixture was diluted with water (4 mL) and extracted with dichloromethane (3×5 mL).,0.0,41989,US20200384451A1,1
21904,21904, The resultant organic layer was dried over anhydrous Na2SO4 and the solvent was evaporated under reduced pressure.,0.0,42104,US20200384451A1,1
21905,21905," The crude mixture was purified by silica gel column chromatography (230-400 mesh size) using petroleum-ether/ethyl acetate as an eluting system.
",0.0,42250,US20200384451A1,1
21906,21906,Colorless oil.,0.0,42264,US20200384451A1,1
21907,21907, Yield: 68%.,0.0,42276,US20200384451A1,1
21911,21911,ii.,0.0,42616,US20200384451A1,2
21912,21912," 2-p-tolyl Pyridine (7b)
",0.0,42641,US20200384451A1,2
21913,21913,Colorless oil.,0.0,42655,US20200384451A1,1
21914,21914, Yield: 79%.,0.0,42667,US20200384451A1,1
21918,21918,iii.,0.0,43007,US20200384451A1,2
21919,21919," 2-(4-methoxyphenyl) Pyridine (7c)
",0.0,43042,US20200384451A1,2
21920,21920,Colorless oil.,0.0,43056,US20200384451A1,1
21921,21921, Yield: 83%.,0.0,43068,US20200384451A1,1
21925,21925,iv.,0.0,43445,US20200384451A1,2
21926,21926," 2-m-tolylpyridine (7d)
",0.0,43469,US20200384451A1,1
21927,21927,Colorless oil.,0.0,43483,US20200384451A1,1
21928,21928, Yield: 69%.,0.0,43495,US20200384451A1,1
21932,21932,"v. 2-octyl Pyridine (7e)
",0.0,43870,US20200384451A1,2
21933,21933,"Ration of alcohol/amino alcohol=1.5/1 has taken under the identical reaction condition.
",0.0,43958,US20200384451A1,1
21934,21934,Colorless oil.,0.0,43972,US20200384451A1,1
21935,21935, Yield: 60%.,0.0,43984,US20200384451A1,1
21942,21942,vi.,0.0,44450,US20200384451A1,2
21943,21943," 2-decyl Pyridine (7f)
",0.0,44473,US20200384451A1,1
21944,21944,Ration of alcohol/amino alcohol=1.5/1 has taken under the identical reaction condition.,0.0,44560,US20200384451A1,1
21945,21945, Colorless oil.,0.0,44575,US20200384451A1,1
21946,21946, Yield: 63%.,0.0,44587,US20200384451A1,1
21957,21957," 2-phenyl Quinoline (7g)
",0.0,45146,US20200384451A1,2
21958,21958,White solid.,0.0,45158,US20200384451A1,1
21959,21959, Yield: 81%.,0.0,45170,US20200384451A1,1
21967,21967," 2-(3-methoxyphenyl) Quinoline (7h)
",0.0,45608,US20200384451A1,2
21968,21968,Colorless oil.,0.0,45622,US20200384451A1,1
21969,21969, Yield: 75%.,0.0,45634,US20200384451A1,1
21970,21970," 1H NMR (200 MHz, CHLOROFORM-d) δ=8.22-8.19 (m, 2H), 7.87-7.80 (m, 3H), 7.74 (t, J=8.5 Hz, 2H), 7.54 (t, J=7.3 Hz, 1H), 7.45 (t, J=7.9 Hz, 1H), 7.04 (d, J=8.5 Hz, 1H), 3.94 (s, 3H).",0.0,45815,US20200384451A1,1
21973,21973,ix.,0.0,46041,US20200384451A1,2
21974,21974," 2-(4-fluorophenyl)quinoline (7i)
",0.0,46075,US20200384451A1,2
21975,21975,White solid.,0.0,46087,US20200384451A1,1
21976,21976, Yield: 72%.,0.0,46099,US20200384451A1,1
21981,21981," 2-(4-(trifluoromethyl)phenyl)quinoline (7j)
",0.0,46526,US20200384451A1,2
21982,21982,White solid.,0.0,46538,US20200384451A1,1
21983,21983, Yield: 67%.,0.0,46550,US20200384451A1,1
21988,21988," 2-(naphthalen-2-yl)quinoline (7k)
",0.0,46985,US20200384451A1,2
21989,21989,White solid.,0.0,46997,US20200384451A1,1
21990,21990, Yield: 87%.,0.0,47009,US20200384451A1,1
21994,21994,"Example 5: General Procedure for the Synthesis of Pyrazine Derivative
",0.0,47526,US20200384451A1,2
21995,21995,"To an oven-dried 15 mL ace pressure tube, 1,2 amino alcohol 3f (0.25 mmol), Co-complex 1 (2.5 mol %) and m-xylene (1 mL) were added under a gentle stream of argon.",0.0,47689,US20200384451A1,1
21996,21996, The mixture was heated at 135° C. (bath temperature).,0.0,47743,US20200384451A1,1
21997,21997," After 24 h, the reaction mixture was diluted with water (4 mL) and extracted with dichloromethane (3×5 mL).",0.0,47851,US20200384451A1,1
21998,21998, The resultant organic layer was dried over anhydrous Na2SO4 and the solvent was evaporated under reduced pressure.,0.0,47966,US20200384451A1,1
21999,21999," The crude mixture was purified by silica gel column chromatography (230-400 mesh size) using petroleum-ether/ethyl acetate as an eluting system.
",0.0,48112,US20200384451A1,1
22000,22000,"Gram-scale synthesis: The present cobalt-catalyzed direct pyrazine synthesis was tested for the gram-scale synthesis, and it worked excellently and gave 8 in 61% (1.02 g) isolated yield.
",0.0,48299,US20200384451A1,1
22001,22001,a.,0.0,48301,US20200384451A1,2
22002,22002," 2,5-Diphenyl Pyrazine (8)
",0.0,48328,US20200384451A1,1
22003,22003,"To an oven-dried 15 mL ace pressure tube, 2-amino-2-phenylethan-1-ol 3f (0.25 mmol), Co-complex 1 (2.5 mol %) and m-xylene (1 mL) were added under a gentle stream of argon.",0.0,48500,US20200384451A1,1
22004,22004, The mixture was heated at 135° C. (bath temperature).,0.0,48554,US20200384451A1,1
22005,22005," After 24 h, the reaction mixture was diluted with water (4 mL) and extracted with dichloromethane (3×5 mL).",0.0,48662,US20200384451A1,1
22006,22006, The resultant organic layer was dried over anhydrous Na2SO4 and the solvent was evaporated under reduced pressure.,0.0,48777,US20200384451A1,1
22007,22007," The crude mixture was purified by silica gel column chromatography (230-400 mesh size) using petroleum-ether/ethyl acetate as an eluting system.
",0.0,48923,US20200384451A1,1
22008,22008,White solid.,0.0,48935,US20200384451A1,1
22009,22009, Yield: 68%.,0.0,48947,US20200384451A1,1
